

























This work has not previously been accepted in substance for any degree and is not concurrently 
submitted in candidature for any degree.  
Signed ……………………………………… (candidate) Date …………………………  
 
STATEMENT 1  
This thesis is being submitted in partial fulfilment of the requirements for the degree of PhD.  
Signed ……………………………………… (candidate) Date …………………………  
 
STATEMENT 2  
This thesis is the result of my own independent work/investigation, except where otherwise 
stated.  Other sources are acknowledged by explicit references.  
Signed ……………………………………… (candidate) Date …………………………  
 
STATEMENT 3  
I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter-
library loan, and for the title and summary to be made available to outside organisations.  
Signed ……………………………………… (candidate) Date …………………………  
 
STATEMENT 4: PREVIOUSLY APPROVED BAR ON ACCESS  
I hereby give consent for my thesis, if accepted, to be available for photocopying and for inter-
library loans after expiry of a bar on access previously approved by the Graduate 
Development Committee.  





This thesis is dedicated to my family, especially to my dear mother, brothers and sisters who 





There are several people to whom I remain indebted to for their support, inspiration and 
advice during my time as a PhD student.  Firstly, I would like to thank my first supervisor 
Dr Matthias Eberl for giving me the opportunity to work in his lab and for his invaluable 
guidance, support and encouragement throughout.  I would also like to thank my second 
supervisor Professor Bernhard Moser for his valuable input into my research.  I am grateful 
to all my group members for their continual counsel and enthusiasm.  
 
Many thanks to all my PhD colleagues and staff at the Institute of Infection & Immunity, 
Henry Wellcome Building, Cardiff University. Thanks to Professor Maurice Hallet and staff 
at the postgraduate research degrees office, School of Medicine, Cardiff University, for their 
friendly continued help, advice and support.  I am also grateful to: Gareth Williams, Marco-
Domenico Caversaccio and Bernd Werle for providing human tissue samples; staff at the 
outpatients department at University Hospital of Wales, Heath Park, Cardiff, especially 
Leslie Bryant for being so helpful and efficient in organising human tissue samples; Hassan 
Jomaa for providing HMB-PP; Donald Foster for IL-21; Martin Lipp for CCR7 antibodies; 
Charles R. Mackay for IL-21R antibodies; Janet Fisher and Chris Pepper for cell sorting; 
Simone Meuter for help with immunofluorescence microscopy; Chan-Yu Lin for peritoneal 
data.  A special thankyou goes to all the volunteers and patients that generously donated 
their blood and tissue. 
 
I remain grateful to the Medical Research Council for funding me throughout my PhD. 
 
Much gratitude and affection to my family and friends for their unreserved love, patience, 
understanding and for keeping me sane.  A special thanks to my mum, Narinder and Nikki, 




Vγ9Vδ2 T cells are a minor subset of T cells in human blood that differ from all other 
lymphocytes by their specific responsiveness to (E)-4-hydroxy-3-methyl-but-2-enyl 
pyrophosphate (HMB-PP), a metabolite produced by a large range of microbial pathogens.  
Vγ9Vδ2 T cells can be skewed towards distinct effector functions, in analogy to, and 
beyond, the emerging plasticity of CD4+ T cells.  Depending on the microenvironment, 
Vγ9Vδ2 T cells can assume features reminiscent of Th1, Th2, Th17 and Treg cells as well 
as professional antigen presenting cells (APCs).  The main focus of this PhD was to 
investigate the role of the follicular B helper T (Tfh) cell derived cytokine IL-21 in 
enhancing the ability of human Vγ9Vδ2 T cells in providing B cell help. 
 
In order to try to mimic the physiological conditions in the GC, an in vitro system of 
autologous Vγ9Vδ2 T cells and B cells from tonsils or blood, the microbial metabolite 
HMB-PP and IL-21 was used.  HMB-PP induced up-regulation of IL-21 receptor on 
Vγ9Vδ2 T cells.  In return, IL-21 played a co-stimulatory role in the expression of the B 
cell-attracting chemokine CXCL13, the CXCL13 receptor CXCR5, the co-stimulatory 
molecules inducible co-stimulator (ICOS), OX40 and CD70 by activated Vγ9Vδ2 T cells.  
IL-21 also enhanced the ability of activated Vγ9Vδ2 T cells to support antibody production 
by B cells.  Furthermore, Vγ9Vδ2 T cells not only themselves became highly activated APC 
marker expressing cells but also modified activation and APC marker expression on B cells. 
 
Findings presented in this thesis provide evidence that IL-21 contributes to the acquisition 
of B cell helper functions by human Vγ9Vδ2 T cells.  In secondary lymphoid tissues, the 
interaction between HMB-PP-responsive Vγ9Vδ2 T cells, IL-21-producing Tfh cells and B 
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OX40L  OX40 ligand 
PAMPs  Pathogen-associated molecular patterns 
PB  Pacific Blue 
PBMCs Peripheral blood mononuclear cells  
PBS   Phosphate buffered saline 
PD1  Programmed death 1  




Pe   Phycoerythrin  
PeCy5  Phycoerythrin-Cy5 
PeCy7   Phycoerythrin-Cy7  
PerCp-Cy5.5  Peridinin Chlorophyll Protein Complex-Cy5.5  
PHA  Phytohaemagglutinin 
PI3K   Phosphatidylinositol 3-kinase 
PKC   Protein kinase C 
PMA   Phorbol myristate acetate 
PNA   Peanut agglutinin  
PRRs   Pattern recognition receptors 
Rad  Radiation absorbed dose 
RLRs   RIG-I like receptors 
RORγt  Retinoid-related orphan receptor γt 
RPMI   RPMI-1640 media 
RT  Room temperature 
SAC   Staphylococcus aureus Cowan strain 1 
SAP  Signalling lymphocytic activation molecule (SLAM)-associated protein 
SCID   Severe combined immunodeficiency 
SD  Standard deviation 
SEM  Standard error of the mean  
SHM   Somatic hypermutation 
sIgA   Secretary IgA 
SLAM  Signalling lymphocytic activation molecule 
SLP-76 SH2-containing leukocyte protein 76 kd 
SSC  Side scatter 
STAT  Signal transducer and activator of transcription 
TAP   Transporter associated protein 
TCM   T central memory  
TCR   T cell receptor 
TD   T cell dependent 
TEM   T effector memory  
TEMRA  Terminally differentiated effector  
Tfh    Follicular B helper T cell 
TGF-β  Transforming growth factor-beta 
Th   T helper 
TI   T cell independent 
TLR   Toll-like receptor 
TNF   Tumour necrosis factor 
TNFR   Tumour necrosis factor receptor  
TNF-α  Tumour necrosis factor-alpha 
Treg  T regulatory 
ULBPs  UL16-binding proteins  
V   Variable 
ZAP-70 Zeta-associated protein 70 kd 
α-GalCer  α-galactosylceramide 
αβ  Alphabeta 












The body’s immune system has evolved to protect the host from a large array of infectious 
pathogens.  The ability to recognise, respond and eliminate many non-self (foreign) 
substances while remaining tolerant to the body’s own self-molecules is important.  Failure 
in maintaining self-tolerance can manifest as autoimmunity (Abbas et al. 2007; 
Manicassamy and Pulendran 2011).  The immune response relies on the complex 
interactions between organs, tissues, cells and molecules (Abbas et al. 2007; Chaplin 2010; 
Moser and Leo 2010).  In vertebrates, the immune response is divided into two major 
branches called innate (or natural) and adaptive (or acquired) immunity.  These divisions are 
not mutually exclusive, as an effective immune response requires the coordinated action of 




The innate immune system uses non-specific defence mechanisms that pre-exist in all 
individuals to protect the host from infection or disease.  These innate defence mechanisms 
act within minutes of infection and provide the initial response of rapid sensing and 
elimination of pathogens.  Innate immunity can be seen to comprise four types of defensive 
barriers: anatomical, physiological, phagocytic and inflammatory (Abbas et al. 2007; 
Bonilla and Oettgen 2010; Janeway et al. 2001). 
 
Anatomical barriers include intact skin and mucous membranes.  Physiological barriers 
include temperature, pH and soluble factors (lysozyme, interferons, complement proteins, 
collectins) (Abbas et al. 2007; Murphy et al. 2008; Turvey and Broide 2010).  Phagocytic 
cells such as neutrophils, monocytes, macrophages and dendritic cells (DCs) rapidly 




pathogenic microbes by the process of phagocytosis (Abbas et al. 2007; Chaplin 2010).  
Other cellular components of innate immunity include natural killer (NK) cells, eosinophils, 
basophils, mast cells, natural killer T (NKT) cells, γδ T cells, CD8αα T cells, B1 B cells and 
marginal zone (MZ) B cells (Abbas et al. 2007; Borghesi and Milcarek 2007; Mogensen 
2009; Turvey and Broide 2010).  Many of these cell populations are also involved in 
adaptive immunity, thus link innate and adaptive immune responses (Abbas et al. 2007; 
Borghesi and Milcarek 2007).  
 
Components of innate immunity recognise pathogens using germ line-encoded pattern 
recognition receptors (PRRs).  PRRs are expressed on the surface or inside various cell 
types and are also present as circulating soluble proteins (Abbas et al. 2007).  Examples of 
PRRs include Toll-like receptors (TLRs), C-type lectin receptors (CLRs), RIG-I like 
receptors (RLRs), and NOD-like receptors (NLRs) (Janeway and Medzhitov 2002; 
Manicassamy and Pulendran 2011).  PRRs recognise and bind to a limited range of common 
pathogenic structures termed pathogen-associated molecular patterns (PAMPs), which are 
shared by a broad range of microbes (but not present on mammalian cells).  PAMPs are 
unique structures essentially required for the survival of microbial organisms.  Some 
examples of PAMPs include lipopolysaccharide (LPS) from Gram-negative cell wall of 
bacteria, lipotechoic acids from the Gram-positive cell wall of bacteria, bacterial and viral 
DNA, and viral RNA (Abbas et al. 2007; Bonilla and Oettgen 2010; Janeway 1989; 
Janeway and Medzhitov 2002; Mogensen 2009).  
 
Within minutes of infection or tissue damage a local response called inflammation is 
induced.  The inflammatory response attempts to rapidly eliminate toxic agents and repair 
injury, thus preventing spread of infection to other organs.  Inflammation results in leakage 
of vascular fluid containing serum proteins with antibacterial activity, influx of phagocytic 
cells, and release of small signalling proteins called cytokines and chemokines, as well as 
other inflammatory mediators into the tissue site of infection (Abbas et al. 2007; Janeway et 





Cytokines are a large group of low molecular weight signalling proteins produced by a wide 
variety of immune and non-immune cells.  Most cytokines act on the cell type that produced 
the cytokine (autocrine) or on nearby cells (paracrine).  Some cytokines can exert activities 
at sites distant from their synthesis, thus act in an endocrine manner (Janeway et al. 2001).  
Cytokines evoke a series of biological activities after binding to specific cytokine receptors 
on responsive target cells.  Cytokines such as interleukins (ILs) and interferons (IFNs) act 
primarily as chemical messengers that influence the development of a cellular and humoral 
immune inflammatory response, as well as survival, proliferation, differentiation and 
homeostasis of lymphoid cells (Habib et al. 2003; Monteleone et al. 2009; Søndergaard and 
Skak 2009). 
 
Tissue resident macrophages, which have matured from blood monocytes migrating into 
tissue, are the first to encounter pathogens.  Binding of pathogen by PRRs on macrophages 
induces secretion of a range of cytokines that mediate the inflammatory response.  Among 
the cytokines released include a family of chemokines, these target all types of leukocytes 
and are produced by a wide variety of cell types (Janeway et al. 2001; Moser 2003).  
Chemokines play important roles in leukocyte traffic control in both inflammatory and 
homeostatic conditions (Moser et al. 2004).  The major function of chemokines is to act as a 
chemoattractant for guiding leukocyte migration in and out of specific organs/tissue sites 
(Moser 2003).  Leukocytes expressing the appropriate chemokine receptors are attracted 
towards the source of the chemokine and follow a gradient of increasing chemokine 
concentration.  For example, during the inflammatory response macrophages secrete the 
inflammatory chemokine IL-8 (also known as CXCL8), this attracts neutrophils (expressing 
the receptors for IL-8) towards the source of IL-8, and as a result neutrophils are recruited 
from the blood to the tissue site of infection.  Similarly, secretion of the chemokine 
macrophage chemoattractant protein-1 (MCP-1; CCL2) recruits more monocytes, which 
differentiate into tissue macrophages (Janeway et al. 2001; Moser 2003; Moser and 
Willimann 2004).  In contrast, homeostatic chemokines regulate leukocyte migration during 
hematopoiesis (in the bone marrow and thymus) and during initiation of adaptive immune 





Recruitment of leukocytes from the blood vessels to tissue (termed extravasation) not only 
depends on the recognition of a chemoattractant gradient but also on their adhesive 
interaction with the extracellular matrix (Moser 2003; Moser and Willimann 2004).  During 
extravasation, circulating leukocytes adhere reversibly to the vessel wall; this allows them 
to roll along the endothelium.  Chemokine receptor triggering arrests rolling and allows 
leukocytes to be firmly attached to vessel walls through the actions of integrins.  This 
enables leukocytes to transmigrate through the endothelial barrier and enter tissue sites 
(Bromley et al. 2008; Förster et al. 2008; Moser and Willimann 2004).  During the 
inflammatory response this allows circulating phagocytes to encounter an infecting 
microorganism (Janeway et al. 2001). 
 
When a pathogen resists, escapes or overwhelms the defence mechanisms of the innate 
immune system the more powerful adaptive immune system is triggered.  The type of 
adaptive immune response triggered is influenced by the innate response and depends on the 
type of microbe (i.e. bacteria or virus) involved (Abbas et al. 2007; Luster 2002).   Several 
days are required for an adaptive immune response to develop, during this time the innate 




The adaptive immune system is unique to jawed vertebrates and provides the second line of 
defence, which can take several days to develop and mount.  The initial-primary response is 
slow but improves (more rapid and powerful) upon repeated exposures to the same 
pathogen.  Two major hall-marks of adaptive immunity are the ability to mount antigen 
specific responses and the formation of immunological memory during a primary response 





Generation of an effective adaptive immune response relies on antigen presenting cells 
(APCs), lymphocytes, effector molecules (cytokines and chemokines) and the anatomic 
organisation of cells, lymphoid tissues and organs (Abbas et al. 2007; Bonilla and Oettgen 
2010; Moser and Leo 2010).  The main mediators of the adaptive immune response are T 
lymphocytes (T cells) and B lymphocytes (B cells).  Both cell types arise from common 
lymphoid progenitor cells within the bone marrow.  Precursor T cells migrate to and mature 
in the thymus whilst precursor B cells continue to mature in the bone marrow (Abbas et al. 
2007; Chaplin 2010) (Figure 1.1).   
 
T and B cell maturation involves generation of highly diverse T cell receptors (TCRs) and B 
cell receptors (BCRs), that are capable of recognising an infinite number of microbial and 
non-microbial foreign substances called antigens.  During generation of antigen receptors 
lymphocytes undergo a process of positive and negative selection, ensuring that only self 
tolerant T cells and B cells emerge.  The vast majority of lymphocytes that recognise self 
antigens is eliminated by a process called clonal deletion (Abbas et al. 2007; Manicassamy 
and Pulendran 2011; Murphy et al. 2008). 
 
Diversity of T and B cell receptors is generated by random genetic rearrangements and 
mutation of a germline set of sequences that encode variable (V), diversity (D) and joining 
(J) regions.  As a consequence each lymphocyte expresses a unique antigen receptor.  This 
process known as V(D)J recombination or gene rearrangement creates a diverse repertoire 
(in the order of >1014) of antigen specific receptors.  Newly generated T and B lymphocytes 
expressing antigen specific receptors exit the primary lymphoid organs and enter the 
periphery as mature but antigen-naive cells (Abbas et al. 2007; Alam and Gorska 2003; 


























Figure 1.1. Primary and secondary lymphoid organs.  
The primary lymphoid organs (thymus and the bone marrow) are sites where lymphocytes 
are generated and differentiate into mature naïve lymphocytes.  Secondary lymphoid organs 
are the tissues in which immune responses are initiated, i.e., tonsils, adenoids and lymph 
nodes scattered throughout the body; bronchial area (lungs), spleen, gastrointestinal area 





The percentage of antigen-specific lymphocytes in peripheral blood is very low (<0.001%) 
(Alam and Gorska 2003).  To increase the chances of encountering specific antigen, resting 
naïve T and B lymphocytes continually recirculate between blood and secondary lymphoid 
organs (Figure 1.1).  Whilst trafficking through the lymph nodes and spleen, lymphocytes 
get exposed to antigens collected by the lymph or blood, respectively (Abbas et al. 2007; 
Bonilla and Oettgen 2010).  Recognition of antigen by a naïve lymphocyte specific for the 
antigen leads to cell activation and proliferation resulting in clonal expansion of 
lymphocytes expressing receptors of the same specificity, in a process called clonal 
selection.  This process allows many clones of lymphocytes with different antigen 
specificities to be generated (Abbas et al. 2007; Sadofsky 2001). 
 
Stimulation by specific antigen induces naïve lymphocytes to differentiate into effector 
cells, followed by the generation of a pool of memory cells.  Antigen specific effector T 
cells undergo clonal expansion to eliminate pathogen.  After clearance of infection, the 
majority of effector cells are removed by apoptosis restoring the immune system to its 
resting basal state.  However, a small proportion of effector cells are retained as long-lived 
memory cells, which remain present for many years in a functionally quiescent state in the 
absence of antigen.  In contrast to naïve cells, memory cells develop a higher affinity for 
antigen and require a lower threshold for activation.  Thus, upon re-encounter with the same 
antigen during secondary immune responses, memory cells are able to respond more rapidly 
and effectively in eliminating the pathogen (Abbas et al. 2007; Appay et al. 2008; 
Boesteanu and Katsikis 2009; Moser and Leo 2010; Sallusto and Lanzavecchia 2009; 
Sallusto et al. 1999).  T and B cell antigen receptors recognise antigen in very different 
ways and each cell type plays unique roles in adaptive immunity.  T lymphocytes mediate 
the cellular response whilst B lymphocytes mediate the humoral response of adaptive 








Distinct populations of leukocyte subsets can be identified based on surface expression of 
membrane proteins.  Cell membrane proteins (also referred to as markers, molecules or 
antigens) are detected by their binding of specific monoclonal antibodies and are assigned 
cluster of differentiation (CD) numbers (Abbas et al. 2007; Chaplin 2010).  CD3 is a surface 
molecule non-covalently linked to the T cell receptor (TCR) and is commonly used to 
identify T cells (Bonilla and Oettgen 2010; Wang et al. 2009; Yang et al. 2005).   
 
Two types of functionally distinct T lymphocytes exist based on the type of TCR expressed.  
T cells either bear heterodimeric, transmembrane glycoprotein TCR comprised of disulfide-
bonded α and β polypeptide chains (αβ T cells) or of γ and δ polypeptide chains (γδ T cells) 
(Ciofani and Zúñiga-Pflücker 2010; O'Brien et al. 2007; Yang et al. 2005).  In human adults 
the peripheral T lymphocyte population is composed of approximately 95% of αβ T cells 
and 0.5 to 5% of γδ T cells (Chaplin 2010; Hayday 2000).  During maturation in the thymus 
αβ T cells differentiate into two major subpopulations based on selective surface expression 
of CD4 or CD8 membrane proteins, known as CD4+ T cells and CD8+ T cells (Chaplin 
2010). 
 
Encounter with specific antigen stimulates naïve CD4+ and CD8+ αβ T cells to clonally 
expand and differentiate into cells with effector functions.  Effector CD4+ T cells are known 
as T helper (Th) lymphocytes and effector CD8+ T cells as cytotoxic T lymphocytes 
(CTLs).  Each subset plays distinct functional roles in host defence (Chaplin 2010; Rock 
and Shen 2005).  CD8+ CTLs primarily kill tumour/transformed or pathogen infected cells 
by inducing cell apoptosis through secretion of effector proteins such as perforin, 




orchestrate different arms of the immune response, including helping B cells make antibody 
as well as recruiting a large array of cell types to sites of infection (Bedoui and Gebhardt 




CD4+ and CD8+ αβ T cells recognise foreign antigen via their TCR in the form of peptide 
fragments only if presented in association with specialised molecules called major 
histocompatibility complex (MHC) (Chaplin 2010).  MHC molecules also known as human 
leukocyte antigens (HLA) are composed of an extracellular peptide binding groove attached 
to immunoglobulin like domains and transmembrane and cytoplasmic domains (Abbas et al. 
2007).  There are 2 major types of MHC molecules which differ in structure, expression, 
and function.  MHC class I molecules (HLA-A, HLA-B, and HLA-C) expressed by all 
nucleated cells are restricted to presenting peptides only to CD8+ T cells.  MHC class II 
molecules (HLA-DR, HLA-DQ, and HLA-DP) expressed predominantly by APCs (DCs, 
macrophages and B cells) can only present peptides to CD4+ T cells (Alam and Gorska 
2003; Bonilla and Oettgen 2010; Chaplin 2010).  CD4 and CD8 co-receptors on T cells 
interact with non-polymorphic regions of class II and class I MHC molecules, respectively 
and are essential for recognition of the MHC antigen complex (Abbas et al. 2007; Medema 
and Borst 1999).  The MHC groove can only bind short linear peptides, thus antigen must 
be processed before it can be bound to MHC molecules (Alam and Gorska 2003; Chang et 
al. 2006; Moser and Leo 2010).  Each class of MHC samples different pools of antigen, 
which are processed and presented using distinct pathways.   
 
1.2.2.1 MHC class I pathway 
MHC class I molecules bind and present endogenously synthesised viral and mutated 
proteins as well as normal intracellular proteins.  CTLs are activated in response to viral and 




but not in response to normal cellular proteins (Abbas et al. 2007; Alam and Gorska 2003).  
MHC class I associated peptides are produced by the proteolytic degradation of cytosolic 
proteins by an enzyme complex found in the cytoplasm called the proteasome.  The 
transporter associated protein (TAP) transports peptides from the cytosol to the endoplasmic 
reticulum (ER), inside the ER peptides are bound to newly synthesised class I molecules.  
The peptide-MHC class I complex is transported to the cell surface for presentation to 
cytotoxic CD8+ T cells (Abbas et al. 2007; Rock and Shen 2005). 
 
1.2.2.2 MHC class II pathway 
In contrast, MHC class II bind and present antigens from the extracellular environment 
which have been internalised by APCs using phagocytosis/and or endocytosis.  APCs found 
in tissues throughout the body actively sample and internalise extracellular components 
such as microbial pathogens, dead or dying cells and immune complexes (Rossi and Young 
2005).  Internalised protein antigens get localised inside intracellular membrane bound 
vesicles called endosomes and lysosomes, which contain enzymes that degrade proteins into 
small peptides.  MHC class II molecules associated with a protein called the invariant chain 
are transported out from the ER in exocytic vesicles.  Endosomes containing processed 
peptides fuse with vesicles transporting MHC class II molecules.  The invariant chain 
occupying the MHC peptide-binding groove is exchanged for antigenic peptides (Abbas et 
al. 2007).  The peptide-MHC class II complex is transported to the cell surface for 
presentation to helper CD4+ T cells.  Mature DCs express high levels of MHC and co-
stimulatory molecules thus are the most potent APCs for stimulation of naïve T cells.  
Macrophages and B cells present antigen to differentiated effector and helper T cells (Abbas 
et al. 2007; Bedoui and Gebhardt 2011; Lewinsohn et al. 2011). 
 
1.2.2.3 Cross‐presentation 
The MHC class I and II antigen-processing and presenting pathways are not entirely 
exclusive.  Studies have shown ingested extracellular proteins to escape from endosomal 




feature enables APCs to present extracellularly obtained microbial proteins or tumour 
antigens to CTLs and elicit a response towards infected tissue and tumour cells, 
respectively.  This phenomenon is known as ‘cross-presentation’ and is generally restricted 
to specialised APCs such as DCs (Segura et al. 2009), and more recently has been 
demonstrated in γδ T cells (Brandes et al. 2009; Brandes et al. 2005; Himoudi et al. 2012; 
Landmeier et al. 2009; Meuter et al. 2010; Moser and Eberl 2011; Wu et al. 2009).  Equally, 
endogenous proteins from the cytosol can be presented in association with MHC class II 
proteins, however, such processes are yet ill-defined (Chaplin 2010; Moser and Leo 2010). 
 
1.2.2.4 CD1 antigen presenting pathway 
A third type of antigen presenting pathway involves the presentation of both foreign and 
self-derived lipid antigens by a MHC-like molecule called cluster of differentiation 1 
(CD1).  CD1 glycoproteins are a family of antigen presenting molecules which are 
expressed on the surface of a variety of APCs.  Similar to extracellular proteins, lipids are 
processed in endosomes and lysosomal compartments and presented to the TCR of CD1-
restricted T cells (Alam and Gorska 2003; Brigl and Brenner 2004; Gumperz 2006; Lawton 
and Kronenberg 2004; Sugita et al. 2004).  For example, NKT cells recognise CD1d-
presented natural self or microbial glycolipids as well as a range of synthetic 
glycosylceramides.  The synthetic antigen α-galactosylceramide (α-GalCer) is known to 
selectively activate NKT cells in the context of CD1d molecules (Borg et al. 2007; Cohen et 




The activation of lymphocytes is a carefully controlled event, which allows inactive cells to 
progress from G0 into G1 phase of the cell cycle.  T cell activation and survival requires 
sustained signalling from both the antigen specific TCR and from co-stimulatory molecules 





The αβ chains of the TCR are non-covalently linked with transmembrane CD3 signalling 
chains consisting of γ, δ, ε and a ζ-ζ homodimer.  Interaction of TCR/CD3 complex and 
CD4/CD8 molecules with MHC-bound antigenic peptide provides only a partial signal for T 
cell activation.  Complete and productive activation requires a second signal, which is 
referred to as co-stimulation and is provided by trans-membrane protein molecules called 
co-stimulators (Bonilla and Oettgen 2010; Chaplin 2010).  Protein expression of surface co-
stimulatory molecules is tightly regulated by negative (co-inhibitory) signals to avoid 
unnecessary lymphocyte activation and autoimmunity (Daoussis et al. 2004; Fife and 
Pauken 2011). 
 
A growing list of cell-associated receptor/ligand pair co-stimulatory molecules exist, which 
provide positive co-stimulatory signals (Leitner et al. 2010).  The majority of co-stimulatory 
molecules belong to one of four superfamilies based on their structural characteristics.  
These include the B7 and tumour necrosis factor (TNF) superfamily members, which 
interact with the CD28 and TNF receptor (TNFR) superfamily members, respectively 
(Frauwirth and Thompson 2002; Leitner et al. 2010; Ribot et al. 2011; Sharpe 2009). 
 
1.2.3.1 Co‐stimulation via CD28 
Full activation of naive T cells is dependent on co-stimulation provided via the T cell 
surface receptor CD28, which is constitutively expressed on resting naïve and newly 
activated αβ T cells (Boesteanu and Katsikis 2009; Chaplin 2010; Rudd et al. 2009; Sansom 
et al. 2003).  B7.1 (CD80) and B7.2 (CD86) expressed on the surface of APCs are the 
ligands for CD28; both are up-regulated following APC activation (Abbas et al. 2007; 
Bhatia et al. 2006; Moser and Leo 2010; Sansom et al. 2003).  During initial antigen 
priming of naive T cells, engagement of CD28 receptor on T cells by CD80 or CD86 on 
DCs delivers signals necessary for optimal T cell activation (Bhatia et al. 2006; Sansom et 
al. 2003).  Upon activation, signals delivered by the TCR and co-stimulatory molecules 




the IL-2 receptor (IL-2R).  Binding of IL-2 to its receptor drives the T cell to enter the cell 
cycle inducing cell survival and proliferation (Létourneau et al. 2009; Murphy et al. 2008).  
Conversely, interaction of peptide-MHC with the TCR in the absence of co-stimulation 
induces a state of T cell non-responsiveness called anergy or cell death.  However, memory 
and effector T cells are less dependent on CD28:CD80/86 co-stimulation (Bjørgo and 
Taskén 2010; Chaplin 2010; Frauwirth and Thompson 2002; Schwartz 2003). 
 
1.2.3.2 Delivery of co‐inhibitory signals via CTLA‐4 
The activating effects of CD28 are counterbalanced by co-inhibitory signals delivered by 
structurally similar molecule called cytotoxic T lymphocyte antigen-4 (CTLA-4 or CD152).  
Surface expression of CTLA-4 is only induced on T cells in response to the co-stimulatory 
signals delivered by CD28 (Bhatia et al. 2006; Leitner et al. 2010).  CTLA-4 expressed on 
activated T cells binds to CD80/86 molecules with much higher affinity in comparison to 
CD28 (Sansom et al. 2003).  Engagement of CTLA-4 with CD80/86 inhibits T cell 
activation, cell cycle progression and IL-2 production, thus counteracting the effects of 




T cell activation requires sustained TCR signalling which can only be achieved through 
hours of stable contact between the APC and T cell (Dustin et al. 2010).  Antigen 
recognition by the TCR supported by co-stimulatory molecules, leads to rapid clustering of 
TCR and associated molecules (i.e. CD3 chains, CD4 or CD8 and CD28) at the contact zone 
between the T cell and APC (Bonilla and Oettgen 2010).  This results in the formation of a 
junction between the two cells called the immunologic synapse, which is stabilised by 
adhesion molecules such as lymphocyte function associated antigen-1 (LFA-1) and 
intercellular adhesion molecule-1 (ICAM-1) (Krummel and Cahalan 2010).  During the 




ligands on the APC, this brings the cytosolic domains of these molecules into proximity 
(Alam and Gorska 2003; Bonilla and Oettgen 2010). 
 
TCR signalling is initiated by enzymes known as tyrosine kinases (i.e. Lck, Fyn and ZAP-
70), which attach phosphate groups to certain tyrosine residues on proteins converting them 
into an active state.  The αβ chains of the TCR are devoid of enzymatic activity.  Signals 
from the TCR are transmitted via associated CD3 (γ, δ, ε) and ζ signalling chains which 
contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic 
domains (Abbas et al. 2007; Chaplin 2010; Rodríguez-Fernández et al. 2010).  Upon 
clustering of TCR and co-receptors, Lck (or Fyn) associated with the cytoplasmic domain of 
CD4 or CD8 molecule becomes activated and phosphorylates the tyrosines in the ITAMs of 
the CD3 and ζ chains.  This recruits ζ-associated protein 70 kd (ZAP-70), which docks on to 
the phosphorylated ITAM and becomes activated upon Lck-mediated phosphorylation 
(Abbas et al. 2007; Chaplin 2010).  Activated ZAP-70 in turn phosphorylates adapter 
proteins such as linker of activated T cells (LAT) and SH2-containing leukocyte protein 76 
kd (SLP-76) (Abbas et al. 2007; Bonilla and Oettgen 2010; Chaplin 2010).  As a result 
distinct downstream signalling pathways are initiated, such as: Ras-MAP (mitogen 
associated protein), protein kinase C (PKC) and Calcium-Calcineurin pathways (Abbas et 
al. 2007).  Activation of these pathways induces activation of NFκB, NFAT and AP-1 
transcription factors, which control the expression of genes that encode IL-2, cyclins and 
Bcl-2 family members (Abbas et al. 2007; Ribot et al. 2011). 
 
Simultaneous to TCR signalling, engagement of CD28 by CD80 or CD86 molecules 
triggers a cascade of signalling events downstream of CD28.  These signalling events 
enhance TCR signalling leading to optimal activation of transcription factors, allowing 
complete T cell activation to proceed (Bjørgo and Taskén 2010; Boomer and Green 2010).  
Synergistic signalling via TCR and CD28 promotes T cell survival (by inducing expression 
of anti-apoptotic proteins), production of growth factors/interleukins (most significantly IL-
2), cell-cycle progression, proliferation and differentiation (Bonilla and Oettgen 2010; 






CD4+ T cells exert most of their effector functions through secreted cytokines.  Naïve CD4+ 
T cells abundantly produce the cytokine IL-2 and upon encounter with antigen have the 
capacity of developing into one of many functionally distinct effector subsets.  Some of the 
major types of CD4+ T cell subsets include: Th1, Th2, Th17, T regulatory (Treg), follicular 
B helper T (Tfh) cells and the more recently discovered, Th9 and Th22.  CD4+ T cell 
subsets are categorised based on the types of cytokines produced, transcription factors and 
cell surface molecules expressed.  Differentiation into a particular subset is determined by 
the pattern of cytokines present in the microenvironment at the time of T cell activation 
(Chaplin 2010; Deenick et al. 2011; Li et al. 2011; Sallusto and Lanzavecchia 2009; Zhu et 
al. 2010) (Figure 1.2). 
 
IL-12 and interferon-γ (IFN-γ) up-regulate expression of the intracellular molecules signal 
transducer and activator of transcription (STAT) 1 and STAT4, which in turn stimulate 
expression of the transcription factor T-bet (also denoted as T-box 21; TBX21), this 
selectively polarises cells toward the Th1 cell differentiation program.  Th1 cells produce 
the inflammatory cytokines IFN-γ and TNF-α, as well as lymphotoxin and IL-2 (Chaplin 
2010; Li et al. 2011; Sallusto and Lanzavecchia 2009; Zhu et al. 2010).  
 
IL-4 up-regulates expression of the transcription factors STAT 6 which in turn stimulates 
expression of the transcription factor GATA binding protein 3 (GATA-3), this promotes 
Th2 cell differentiation.  Th2 cells produce a wide range of cytokines including IL-4, IL-5, 
IL-9, IL-10, IL-13, IL-25 and granulocyte macrophage-colony stimulating factor (GM-
CSF).  Th1 secreted cytokines inhibit Th2 mediated reactions and Th2 secreted cytokines 
inhibit Th1 mediated reactions.  IL-2 and IL-4 act as autocrine growth factors on Th1 and 
Th2 cells, respectively (Abbas et al. 2007; Bonilla and Oettgen 2010; Chaplin 2010; 





Figure 1.2. CD4+ T helper subsets.  
Differentiation of naïve CD4+ T cells into effector subsets is regulated by cytokines and 
transcription factors.  Each subset can be uniquely identified based on the set of ‘canonical’ 
cytokines produced, which allows cells to perform specific functions; (h): human; (m): 





The different cytokines secreted reflect the different biological functions of a subset.  The 
main function of Th1 cells is to enhance phagocyte-mediated defence against intracellular 
microbes.  Th1 secreted cytokines act on macrophages, neutrophils, B cells and NK cells.  
The main function of Th2 cells is to promote IgE and eosinophil/mast cell mediated immune 
reactions in response to extracellular parasites and allergens.  IL-4 secreted by Th2 cells can 
act on B cells to stimulate production of IgG and IgE antibodies (Abbas et al. 2007; King et 
al. 2008; Sallusto and Lanzavecchia 2009).  IL-4 producing Th2 cells have long been 
viewed as the main subset that supports B cell antibody production.  Recently, a bona fide 
subset of CD4+ T cells expressing the CXC-chemokine receptor 5 (CXCR5) termed 
Follicular B helper T (Tfh) cells have been established as a subset distinct from Th2 or Th1 
cells (Moser et al. 2002; Schaerli et al. 2001; Schaerli et al. 2000).  Tfh cells are now known 
as true helper cells for B cells (Crotty 2011; Haynes 2008; King 2009; King et al. 2008).  
Tfh cells are discussed in further detail later in this chapter. 
 
A third effector T helper cell subset called Th17 cells, are characterised by the production of 
IL-17A, IL-17F and IL-22.  Th17 cells also secrete IL-21 which feeds back on developing 
Th17 cells.  These cells do not express GATA3 or T-bet but express high levels of the 
transcription factors retinoid-related orphan receptor γt (RORγt), which is induced by 
transforming growth factor-β (TGF-β) together with IL-6, IL-1, or other pro-inflammatory 
cytokines.  Th17 cells play an important role in the clearance of pathogens such as 
extracellular bacteria and fungi and induce tissue inflammation in various autoimmune 
diseases (Annunziato and Romagnani 2009; Bonilla and Oettgen 2010; Chaplin 2010; Korn 
et al. 2009; Sallusto et al. 2004; Sallusto and Lanzavecchia 2009; Zhu et al. 2010).  
 
More recently identified effector T helper cell subsets include Th9 and Th22 cells.  Th9 
cells selectively secrete high amounts of IL-9 and express the transcription factor PU.1 
which is required for Th9 cell development.  Differentiation of activated CD4+ T cells into 
Th9 cells requires balanced signals from both TGF-β and IL-4.  The precise 
pathophysiological role of Th9 cells remains unclear, evidence suggests Th9 cells to  
contribute to inflammation in several autoimmune diseases (Annunziato and Romagnani 




2012).  Th22 cells express high levels of aryl hydrocarbon receptor (AHR) and IL-22. 
Differentiation of Th22 cells is dependent upon the presence of both IL-6 and TNF-α. Th22 
cells are thought to be involved in wound healing, tissue re-modelling and skin homeostasis 
(Annunziato and Romagnani 2009; Deenick et al. 2011; Witte et al. 2010).  
 
Briefly, Tregs, defined as CD4+ T cells that constitutively express IL-2Rα (also known as 
CD25) and the transcription factor forkhead box protein P3 (FOXP3), play an indispensable 




Following clearance of infection the majority of effector T cells are removed by apoptosis, 
while a small fraction is retained as antigen primed circulating memory cells.  Memory T 
cells are further divided into central memory (TCM) and effector memory (TEM) subsets.  
This division is defined based on the expression of homing receptors and effector functions.  
Similar to naïve T cells, TCM cells co-express lymph node homing receptor CC-chemokine 
receptor 7 (CCR7) and adhesion receptor L-selectin (CD62L), but lack immediate effector 
functions (Moser and Loetscher 2001; Rosen 2004; Sallusto et al. 1999).  In contrast, TEM 
cells do not express lymph node homing receptors but express other homing receptors 
which allow migration to peripheral tissues (i.e. skin and the gut).  TEM cells can rapidly 
display effector functions such as cytokine secretion and cytotoxicity (Boyman et al. 2009; 
Moser and Loetscher 2001; Sallusto et al. 2004; Sallusto and Lanzavecchia 2009). 
 
Naive, TCM, TEM and terminally-differentiated effector T cells (TEMRA) subsets are 
commonly distinguished based on the differential expression of cell surface molecules 
CD45RA (or CD45RO), CCR7, CD27, CD62L and CD28 (Appay et al. 2008; Moser and 
Loetscher 2001; Sallusto et al. 2004; Sallusto and Lanzavecchia 2009).  However, 




re-stimulation, differentiating TCM cells lose CCR7, while TEM transiently up-regulate CCR7 







Immunoglobulins (Igs) are a primary product of B lymphocytes and plasma cells (Bonilla 
and Oettgen 2010; Vale and Schroeder 2010).  Immunoglobulins exist either as surface 
BCR anchored in the membrane of B cells, or as circulating effector molecules (antibodies) 
secreted by plasma cells within lymph nodes, spleen and bone marrow.  Secreted antibodies 
circulate in blood, mucosal secretions and in the interstitial fluid of tissues (Abbas et al. 
2007; Schroeder and Cavacini 2010). 
 
The basic structure of an antibody molecule is composed of four polypeptide chains (two 
identical heavy chains and two identical smaller light chains) linked by disulfide bonds.  
Each of the four chains contains one NH2-terminal variable and one or more COOH-
terminal constant regions (domains).  There are two types of light chain, lambda (λ) and 
kappa (κ); a B cell will produce antibodies either expressing Igλ or Igκ, but not both.  The 
variable domains of both the heavy and light chains contain 3 hypervariable regions also 
known as complementarity determining regions (CDRs) that are brought together to form an 
antigen-binding site (containing 6 CDR regions), which contribute to the diversity of the 
antibody molecules.  Thus, two identical antigen-binding sites are formed for each antibody 





Elimination of bound antigen requires the interaction of antibody with effector cells and 
proteins.  Two heavy chains containing two to three constant domains pair to form the Fc 
fragment (Mix et al. 2006).  The Fc fragment binds to complement proteins and Fc receptors 
(FcR) on effector cells, such as mononuclear phagocytes, NK cells and mast cells (Abbas et 
al. 2007; Radaev and Sun 2002; Schroeder and Cavacini 2010).  This triggers several 
effector mechanisms such as: neutralisation of microbes and toxins, opsonisation (coating) 
of pathogens, activation of complement proteins, antibody-dependent cell-mediated 
cytotoxicity and immediate hypersensitivity (Abbas et al. 2007; Mix et al. 2006; Schroeder 
and Cavacini 2010) (Figure 1.3).   
 
Antibody molecules can be divided into distinct classes (or isotypes) and subclasses, based 
on the amino acid sequences in the constant region of the heavy chains.  The five major 
classes are IgM, IgD, IgG, IgA, and IgE which are denoted by the corresponding lower-case 
Greek letter (µ, δ, γ, α, and ε, respectively).  In humans IgG is further divided into four 
subclasses (IgG1, IgG2, IgG3 and IgG4) and IgA into two subclasses (IgA1 and IgA2).  In 
mice the IgG subclasses are known as IgG1, IgG2a, IgG2b and IgG3.  The different 
antibody isotypes and subtypes mediate different immune functions important for control of 
a diverse range of pathogens (Crotty 2011; Mix et al. 2006; Schroeder and Cavacini 2010). 
 
1.3.1.1 IgM 
IgM comprises approximately 10% of total serum Ig.  IgM is the first Ig to be expressed on 
the surface of developing B cells.  Low affinity IgM (or natural) antibodies are produced at 
the early stage of an antibody response.  Circulating molecules of IgM form pentamers (or 
hexamers) expressing many antigen-binding sites.  This makes IgM highly efficient at 
opsonising multivalent antigens such as bacterial capsular polysaccharides for destruction 
















C = Constant domain
V = Variable domain
H, L = Heavy, Light chains           
Fc, effector region















































With the longest serum half-life out of the five Ig isotypes, IgG makes up approximately 
75% of total serum Ig (Schroeder and Cavacini 2010).  High-affinity IgG antibodies are 
abundantly produced during secondary immune responses to both bacterial and viral 
infections.  IgG antibodies are predominantly found in the blood and extracellular fluid.  
IgG can diffuse into tissue, enter mucosal sites and be transported across the human 
placenta.  Some of the major functions of IgG include blocking entry of microbes into host 
cells, opsonisation of pathogens for engulfment by phagocytes, activation of the 
complement system and release of granule enzymes from neutrophils that can directly 
neutralise viruses.  IgG subclasses are numbered in order (IgG1 > IgG2 > IgG3 > IgG4) of 
their serum levels in healthy individuals and perform different biologic functions.  IgG1 and 
IgG3 antibodies bind to protein antigens, whereas IgG2 and IgG4 antibodies bind to 




IgA antibodies are major players in mucosal immunity.  In contrast to the low levels found 
in serum (15% of total Ig), IgA makes up two thirds of Igs found in extravascular secretions.  
As a monomer in serum, IgA is transported across the epithelium and released as a dimer 
(or trimer) at mucosal surfaces and in secretions (tears, saliva, breast milk, bronchial and 
digestive tract mucus).  Secretary IgA (sIgA) protects mucosal surface from commensal 
bacteria, toxins, viruses and bacteria by direct neutralisation or by inhibiting adherence to 
epithelial surface (Brandtzaeg 2007; McGhee et al. 2007; Schroeder and Cavacini 2010).  
IgA is mainly produced by activated B cells in mucosa-associated lymphoid tissue (MALT) 
such as the gut-associated lymphoid tissue (GALT) (i.e. Peyer’s patches, appendix and 
numerous isolated lymphoid follicles), lymphoepithelial structures such as palatine tonsils, 






Despite its very low concentration in serum (0.01% of total) and a short half-life of 
approximately 2 days, monomeric IgE functions as a very potent antibody.  IgE protects 
against parasitic infections and is involved in hypersensitivity and allergic reactions.  Serum 
concentration of IgE is found at low concentrations because the majority become rapidly 
bound to cell surface Fc receptors.  Antigen crosslinking of IgE bound to high affinity Fc 
receptors (FcεRI) on mast cells and basophils triggers the release of inflammatory 
mediators, which can expel infectious agents.  IgE can also binds to low-affinity receptor 
(FceRII; CD23) expressed on B cells T cells, Langerhans cells, macrophages, monocytes, 
eosinophils, and platelets (Rindsjö and Scheynius 2010; Schroeder and Cavacini 2010; 
Stone et al. 2010). 
 
1.3.1.5 IgD   
Membrane IgD is expressed on mature B lymphocytes and is thought to regulate B cell fate 
and early development.  With a short half-life, circulatory monomeric IgD constitutes only 
0.05% of total serum Ig, the function of which remains unknown (Schroeder and Cavacini 




Generation of B cells is a highly regulated process, which begins in the foetal liver before 
birth and proceeds throughout life in the bone marrow (Hardy and Hayakawa 2001).  In 
these organs, B cell development progresses in a sequential antigen-independent manner 
(Moura et al. 2008).  Hematopoietic stem cells differentiate into common lymphocyte 
progenitors (CLP), which differentiate further into pro-B cells, pre-B cells and then into 
immature B cells.  In the bone marrow, generation of B cells is supported by stromal cells 





B cell surface bound antibodies are used as receptors for recognition of specific antigen, cell 
signalling and cell activation (Schroeder and Cavacini 2010).  A functional surface Ig 
receptor is assembled during early B cell development, by random rearrangement of V(D)J 
gene segments encoding the Ig heavy and Ig light chains (Schroeder and Cavacini 2010; 
Vale and Schroeder 2010; van Zelm et al. 2007). 
 
At the pro-pre-B cell stage a precursor BCR is formed after Ig heavy gene rearrangement 
resulting in the synthesis of Igµ heavy chains which associate with surrogate light chains.  
This precursor BCR is expressed on the cell surface of pre-B cells.  Similar to the TCR, the 
very short cytoplasmic domain of the BCR can not transduce signals into the cell.  Thus, the 
BCR is expressed in association with two transmembrane signalling proteins designated Igα 
(CD79a) and Igβ (CD79b), which have ITAM domains in their cytoplasmic regions 
(Benschop and Cambier 1999; Cambier et al. 2007; Chaplin 2010; Herzog et al. 2009).  Pre-
B cell receives signals via the BCR complex to undergo proliferation, during which IgL 
chain genes are rearranged and synthesised to form a complete IgM molecule.  This drives 
Pre-B cells to differentiate into immature B cells expressing surface IgM as their antigenic 
receptor.  Development proceeds through sequential molecular checkpoints that assure 
selection of only those B cells that do not react to self antigens.  B cells which express self-
reactive BCR enter apoptosis or undergo receptor editing (Ollila and Vihinen 2005; 
Vaughan et al. 2011; Zhang et al. 2004). 
 
Negatively selected B cells exit the bone marrow and enter the blood as 
immature/transitional cells.  These newly generated B cells home to the spleen, where 
development continues into IgM and IgD expressing mature (or naïve) B cells.  Naïve B 
cells re-enter the circulation and home to lymph nodes, where development continues in an 







Newly formed mature antigen-naive B cells survive for only days or weeks unless 
stimulated with antigen.  Unlike the TCR, the antigen specific BCR can directly bind to a 
wide range of small and large protein and non-protein antigens.  Depending on the size and 
nature of the antigen B cell responses occur in a T cell dependent (TD) or T cell 
independent (TI) manner (Abbas et al. 2007; Vale and Schroeder 2010). 
 
The B cell response to protein antigens such as viruses is dependent on cognate help 
provided by T cells.  The BCR cannot bind to native proteins as a whole, but instead binds 
to specific surface segments called antigenic determinants or conformational epitopes 
(Abbas et al. 2007).  Once bound, protein antigens are internalised into endosomal vesicles 
by receptor mediated endocytosis.  The antigen is processed inside vesicles and presented 
on MHC class II or class I molecules to CD4+ or CD8+ T cells, respectively (Alam and 
Gorska 2003; Fairfax et al. 2008; Vale and Schroeder 2010). 
 
Antigens with particular structural and/or compositional properties, i.e. non-protein antigens 
such as polysaccharides, lipids and nucleic acids are able to stimulate the differentiation of 
B cells into antibody-secreting cells in the absence of cognate T cell help.  These antigens 
are known as TI antigens and are further divided into TI-1 and TI-2.  T1-1 antigens are B 
cell mitogens capable of stimulating B cells independently of the BCR.   An example of a 
TI-1 antigen is LPS, a major constituent of the cell wall of Gram-negative bacteria.  B cells 
recognise such pathogen specific structures via expression of various TLRs, e.g. LPS is 
detected via TLR4 (Oracki et al. 2010).  In contrast, TI-2 antigens deliver prolonged and 
persistent signalling through the BCR.  TI-2 antigens include macromolecules such as 
polysaccharides and lipids, these are known as polyvalent antigens because they have 
repeating epitopes.  Polyvalent antigens induce cross-linking and clustering of the BCR, this 




mainly initiated in the spleen, bone marrow, peritoneal cavity and at mucosal sites (Abbas et 
al. 2007; Mond et al. 1995; Oracki et al. 2010). 
 
Furthermore, B cells recognise and produce antibodies against different epitopes on an 
antigen; this is known as a polyclonal response (Abbas et al. 2007).  B cells can be 
stimulated polyclonally with superantigens, such as microbial or viral toxins.  Superantigens 
interact with the BCR outside the antigen binding site and stimulate a larger number 
(approximately 500-fold increase) of lymphocytes in comparison to conventional peptide 
antigens (McGhee et al. 2007; Silverman 1998).  A membrane protein produced by 
Staphylococcus aureus called protein A has the properties of a superantigen.  Soluble 
protein A does not stimulate B cells alone but only when fixed on to bacteria.  
Staphylococcus aureus Cowan strain 1 (SAC) is a powerful surface Ig cross-linker 





In the spleen, immature B cells develop into one of three functionally and anatomically 
distinct population of mature B cells, which respond to preferentially different types of 
antigens (Abbas et al. 2007; Vale and Schroeder 2010). 
 
1.3.4.1 Marginal zone B cells 
A small population of mature B cells home to the marginal zone of the spleen and reside 
there as non-circulating Marginal zone (MZ) B cells (Spencer et al. 1998; Weill et al. 2009).  
MZ B cells initiate early TI and TD immune responses, thus are thought to play an 
important role in linking innate and adaptive immune responses.  This distinct population of 




blood-borne antigens, such as bacterial polysaccharides (Batista and Harwood 2009; Carter 
2006; Pillai and Cariappa 2009; Vale and Schroeder 2010). 
 
1.3.4.2 B1 B cells 
B1 B cells represent a unique but minor population of B cells that are mainly found residing 
in mucosal tissue and the peritoneum of mice.  B1 B cells produce non-specific natural IgM 
antibodies in response to non-specific stimuli such as TLR agonists.  Studies carried out in 
mice support the existence of B1 B cell cells; whether B1 B cells exist in humans is still a 




The majority of mature B cells in the body exist as re-circulating or follicular B cells that 
continuously traffic from blood to follicles of secondary lymphoid organs such as lymph 
nodes, spleen, Peyer’s patches and tonsils (Batista and Harwood 2009; Cyster 2010; Klein 
and Dalla-Favera 2008) (Figure 1.1).  Follicular B cells critically rely on an intricate 
cellular collaboration with Tfh cells in generating a diverse repertoire of high-affinity class-
switched antigen-specific antibodies, essential for the clearance of a plethora of different 
protein antigens.  These tightly controlled processes take place within specialised structures 
called germinal centres (GCs), which are formed within the central region of primary B cell 
follicles in response to TD antibody responses (Allen et al. 2007; Batista and Harwood 
2009; Crotty 2011; Cyster 2010; Gatto and Brink 2010; King et al. 2008; Vale and 







Figure 1.4. Schematic structure of a lymph node. 
The lymph node structure is organised into defined B cell (follicles) and T cell areas 
(paracortex).  Proliferating B cells are concentrated in germinal centres, which form within 
the central region of primary B cell follicles in response to T-dependent antibody responses.  






The GC is a dynamic microenvironment where antigen-activated B cells undergo a number 
of important modifications such as clonal expansion, somatic hypermutation (SHM), 
selection of high-affinity B cells and class-switch recombination (CSR).  The GC is 
segmented into two major zones referred to as the dark zone and light zone.  The dark zone 
is densely packed with rapidly proliferating large GC B cells known as centroblasts which 
migrate to the light zone and give rise to smaller non-proliferating centrocytes.  In the light 
zone centrocytes are intermixed with tingible body macrophages, Tfh cells (known as GC 
Tfh cells) and follicular dendritic cells (FDCs) displaying intact antigen via immune 
complexes (Allen et al. 2007; Batista and Harwood 2009; Good-Jacobson and Shlomchik 
2010; Pistoia and Cocco 2009; Vinuesa et al. 2010) (Figure 1.5). 
 
To increase antibody diversity and affinity, expanding centroblasts undergo SHM, a step-
wise process that permits Ig variable genes to undergo point mutations at a very high rate 
(hypermutation).  In the light zone, only those centrocytes that bind to the original antigen 
on FDCs with the highest affinities are selected for survival and expansion.  Important 
survival signals are also provided by GC Tfh cells.  Selected high affinity antigen-reactive B 
cells may undergo CSR of constant region genes, a molecular mechanism which allows 
heavy chain isotype switching from IgM to IgG, IgA, or IgE whilst maintaining antigenic 
specificity (isotype-switching) (Allen et al. 2007; Good-Jacobson and Shlomchik 2010; 
Klein and Dalla-Favera 2008; Pistoia and Cocco 2009; Vinuesa et al. 2010).  SHM and CSR 
require the presence of a key enzyme called activation-induced cytidine deaminase (AID) 
which initiates DNA strand-breaks in Ig variable regions and is expressed by proliferating 








Figure 1.5. The germinal centre reaction. 
SHM (somatic hypermutation); CSR (class-switch recombination); FDCs (follicular 







The purpose of the GC reaction is to enhance host protection for long periods of time by 
forming long-lived, high-affinity, class-switched, antigen-specific antibodies.  Long-lived 
serological memory (antibodies that persists for decades) is formed when surviving antigen-
reactive GC B cells differentiate into either memory B cells or long-lived plasma cells 
(Figure 1.5).  The factors that control which differentiation path a B cell takes or the 
quantity of memory and plasma cell populations generated are poorly understood.  Both 
memory and plasma cells persist in the absence of sustained antigenic challenge and can 
directly or indirectly provide effector functions (Elgueta et al. 2010; Good-Jacobson and 
Shlomchik 2010; Tangye and Tarlinton 2009). 
 
Memory B cells are antigen-experienced long-lived, quiescent B cells that express high-
affinity surface antibodies.  Compared to antigen-inexperienced naive B cells, memory B 
cells are capable of eliciting rapid and robust responses upon re-encounter with the 
pathogen.  Memory B cells can rapidly proliferate and differentiate into short- and long-
lived plasma cells, as well as perform other immediate effector and regulatory functions 
such as: antigen-presentation, T cell and DC regulation and cytokine and chemokine 
production (Good-Jacobson and Shlomchik 2010; Klein and Dalla-Favera 2008; Tangye and 
Tarlinton 2009). 
 
Memory B cells in peripheral blood and secondary lymphoid organs exist as a 
phenotypically and functionally heterogeneous population (Good-Jacobson and Shlomchik 
2010; Tangye and Tarlinton 2009).  CD27, a TNFR family member, is as a transmembrane 
homodimer found expressed on all memory B cells, the majority of T cells, but not on naïve 
B cells (Agematsu et al. 2000).  In humans, the CD27 positive memory B cell population 
can be subdivided into isotype-switched and non-switched (IgM positive) cells.  Naive and 
memory B cells are commonly identified based on the differential expression of IgD and 




2008; Tangye and Good 2007; Tangye and Tarlinton 2009).  In comparison to CD27 
negative B cells, CD27 positive B cells are more rapidly activated and produce higher levels 
of IgA, IgM, and IgG antibodies in response to in vitro stimulation with SAC plus IL-2, 
(Agematsu et al. 2000; Tangye and Good 2007).  Furthermore, memory B cells are more 
sensitive to in vitro stimulation with the co-stimulatory molecule CD40 ligand (CD40L) 
plus IL-21 in producing IgG, IgA and IgM antibodies and in differentiating into Ig-secreting 




Plasma cells are defined as terminally differentiated non-proliferating, antibody secreting 
cells.  Plasma cells can either arise from extrafollicular regions or from GCs.  Extrafollicular 
plasma cells are short-lived plasma cells that mount early response to antigen by secretion 
of low-affinity antibodies, predominantly IgM.  In contrast, the GC response allows the 
generation of long-lived plasma cells, which secrete high-affinity antibodies (Elgueta et al. 
2010; Oracki et al. 2010; Wols 2005).  Down-regulation of the chemokine receptors 
CXCR5 and CCR7 guides plasma cells to exit GCs and secondary lymphoid organs, 
respectively.  Depending on the expression of adhesion molecules, chemokines, and their 
receptors immature plasma cells home to various tissue sites in the body, such as the splenic 
red pulp, lymph node medulla, bone marrow, tonsils, gut and to sites of inflammation.  
However, the majority of plasma cells reside in bone marrow niches, which provide the 
contact (stromal cells) and growth factors (APRIL and IL-6) required for survival of long-
lived plasma cells.  Plasma cells are rarely found in the circulation, any cells found are 
likely to be precursors called plasmablasts, emigrating to their organ of choice (Fairfax et al. 
2008; Ingold et al. 2005; Wols 2005).   
 
B cell maturation to plasma cells is promoted by the induction of transcriptional repressor B 
lymphocyte induced maturation protein 1 (Blimp1).  Plasma cells can be divided into 




found in mature cells.  Furthermore, Plasma cells can be distinguished from mature B cell 
subsets based on cell size, morphology and surface marker expression.  On differentiation 
into plasma cells B cells down-regulate surface expression of CXCR5, CD19, B220, MHC 
class II, CD79, CD86, CD22, CD21, surface Ig in mouse and additionally CD20 in human.  
Surface markers which are up-regulated or remain expressed on human plasma cells include 







Human Tfh cells are defined by the expression of the following characteristic markers: the 
transcriptional repressor B cell lymphoma 6 (Bcl6), CXCR5 (also known as Burkitt 
lymphoma receptor 1; BLR-1), the CXCR5 ligand CXC-chemokine ligand 13 (CXCL13; 
also known as B cell-attracting chemokine 1; BCA-1), the co-stimulatory molecules 
inducible co-stimulator (ICOS; CD278), CD40L (CD152), co-inhibitory molecule 
programmed death 1 (PD1; CD279), the signalling lymphocytic activation molecule 
(SLAM)-associated protein (SAP; also known as SH2D1a), cytokines IL-21, IL-4 and IL-
10; IL-21R and IL-6R (Crotty 2011; King 2009; King et al. 2008; Ribot et al. 2011) (Figure 
1.6).  Murine Tfh cells express the same panel of markers with the exception of CXCL13 
(Crotty 2011).  Heightened expression of a combination of these molecules allows Tfh cells 
to be superior in facilitating B cells for antibody production (Yu et al. 2009).  Some of the 
above Tfh cell-associated molecules are often used as markers to identify and distinguish 
Tfh cells from other Th subsets (Yu and Vinuesa 2010).  The significance and function of 
the most key and best characterised Tfh cell-expressed molecules, in the context of B cell 






Figure 1.6. Important molecules for Tfh cell function. 
(Left) Human tonsil stained for IL-21 expression, cells positive for IL-21 shown stained in 
dark purple. Regions of the tonsil indicated as T cell areas (T), the B cell follicle (F), and 
the germinal centre (GC). Note the positioning of IL-21-expressing cells at the border of the 
GC. (Right) Some of the best-characterised molecules involved in Tfh and B cell 
interactions.  Listed below are numerous other molecules over-expressed in Tfh cells that 






Where and when a Th cell becomes a Tfh cell is controversial and remains to be defined. At 
present, four models have been proposed: Model 1) a distinct subset directly induced by 
cytokine (IL-6 or IL-21); Model 2) a distinct subset directly induced by B cells; Model 3) a 
non-distinct subset differentiated from Th1/Th2/Th17 cells; Model 4) Tfh differentiation is 
initially induced by antigen-presenting DCs and maintained by cognate interaction with B 
cells (Crotty 2011; Fazilleau et al. 2009; Yu and Vinuesa 2010).  In support of the third 
model, studies have shown Tfh cells to develop from other Th subsets under certain 
conditions (Zaretsky et al. 2009).  The fourth model of Tfh differentiation is based on more 
recent findings which suggest prolonged antigen presentation by DC to be critical in the 
generation of Tfh cells (Deenick et al. 2011).  This new model considers Tfh cells as a non-
restricted subset that can secrete moderate amounts of Th1, Th2, or Th17 cytokines, 




Bcl6 has been identified as the transcription factor that specifically drives Tfh cell 
formation.  Expression of Bcl6 is thought to be induced by the cytokines IL-21 and IL-6 
through their ability to activate STAT3. Tfh cells selectively express high levels of Bcl6 
whilst other Th subsets (Th1, Th2, or Th17 cells) express high levels of Blimp1.  Bcl6 and 
Blimp1 act as transcriptional repressors; one inhibits the transcription of the other.  Bcl6 
controls Tfh differentiation by suppressing the activity of Blimp1 and other master 
transcription factors required for Th1, Th2 and Th17 generation (Crotty 2011; King 2009).  
Tfh cells can be distinctly characterised from other Th subsets by the high expression of 
both Bcl6 and CXCR5.  In the absence of Bcl6 activated Th cells fail to express Tfh cell–




Maf, Batf, and Bcl6-binding partners also play fundamental roles in the development and 




Tfh cells were first described in 2000 and 2001, as a subset of CD4+ T cells found localised 
within GCs of human tonsils expressing high levels of CXCR5 (Breitfeld et al. 2000; Kim et 
al. 2001; Schaerli et al. 2001; Schaerli et al. 2000).  Since then CXCR5 has been the 
canonical phenotypic marker for Tfh cells.  CXCR5 is a G protein-coupled seven 
transmembrane chemokine receptor, which specifically allows migration of cells towards 
the follicular chemokine ligand CXCL13 (Cyster et al. 2000; Förster et al. 1994).  In 
peripheral blood surface CXCR5 is uniformally expressed on all mature B cells and on a 
subpopulation of memory (CD45RO+) T cells but not on naïve T (CD45RA+) or TEMRA 
cells.  The majority of blood CXCR5+ T cells are CD4+ (90%) and a minority CD8+ (10%).  
In the CD4+ CD45RO+ memory population about 20% are found to express CXCR5, these 
cells are thought to be resting Tfh cells (Förster et al. 1994; Schaerli et al. 2001; Schaerli et 
al. 2000).   
 
The CXCR5-CXCL13 axis plays a unique role in bringing together CXCR5+ Tfh cells and 
B cells within secondary lymphoid organs, which is critical for T-B interactions (Allen and 
Cyster 2008; Crotty 2011; Ebert et al. 2005; Moser et al. 2002; Rasheed et al. 2006).  In 
humans, CXCL13 is produced in abundance in the light zone of GCs by FDCs and Tfh cells 
(Allen and Cyster 2008; Crotty 2011). 
 
Secondary lymphoid organs such as the lymph nodes are divided into two major regions 
called follicles enriched by B cells and the paracortex or T cell zone enriched predominantly 
by T cells (Figure 1.4 and 1.6).  Follicles and T cell zone also contain FDCs and resident 




lymph nodes is guided by adhesion receptor CD62L and the chemokine receptor CCR7.  
Expression of CCR7 on peripheral blood naïve T and B cells as well as TCM cells, permits 
entry into lymph nodes by passing through specialised vessels called high endothelial 
venules (HEVs) located in the paracortex (Figure 1.4).  Lymphocytes bearing CCR7 are 
selectively attracted towards homeostatic chemokines ELC/CCL19 and SLC/CCL21, which 
are expressed on the luminal side of HEVs and are produced by stromal cells in the T cell 
zone (Batista and Harwood 2009; Bromley et al. 2008; Ebert et al. 2005; Moser and 
Loetscher 2001; Moser et al. 2002).  CCR7 retains naïve CD4+ T cells in the T cell zone, 
which is adjacent to B cell follicles.  Within the T cell zone, T cells co-localise with 
antigen-loaded mature DCs.  T cells specific for antigen become activated and receive 
signals from DCs to down-regulate CCR7 and up-regulate CXCR5.  Expression of CXCR5 
makes CD4+ T cells (or pre-Tfh cells) responsive to CXCL13,  this permits relocation from 
the T cell zone towards the B cell follicle where CXCL13 is produced at high concentration.  
In contrast, antigen-stimulated B cells up-regulate CCR7 and down-regulate CXCR5, this 
enables B cells to migrate from the follicle towards the T cell zone.  Consequently, both cell 
types meet at the boundary between the B cell follicle and T cell zone (Figure 1.6).  Here, 
activated CXCR5+ CD4+ T cells interact with B cells presenting processed antigen. Cognate 
recognition of antigen drives development of Tfh cells and permits delivery of T cell help to 
B cells.  Recognition of the same antigen by both cell types is critical in TD antibody 
responses.  Antigenic peptide recognised by the T cell must also be associated with the 
antigen recognised by the B cell.  Upon receiving T cell help (i.e. via co-stimulatory 
molecules and cytokines), fully activated B cells can either migrate into extrafollicular areas 
and become short-lived plasma cells or colonise primary follicles to form GCs.  At the same 
time, signals delivered via co-stimulatory molecules CD28, OX40, and ICOS on Tfh cells 
induces up-regulation of CXCR5 expression, allowing Tfh cells to enter into follicles.  
Some of these Tfh cells go on to support GC formation and the production of long-lived 
antibodies (Allen et al. 2007; Deenick et al. 2011; Ebert et al. 2005; King et al. 2008; 
Rasheed et al. 2006) (Figure 1.5).   
 
The ontogeny of blood CXCR5+ CD4+ T cells and their relationship with tissue derived Tfh 




CD4+ T cells have been carried out using peripheral blood and tonsillar derived cells (Ebert 
et al. 2004; Förster et al. 1994; Kim et al. 2001; Quigley et al. 2007; Rasheed et al. 2006; 
Schaerli et al. 2001; Schaerli et al. 2000).  The T cell zone and B cell follicles of inflamed 
tonsils are found to be highly enriched with CXCR5+ CD4+ T cells.  In comparison to the 
20% of memory CD4+ T cells found to express CXCR5 in blood,  about 90% of memory 
CD4+ T cells found in tonsils are CXCR5+ (Ebert et al. 2004).  Peripheral blood CXCR5+ 
CD4+ T cells lack the expression of activation markers (CD25, CD69 and HLA-DR) and co-
stimulatory molecules (CD40L, OX40 and ICOS), thus are in resting state.  In contrast 
tonsillar derived GC Tfh cells do express activation (CD69 and HLA-DR) and co-
stimulatory molecules markers (ICOS) and are highly active at providing B cell help in vitro 
(Schaerli et al. 2000).  Surface CXCR5 expression can be induced by in vitro stimulation on 
naïve T cells with superantigen-loaded DCs and on CXCR5-negative memory CD4+ T cells 
with PHA or anti-CD3 (Schaerli et al. 2001).  However CXCR5 expression on both tissue 
derived and peripheral CD4+ T cells is rapidly lost in vitro.  This transient expression of 
CXCR5 makes it a challenging marker for in vitro studies (Ebert et al. 2005; Schaerli et al. 
2001; Schaerli et al. 2000).  In vivo studies using IL-21-knock out mice have helped reveal 
the importance of IL-21 in promoting and maintaining CXCR5 surface expression on CD4+ 
T cells (Lüthje et al. 2012; Silver and Hunter 2008; Spolski and Leonard 2010; Vogelzang 




The Tfh cell subset not only express appropriate cell surface molecules required for T cell 
priming by DCs (i.e. CD28:CD80/CD86) but also express specific molecules required for B 
cell help (Rolf et al. 2010).  The specialised capacity of Tfh cells to provide B cell help 
requires co-localisation of both cell types and the delivery of signals to B cells via Tfh 
expressed co-stimulatory molecules and cytokines (Crotty 2011; King 2009; Spolski and 
Leonard 2010) (Figure 1.6).  Tfh cells express high levels of transmembrane co-stimulatory 
molecules such as CD40L, ICOS, OX40 and CD70 that interact with counter 




(Crotty 2011).  These and several other receptor/ligand pairs provide positive signals and 
allow extended cell-cell contacts to form, which is essential for bidirectional 
communication, mutual co-stimulation and activation of cells (Frauwirth and Thompson 
2002).  The co-stimulatory molecules CD40L, OX40, ICOS, CD70 and co-inhibitory 
molecule PD-1 in Tfh:B cell interactions, are discussed in more detail below. 
 
1.4.4.1 CD40L   
CD40L (CD154), a TNF family member, is an integral membrane glycoprotein transiently 
expressed on the surface of recently activated CD4+ T cells.  CD40, the receptor for CD40L, 
is constitutively expressed mainly on the surface of APCs and is required for their activation 
(Daoussis et al. 2004).  Sustained TCR ligation and CD28 co-stimulation provided by DCs 
during T cell priming induce up-regulation of CD40L on CD4+ T cells.  Subsequent binding 
of CD40 on DCs by CD40L on T cells results in DC activation, secretion of cytokines, and 
further up-regulation of MHC and co-stimulatory molecules.  In turn, activated DCs provide 
specific signals (e.g. secretion of IL-12) which activate and stimulate naïve CD4+ T cells to 
become pre-Tfh cells (Deenick et al. 2011; Leitner et al. 2010; Ma and Clark 2009).  
 
At the edge of B cell follicles, pre-Tfh cells interact with B cells via CD40L:CD40 
interactions, respectively.  In B cells, CD40 signalling induces GC B cell activation, 
survival, proliferation and in the presence of specific cytokines isotype switching (Daoussis 
et al. 2004; King 2009; Yong et al. 2009).  Stimulation provided by both CD40L and 
cytokines (IL-21 or IL-4) maintains B cell proliferation but inhibits plasma cell 
differentiation.  However, reduction or elimination of CD40L signals with continued 
cytokine stimulation (most potently with IL-21) allows B cells to differentiate into IgM 
secreting plasma cells (Crotty 2011).   
 
The regulation of CD40L expression both at the mRNA and protein level has been studied 
in vitro.  CD40L can be induced upon PMA and ionomycin stimulation of peripheral blood 




stimulation, which were rapidly lost and found undetectable by 16 hours, demonstrating a 
tight regulation of CD40L on T cells (Daoussis et al. 2004).  Expression of other co-
stimulatory molecules such as CD28 and ICOS are thought to assist CD40L expression.  
Furthermore, cytokines such as IL-2, IL-12, and IL-15 up-regulate CD40L expression, 
while IL-4 and IL-10 down-regulate CD40L (Daoussis et al. 2004; King 2009; Ma and 
Clark 2009; Yong et al. 2009). 
 
It is important to note that both CD40L and CD40 can be reciprocally expressed.  CD40L is 
also found on activated B cells and DCs and CD40 can be detected on activated αβ T cells 
(Ma and Clark 2009) and on Vγ9Vδ2 T cells (Brandes et al. 2005; Moser and Eberl 2011). 
 
1.4.4.2 OX40   
OX40 (CD134), a TNFR family member, is expressed at high levels on activated Tfh cells 
including GC Tfh cells and under certain conditions on activated CD8+ T cells and Tregs 
(Croft et al. 2009; Crotty 2011; King 2009).  OX40 is not only required during DC:T and 
T:B cell-cell interactions, its expression is also vital for survival of activated T cells (Crotty 
2011; Deenick et al. 2011).  Unlike CD28, OX40 is not found on resting naïve or memory T 
cells, but is transiently induced within the first hours of T cell activation.  Peak levels of 
OX40 can be detected both in vitro and in vivo between 1-5 days after initial stimulation.  
Although transient expression of OX40 can be induced with TCR and CD3 signals alone, 
sustained expression requires CD28:CD80/86 interactions, which can be further prolonged 
in the presence of specific cytokines (i.e. IL-1, IL-2, and TNF) (Croft et al. 2009; Salek-
Ardakani and Croft 2006).   
 
Correspondingly, OX40 ligand (OX40L, CD252) is also induced within 24 hours of DC and 
B cell activation, this is secondary to CD40:CD40L interactions (Croft et al. 2009; Deenick 
et al. 2011; Salek-Ardakani and Croft 2006).  The extent and duration of OX40L expression 
is also determined by CD28:CD80/86 interactions.  A chronological sequential engagement 




promotes T cell survival and division by inducing anti-apoptotic molecules (Croft et al. 
2009; Crotty 2011; Salek-Ardakani and Croft 2006).  Expression of OX40 and OX40L on T 
cells and APCs, respectively, regulates cytokine production and cytokine receptor signalling 
(Croft et al. 2009).  Due to the limited number of studies, the exact role of OX40 in Tfh 
function remains unknown (King 2009).  Initial studies suggested OX40 signalling to be 
important in Tfh cell formation and for the expression of CXCR5 on CD4+ T cells (Deenick 
et al. 2011; King 2009; King et al. 2008).  However, more recent in vivo murine studies 
showed that the absence of OX40 signalling had no effect on CXCR5 expression, Tfh 
differentiation, GC development and antibody titers (Crotty 2011).  Overall, published 
literature suggests OX40 signals to play an important role in driving B cell differentiation 
toward antibody-secreting plasma cells and long-lived memory B cells (King 2009; King et 
al. 2008; Ma and Clark 2009). 
 
1.4.4.3 ICOS 
ICOS (CD278) is a CD28-like T cell co-stimulatory molecule expressed at low levels on the 
surface of resting naïve T cells, which is rapidly up-regulated following TCR engagement 
and CD28 signalling.  Highest expression of ICOS is found on Tfh cells, particularly on GC 
Tfh cells.  However, ICOS is not restricted to Tfh cells, as it is also expressed on other 
helper subsets such as Th1, Th2, Th17 and Tregs (Hutloff et al. 1999; King et al. 2008; 
Simpson et al. 2010).  ICOS binds to its specific ligand, ICOS-L (also known as CD275) 
expressed at low levels on APCs.  ICOS-L is up-regulated following activation of APCs 
with highest levels found on B cells (Bauquet et al. 2009; Yong et al. 2009).  ICOS-L on B 
cells is down-regulated following interaction with ICOS, thus suggesting tight regulation of 
ICOS:ICOSL interactions (Crotty 2011; Yong et al. 2009). 
 
While CD28:B7/CD40L:CD40 interactions facilitate DC-priming of pre-Tfh cells, 
ICOS:ICOS-L interactions are central to B cell mediated Tfh cell formation and the 
maintenance of GCs (Deenick et al. 2011; Yong et al. 2009).  However, recent data also 




ICOS is predominantly expressed by Tfh cells residing in the light zone of GCs, sites where 
Tfh cells interact with GC B cells (Allen et al. 2007; Yong et al. 2009).  Sustained ICOS 
expression is required for GC formation.  B cell signalling through ICOS-L is important for 
isotype class switching, affinity maturation and the development of memory B cells (Crotty 
2011; King et al. 2008; Suh et al. 2004; Yong et al. 2009).   
 
On the T cell side, signalling through ICOS in the presence of TCR stimulation results in 
strong activation of the phosphatidylinositol 3-kinase (PI3K) signalling pathway.  The exact 
signalling mechanism employed by ICOS remains poorly understood, however, data have 
suggested that a series of signalling cascades may be involved (Deenick et al. 2011; 
Simpson et al. 2010; Yong et al. 2009).  Ligation of ICOS does have multiple downstream 
consequences such as Th cell survival, up-regulation of cell surface molecules (i.e. CD40L), 
production of cytokines such as IL-4, IL-10, IL-21 and, to a lesser extent, the production of 
IL-2, IFN-γ and TNF-α (Bauquet et al. 2009; King 2009; King et al. 2008; Vu et al. 2008).  
IL-4 and IL-10 assist in T:B interactions, promote B cell proliferation and plasma cell 
differentiation (King et al. 2008; Yong et al. 2009).  IL-10 also supports antibody 
production and the survival of GC B cells (Yong et al. 2009).  The amount of IL-10 and IL-
21 produced by Tfh cells is relative to the levels of ICOS expressed (King et al. 2008; 
Vogelzang et al. 2008).  In the absence of ICOS, IL-10 production is impaired (King et al. 
2008).   
 
Both human and murine studies have shown the importance of ICOS in the development 
and function of Tfh cells.  Patients with human common variable immunodeficiency 
(CVID) have a homozygous loss of ICOS (Rasheed et al. 2006).  CVID patients lack GCs in 
their lymph nodes and consequently have reduced number of memory B cells, low IL-10 
and reduced serum IgG and IgA levels (Bauquet et al. 2009; King et al. 2008; Yong et al. 
2009).  Such defects result from inadequate B cell help due to the absence of ICOS:ICOS-L 
interactions (Yong et al. 2009).  Furthermore, circulating CXCR5+CD4+ T cells were 
reduced in CVID patients.  Thus, ICOS deficiency also had an effect on Tfh development 




(Haynes 2008; King et al. 2008).  In connection to the above, one in vitro study showed that 
only those Tfh cells that expressed high levels of ICOS were potent inducers of IgG 
production and CXCL13 secretion (Rasheed et al. 2006).  Furthermore, data from recent 
studies suggest that ICOS:ICOS-L interactions may mediate Tfh development by regulating 
IL-21 production, possibly through c-Maf, which is ‘downstream’ of ICOS (Bauquet et al. 
2009; Vogelzang et al. 2008).  IL-21 produced in response to ICOS stimulation may support 
Tfh development and drive ICOS expression in an autocrine manner (King et al. 2008; 
Yong et al. 2009). 
 
1.4.4.4 CD70 
CD70, another TNF family member, is only transiently expressed on activated T cells, B 
cells and DCs.  CD70 binds to its receptor CD27, which is constitutively expressed on T 
cells and induced through antigen receptor triggering on B cells.  CD27 is maintained 
throughout B cell differentiation with highest expression found on GC B cells, which is 
progressively lost after the centroblast stage.  CD27:CD70 interactions between T cells and 
DCs come into play during the T cell priming phase.  CD27 signalling appears critical for T 
cell expansion and survival (Denoeud and Moser 2011).  Ligation of CD27 on B cells by 
CD70 on Tfh cells stimulates B cell activation and antibody production by promoting 
plasma cell differentiation (Borst et al. 2005; Elgueta et al. 2010; Jacquot 2000; Nolte et al. 
2009).  In vitro studies using human B cells have shown triggering of CD27 to enhance 
IgM, IgG, IgA, and IgE production (Xiao et al. 2004).  In contrast, triggering of CD70 on B 
cells was shown to inhibit IgG production, thus has the opposite effects to CD27 (Arens et 
al. 2004; Borst et al. 2005; Kobata et al. 1995).  However, in CD27 knockout mice the 
absence of CD27 on B cells had no effect on isotype switching, somatic hypermutation, or 
antibody production (Nolte et al. 2009; Xiao et al. 2004). 
 
1.4.4.5 PD‐1 
In addition to the high expression of co-stimulatory molecules, GC Tfh cells also express 




not restricted to T cells and can also be up-regulated on activated B cells (Good-Jacobson 
and Shlomchik 2010).  Ligands for PD-1 include PD-L1 (B7-H1 or CD274) and PD-L2 
(B7-DC) which are expressed at high levels on GC B cells, but are also found on activated T 
cells, macrophages and DCs (Haynes 2008; Ribot et al. 2011).  Within GCs, engagement of 
PD-1 delivers negative signals that counteract positive signals provided by ICOS (Yong et 
al. 2009).  This limits T cell responses such as proliferation and cytokine production (Fife 




IL-21 is a potent immunomodulatory four-α-helical-bundle type I cytokine that shows 
significant homology to IL-2, IL-4, and IL-15.  IL-21 is produced by activated CD4+ T cells 
and NKT cells.  The highest expression of IL-21 is found in Tfh and Th17 cells.  IL-21 is 
known as a ‘helper’ Tfh cell associated cytokine because it is the major cytokine abundantly 
produced by GC Tfh cells (Crotty 2011; King et al. 2008; Spolski and Leonard 2008) 
(Figure 1.6).  In vitro studies have shown several cytokines such as IL-6, IL-12, IL-21 and 
IL-23 to be inducers of IL-21 expression in naïve CD4+ T cells.  During initial DC priming 
of naïve CD4+ T cells, IL-12 produced by activated DCs is thought to induce both Tfh cell 
development and production of IL-21 (Deenick et al. 2011).  In B cell follicles, Tfh cell 
derived IL-21 has several very important functions on both GC B cells and Tfh cells 
(Spolski and Leonard 2008). 
   
IL-21 is a key determinant of B cell proliferation, isotype switching and differentiation of B 
cells into antibody-forming cells.  In comparison to other Tfh-secreted cytokines (IL-2, IL-4 
and IL-10) IL-21 is the most potent at inducing plasma cell differentiation and regulating 
CSR.  IL-21 alone or in combination with various other cytokines regulates class switching 
to IgG, IgA, or IgE isotypes.  This has been extensively shown using in vivo mouse models 
and in vitro culture systems with human B cells.  However, some differences where found 




studies using CD40L-stimulated human B cells showed the following: IL-21 predominantly 
induced CSR to IgG (particularly IgG1 and IgG3), IL-10 in the presence of IL-21 induced 
switch to IgA whereas the addition of IL-4 had an inhibitory effect, TGF-β1 also induced 
IgA production, IL-4 promoted production of IgE and finally IFN-γ inhibited switching of 
certain isotypes such as IgE (Konforte et al. 2009; Pistoia and Cocco 2009).  The type of 
cytokines present at the time of B cell stimulation is associated with the type of defence 
required against the pathogen involved.  For example an IL-4 induced switch to IgE is 
important for a response to parasites, whereas isotype switching in response to IFN-γ is vital 
for antiviral immunity (King et al. 2008). 
 
A unique role of IL-21 is controlling the fate of activated B cells.  IL-21 stimulation only 
promotes the survival of those B cells that are antigen specific and have received 
appropriate signals (via the BCR and CD40) from cognate T cells.  B cells that have been 
activated non-specifically through the BCR alone (without CD40 co-stimulation) or by TLR 
ligands (i.e. LPS and CpG) are instructed to undergo apoptosis (King et al. 2008; Konforte 
et al. 2009).  IL-21 also acts as an autocrine growth factor for Tfh cell development and 
long-term survival.  In contrast to IL-2 and IL-15, IL-21 only induces proliferation of T 
cells that have been stimulated via the TCR.  Thus, IL-21 functions as a T cell co-stimulator 
with the ability of possibly enhancing TCR signalling (King et al. 2008; Rolf et al. 2010; 




The effects of IL-21 are mediated by binding to the transmembrane IL-21R, which is 
predominantly found on αβ T cells and B cells (King et al. 2008).  The level of IL-21R 
expressed on peripheral blood naïve CD4+ and CD8+ T cells is low.  Expression of IL-21R 
is regulated biphasically in T cells.  An early up-regulation of IL-21R is seen following 
TCR stimulation with subsequent decline, a secondary spontaneous response is induced 




IFN-α can decrease expression of IL-21R mRNA in T cells (Leonard et al. 2008).  In 
regards to B cell subsets, IL-21R is found on naïve and GCs B cells, but not on memory B 
cells and plasma cells.  IL-21R can also be found on NK cells, NKT cells, macrophages, and 
DCs and a variety of non-immune cells such as fibroblasts, keratinocytes, epithelial and 
endothelial cells (Davis et al. 2007; Konforte et al. 2009; Monteleone et al. 2009; Spolski 
and Leonard 2008).  
 
The IL-21R is a heterodimer, composed of a common γ-chain subunit (γc; CD132) and an 
IL-21 specific α chain.  The γc subunit is a component shared by the cytokine receptors for 
IL-2, IL-4, IL-7, IL-9, and IL-15.  Like other γc-dependent cytokines, IL-21:IL21R binding 
initiates intracellular signalling through Jak1 and Jak3, which activate STAT3 and STAT1 
and to a weaker extent STAT4 and STAT5 proteins (Brandt et al. 2007; Davis et al. 2007; 
Konforte et al. 2009; Leonard et al. 2008; Schmitt et al. 2009).  In CD4+ T cells and B cells, 
STAT3 is the most sustained and important STAT protein for IL-21 signalling and cell 
proliferation (Crotty 2011; Spolski and Leonard 2008).  IL-21 ligand binding can also 
trigger activation of mitogen-activated protein kinase (MAPK) and PI3K pathways, which is 
important for IL-21-mediated cell proliferation (Davis et al. 2007; Leonard et al. 2008; 
Spolski and Leonard 2008).  
 
In B cells, IL-21 signalling can result in the induction of the proapoptotic factor Bim, Bcl6 
and Blimp1, depending on the co-stimulatory signals present.  High expression of Bcl6 in 
the centroblast subset of GC B cells promotes cell cycle progression but inhibits B cell 
differentiation.  In contrast, IL-21 induced expression of Blimp1 through activation of 
STAT3 and to a lesser extent STAT5 promotes formation of plasma cells and isotype-






























Figure 1.7. IL-21R signalling pathways.  
IL-21 mainly signals via the Janus-activated kinase (Jak)/STAT pathway with STAT1 and 
STAT3 as primary targets.  Signalling through the phosphatidylinositol 3-kinase (PI3K) and 
mitogen-activated protein kinase (MAPK) pathways may also occur in certain physiologic 






While the crucial role of Tfh cells in providing B cell help is undisputed other T cell subsets 
including CD8+ T cells, NKT cells and γδ T cells contribute to the outcome of humoral 
immune responses (Brandes et al. 2003; Ebert et al. 2004; Galli et al. 2003; Quigley et al. 
2007).  This chapter will focus primarily on the role of human γδ T cells in immune 




γδ T cells were first described in the mid 1980s as a small but unique subset of T cells 
expressing a TCR composed of γ and δ chains (Allison et al. 2001; Brenner et al. 1986).  
Similar to αβ T cells, γδ T cells express a rearranged TCR complexed with CD3 (γ, δ, ε) and 
ζ signalling chains, which are associated with cytoplasmic cell signalling proteins (Allison 
et al. 2001).  However the majority of γδ T cells do not express CD4 or CD8 membrane 
proteins (Hayday 2000).  γδ T cells differ from conventional αβ T cells in that they have a 
unique pattern of antigen recognition, which does not require processing by professional 
APCs or presentation by MHC or MHC-related molecules (Eberl and Moser 2009; 
Holtmeier and Kabelitz 2005).   
 
Furthermore, the majority of human γδ T cells do not respond to peptide antigens but 
instead use their TCR in a pattern recognition receptor-like way in recognising relatively 
conserved structures (i.e. non-peptide metabolites) on a diverse array of pathogens (Carding 
and Egan 2002; Hayday 2000; Holtmeier and Kabelitz 2005; Morita et al. 2007).  γδ T cells 
also express several TLRs (TLR1, 2, 3, 5, 6, and 7) (Beetz et al. 2007) and NK receptors 
(i.e. NKG2D and CD94) (Battistini et al. 1997; Beetz et al. 2007).  Expression of these 




components or to self-antigens that have been up-regulated upon stress, e.g., infection, cell 
death, or cellular transformation such as MHC class I-related chains A/B (MICA and 
MICB) and UL16-binding proteins (ULBPs) (Beetz et al. 2007; Holtmeier and Kabelitz 
2005; Morita et al. 2007).  Due to the combination of innate like features and characteristics 
of T cells, γδ T cells have been termed unconventional, or transitional T cells thought to be 
involved in bridging the gap between innate and adaptive immune response (Bonneville et 
al. 2010; Pennington et al. 2005).   
 
In humans, γδ T cells are divided into subsets based on TCR δ chain usage.  There is 
estimated to be eight to ten distinct Vδ γδ T cell subsets in total (Hayday 2000).  Vδ1 and 
Vδ2 are the two prominent subsets existing in humans, the others Vδ subsets exist in much 
lower frequencies and on which data is very limited.  The Vδ1 (associated with different Vγ 
chains) subset is predominantly found resident within epithelial tissues and the Vδ2 
(predominantly associated with the Vγ9 chain) subset represent the majority (>80%) of γδ T 
cell in peripheral blood (Beetz et al. 2007; Fagioli et al. 1990; Holtmeier and Kabelitz 






In healthy individuals Vγ9Vδ2 γδ T cells (also known as Vγ2Vδ2 T cells according to an 
alternative nomenclature) normally constitute 0.5–5% of circulating T cells (Caccamo et al. 
2006b).  However, some healthy individuals present with consistently high (up to 15–40% 
of circulating T cells) Vγ9Vδ2 T cell counts (Eberl and Moser 2009).  Vγ9Vδ2 T cells 
expand rapidly both in vivo and in vitro, in response to infections with microbes producing 
the low molecular weight metabolite (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate 




invariant intermediate of the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway (also 
known as the non-mevalonate pathway) of isoprenoid biosynthesis, a pathway essentially 
required for microbial physiology (Figure 1.8).   
 
HMB-PP is produced by numerous potentially harmful Gram-positive and Gram-negative 
bacteria, as well as by malaria parasites but not by higher eukaryotes, thus HMB-PP is 
unique to micro-organisms (Bonneville et al. 2010; Eberl and Moser 2009; Morita et al. 
2007).  Many of these HMB-PP producing pathogens are the causative agents of lethal 
infectious diseases such as cholera, diphtheria, plague, tuberculosis and typhoid (Davey et 
al. 2011).  Activated Vγ9Vδ2 T cells are found to be elevated in patients suffering from 
acute infections with HMB-PP+ bacteria; this has been well documented in patients 
undergoing peritoneal dialysis and in Mycobacterium tuberculosis infected patients (Davey 
et al. 2011; Meraviglia et al. 2011; Morita et al. 2007). 
 
In vitro, Vγ9Vδ2 T cells can be activated with synthetic HMB-PP at concentrations as low 
as 0.1 nM, which displays identical stimulatory activities to the E.coli derived natural HMB-
PP (Eberl et al. 2003; Moser and Eberl 2007).  Thus, since its discovery, HMB-PP has been 
identified as the most potent, pathogen specific and natural activator of Vγ9Vδ2 T cells 
(Eberl et al. 2003; Hintz et al. 2001).  For reasons that are not yet understood, Vγ9Vδ2 T 
cells and the responsiveness to HMB-PP are only found in higher primates including 
humans but are absent in all other vertebrates including rodents (Bonneville et al. 2010; 







Figure 1.8. MEP and mevalonate pathways for isoprenoid biosynthesis. 
Isopentenyl pyrophosphate (IPP) is a product of the MEP (in many prokaryotes) and 
mevalonate pathway (in eukaryotes and in some prokaryotes) whereas (E)-4-Hydroxy-3-
methyl-but-2-enyl pyrophosphate (HMB-PP) is specifically produced via the MEP pathway 
in prokaryotes and apicomplexan parasites (and in the chloroplasts of all green plants). 





Molecules structurally related to HMB-PP (with a 10,000-fold lower potency) such as 
isopentenyl pyrophosphate (IPP) are also capable of activating Vγ9Vδ2 T cells.  IPP is a 
central intermediate of isoprenoid biosynthesis, synthesised by the mevalonate and or non-
mevalonate pathways, which are utilised by all living eukaryotic and prokaryotic organisms 
(Figure 1.8).  The mevalonate pathway is essential for cell survival.  However, IPP is much 
less potent than HMB-PP and under normal physiological conditions, levels of IPP are not 
sufficient enough to induce significant Vγ9Vδ2 T cell activation (Holtmeier and Kabelitz 
2005; Jomaa et al. 1999; Kistowska et al. 2008; Morita et al. 2007; Moser and Eberl 2011; 
Urban et al. 2010).   
 
1.5.2.3 Alkylamines 
Other natural compounds capable of activating Vγ9Vδ2 T cells are alkylamines, which are 
ubiquitously present in human body fluids of healthy individuals, plant foods such as tea, 
apples and wine and are also produced by certain commensal and pathogenic bacteria 
(Bukowski et al. 1999; Holtmeier and Kabelitz 2005; Morita et al. 2007).  However their 
physiological relevance remains questionable as millimolar concentrations are required for 




Recently, synthetic aminobisphosphonates (i.e. pamidronate and zoledronate), a class of 
drugs widely used to treat osteoporosis and bone metastasis, have demonstrated to be potent 
(in vitro and in vivo) activators of Vγ9Vδ2 T cells.  Recognition of aminobisphosphonates 
by Vγ9Vδ2 T cells is TCR dependent and requires antigen presentation by APCs (Morita et 
al. 2007).  Zoledronate induces Vγ9Vδ2 T cell secretion of high levels of proinflammatory 
cytokines and enhances cytotoxicity (required for tumour clearance), as demonstrated by 




2007; Thedrez et al. 2007).  In vitro studies have shown highly activated Vγ9Vδ2 T cells to 
kill a variety of tumour cells in a TCR-independent and dependent manner using natural 
killer cell-like activity and/or CD8 T cell activity, respectively (Ferrarini et al. 2002; Tanaka 
2006).  Furthermore, in studies involving treatment of patients with lymphoid malignancies, 
breast or prostate cancer, clinical evidence suggested treatment with pamidronate or 
zoledronate (plus IL-2), to have anticancer effects in the presence of Vγ9Vδ2 T cells (Dieli 
et al. 2007; Meraviglia et al. 2010; Wilhelm et al. 2003). 
 
The effects of aminobisphosphonates is thought to be due to an indirect mechanism, 
whereby aminobisphosphonates function intracellularly by blocking farnesyl pyrophosphate 
synthase (FPP), this leads to accumulation of intracellular IPP which in turn, stimulates 
Vγ9Vδ2 T cells (Benzaïd et al. 2011; Holtmeier and Kabelitz 2005; Morita et al. 2007).  A 
current novel strategy for cancer immunotherapy is to sensitise tumour cells for target 
killing by Vγ9Vδ2 T cells by inducing intracellular accumulation of IPP by 




The exact mechanism of how Vγ9Vδ2 T cells recognise and become activated by non-
peptide antigens remains unclear.  Attempts to show direct γδ TCR:ligand binding by 
crystallisation studies have failed so far.  However, studies involving antibody blocking of 
TCR and gene transfer approaches showed that recognition of non-peptide antigens and cell 
activation was dependent on the Vγ9Vδ2 TCR (Bukowski et al. 1995; Morita et al. 2007; 
Tanaka 2006; Thedrez et al. 2007).  
 
The Vγ9Vδ2 T cell response to non-peptide antigens is not dependent on any known antigen 
presenting molecule, as demonstrated by mutant APCs that lacked MHC class I, β2-




Vγ9Vδ2 T cells, possibly by unknown surface molecules (Eberl and Moser 2009; Morita et 
al. 2007).  HMB-PP induced robust Vγ9Vδ2 T cell activation and proliferation requires cell-
cell contact with accessory (or feeder) cells of human origin that do not need to be APCs, 
such as human monocytes/DCs, αβ T cells or B cells (Eberl et al. 2009; Moser and Eberl 
2007, 2011).   
 
What remains to be determined is exactly how an intracellular metabolite such as HMB-PP 
gets released by invading bacteria or becomes visible to the immune system.  Findings have 
suggested uptake of whole bacteria by monocytes, macrophages, or DCs and the killing of 
these infected cells by Vγ9Vδ2 T cells (Dieli et al. 2001; Eberl and Moser 2009).  Vγ9Vδ2 T 
cells have been shown to kill both extracellular and intracellular bacteria such as 
Mycobacterium tuberculosis through the release of perforin and granulysin (Dieli et al. 
2001).  A recent study showed Vγ9Vδ2 T cell specific response to neutrophils harbouring 
phagocytosed HMB-PP producing live bacteria, which was amplified in the presence of 
monocytes.  This indicated direct communication and interplay between the three cell types 
in response to pathogen.  From these findings it was concluded that under physiological 
conditions HMB-PP is unlikely to be released into the microenvironment by live micro-
organisms, however, biologically relevant traces may escape after phagocytosis of 




Unlike αβ T cells, the majority of circulating Vγ9Vδ2 T cell in human adults are effector 
memory cells, which lack the lymph node homing receptor CCR7 but instead express 
multiple inflammatory chemokine receptors, such as CXCR3, CCR1, CCR2 and CCR5 
(Brandes et al. 2003).  Such characteristics (also shared by granulocytes, monocytes, 
immature DCs, and NK cells) indicate a prerequisite for the rapid recruitment of Vγ9Vδ2 T 
cells to tissue sites of inflammation and infection, where they may encounter recently 




activated upon exposure to HMB-PP, either released after phagocytosis by neutrophils and 
presented by neighbouring monocytes or presented on the surface of infected monocytes or 
DCs.  As an innate immune response activated Vγ9Vδ2 T cells may perform immediate 
effector functions such as secretion of cytokines and chemokines, lysis of infected cells and 
processing of bacterial antigen (Hayday 2000; Moser and Eberl 2007).  TCR triggering of 
resting Vγ9Vδ2 T cells has been shown to induce a switch from inflammatory profile to a 
lymph node homing phenotype (Brandes et al. 2003).  A rapid and transient up-regulation of 
CCR7 (and other lymph node homing receptors) allows pathogen activated Vγ9Vδ2 T cells 
to migrate to secondary lymphoid tissue (Moser and Brandes 2006; Moser and Eberl 2007, 




In freshly isolated peripheral Vγ9Vδ2 T cells, Dieli et al. (2003) identified four different 
functional subsets of Vγ9Vδ2 T cells based on the co-expression of surface CD45RA and 
CD27, as follows:  CD45RA+ CD27+  as naïve, CD45RA– CD27+ as central memory, 
CD45RA–CD27– as effector memory and CD45RA+CD27– as terminally differentiated 
cells.  Lymph node homing receptors CCR7 and CD62L were found to be expressed on 
naïve and central memory Vγ9Vδ2 T cells but not on effector memory cells.  Furthermore, 
Vγ9Vδ2 T cells found in lymph nodes expressed CCR7 and CD62L, but not the 
inflammatory chemokines CCR5 and CXCR3.  Conversely, Vγ9Vδ2 T cells found at 
inflammatory sites expressed CCR5 and CXCR3 but not CCR7 and CD62L.  Thus, central 
memory Vγ9Vδ2 T cells home to lymph nodes and upon antigen re-encounter provide a 
secondary immune responses with a proportion of cells differentiating into effector memory 
cells.  On the other hand, effector memory Vγ9Vδ2 T cells migrate to peripheral tissues 
where they provide immediate effector functions and can further differentiate into 







Freshly isolated resting human Vγ9Vδ2 T cells are characterised by a largely pro-
inflammatory cytokine profile comprising IFN-γ, TNF-α and GM-CSF although co-
expression of IL-4 is observed (Eberl et al. 2009; Sireci et al. 1997; Vermijlen et al. 2007).  
Importantly however, they can be skewed toward distinct effector functions depending on 
the microenvironment, in analogy to, and even beyond, the emerging plasticity of CD4+ αβ 
T cells.  As such, under appropriate culture conditions, Vγ9Vδ2 T cells divert from the 
‘default’ Th1/CTL-like phenotype and assume features reminiscent of Th2 cells (Vermijlen 
et al. 2007; Wesch et al. 2001), Th17 cells (Caccamo et al. 2011; Ness-Schwickerath et al. 
2010), Treg cells (Casetti et al. 2009) and even professional APCs (Brandes et al. 2005).  
This illustrates the multi-functional nature of Vγ9Vδ2 T cells, which reflects their 
involvement in diverse pathophysiological processes (Bonneville et al. 2010; Moser and 




As reported by several studies, activated human Vγ9Vδ2 T cells have the potential to act as 
professional APCs (Brandes et al. 2009; Brandes et al. 2005; Himoudi et al. 2012; 
Landmeier et al. 2009; Meuter et al. 2010; Moser and Eberl 2011; Wu et al. 2009).  APC 
markers are found to be absent on freshly isolated resting peripheral Vγ9Vδ2 T cells, 
however in vitro stimulation with IPP or HMB-PP results in rapid up-regulation of 
molecules required for APC function such as, antigen presenting molecules (MHC class I 
and II), co-stimulatory (CD80 and CD86) and adhesion receptors (CD11a, CD18, CD54) 
(Brandes et al. 2005).  Activated Vγ9Vδ2 T cells not only express phenotypical APC 
features but also function as potent and professional APCs (Brandes et al. 2009; Brandes et 
al. 2005; Meuter et al. 2010).  As professional APCs Vγ9Vδ2 T cells have the ability to 
induce differentiation of naïve CD4+ and CD8+ T cells into cytokine secreting effector cells.  




which is in clear contrast to the transient APC nature of monocyte-derived DCs (Brandes et 
al. 2009; Brandes et al. 2005; Moser and Brandes 2006; Moser and Eberl 2011). In support 
to the above, a large proportion of tonsillar γδ T cells express activation markers (CD69) 
and high levels of MHC class II and CD80 and CD86 (Brandes et al. 2005).  Also, Vγ9Vδ2 
T cells were recently shown to phagocytose opsonised bacteria (Wu et al. 2009).   
 
Furthermore, human Vγ9Vδ2 T cells have been shown to perform robust cross-presentation 
functions, more efficient than monocyte-derived DCs.  Activated Vγ9Vδ2 T cells displaying 
APC features have been shown to process and cross-present antigens such as: purified 
influenza matrix protein M1, inactivated influenza particles and extracts from influenza-
infected cells (Brandes et al. 2009; Meuter et al. 2010).  Most viruses and tumours do not 
arise in APCs, thus elicitation of CD8+ CTL response to exogenous tumour antigens (such 
as mutant proteins) by APCs relies on cross presentation routed via the MHC class I 
pathway (Meuter et al. 2010; Moser and Eberl 2011).  Cross presentation of a range of 
mutant proteins from tumours by γδ T cell APCs could provide a novel cellular vaccine for 
induction of a more broader and effective tumour specific CTL response in cancer patients 




γδ T cells have been demonstrated to support antibody production in immunised and 
infected mice (Huang et al. 2009; McMenamin et al. 1994; Wen et al. 1996).  GCs are 
present in TCRα-/- and TCRβ-/- mice and develop in SCID mice upon adoptive transfer of 
γδ T cells and B cells, demonstrating that γδ T cells are sufficient to orchestrate follicular 
responses (Dianda et al. 1996; Pao et al. 1996; Wen et al. 1996) (Figure 1.9).  In humans, 
γδ T cells can be found in secondary lymphoid tissues (Brandes et al. 2003; Dieli et al. 
2003; Groh et al. 1989), where they are scattered throughout the T zone and clustered within 














Figure 1.9. Murine γδ T cells support the formation of germinal centres in severe 
combined immunodeficiency (SCID) mice.    
SCID mice are a strain of mice lacking in T and B lymphocytes and immunoglobulins.  
Adoptive transfer of splenocytes from mice congenitally deficient in αβ T cells resulted in 
the formation of GCs in SCID mice.  GCs were probed with peanut agglutinin (PNA); 














Figure 1.10. Clusters of human γδ T cells found within a reactive germinal centre.  
A tissue section of an active gut follicle from a patient with Yersinia ileitis, 






Furthermore, a higher number of γδ T cells were found in disease-associated lymph nodes in 
comparison to non-involved lymph nodes (Brandes et al. 2003).   
 
Early studies in lupus patients led to the isolation of human γδ T cell lines capable of 
inducing autoantibody production by autologous B cells (Rajagopalan et al. 1990).  
Subsequent investigations demonstrated that in vitro activated human γδ T cells, stimulated 
with IPP, or the T cell specific mitogen phytohaemagglutinin (PHA), or with the synthetic 
compound bromohydrin pyrophosphate (BrHPP), can readily provide help to B cells via 
contact-dependent mechanisms, involving CD40L and ICOS and soluble factors including 
IL-4 and IL-10 (Brandes et al. 2003; Caccamo et al. 2006a).  Activated human γδ T cells 
may also express additional markers of relevance for a possible interaction with B cells 
including OX40, PD-1, CD27 and CD70 (Brandes et al. 2003; DeBarros et al. 2011; Iwasaki 
et al. 2011).  CXCR5 expression is required for follicular homing and GC localisation, 
which has been detected on peripheral human Vγ9Vδ2 T cells by some (Caccamo et al. 
2006a) but not by others (Brandes et al. 2003), therefore the regulation of CXCR5 
expression on peripheral human Vγ9Vδ2 T cells is still a subject of debate.  More recent 
data from microarray studies revealed that Vγ9Vδ2 T cells express a range of Tfh cell 
associated molecules when stimulated with HMB-PP in the presence of IL-21, including the 
B cell attracting chemokine CXCL13, thus suggesting a potential role in the GC reaction 
(Vermijlen et al. 2007). 
 
Collectively, all the above findings strongly suggest γδ T cells to possess Tfh-like B cell 
helper qualities, however a number of questions still remain, such as, exactly how Vγ9Vδ2 
T cells acquire the ability to provide B cell help in secondary lymphoid tissue and what the 







The overall aim of this study was to gain a better understanding of Vγ9Vδ2 T cell role in 
humoral immune response and to provide a functional validation of previous microarray 
data/findings (Vermijlen et al. 2007).  I here hypothesised that in response to HMB-PP 
during microbial infection activated γδ T cells respond to IL-21 produced by Tfh cells. This 
induces or modulates γδ T cell phenotypes associated with B cell help, thus allowing γδ T 
cells to interact with B cells leading to antibody production and class switching. 
 
Specific aims of this study were to investigate the following: 
 
1. The effects of IL-21 in regulating expression of IL-21R, CXCL13, CXCR5, co-
stimulatory molecules and APC markers on in vitro HMB-PP stimulated 
peripheral Vγ9Vδ2 T cells. 
 
2. Expression of IL-21R, CXCL13, CXCR5, co-stimulatory molecules and APC 
markers by Vγ9Vδ2 T cells in secondary lymphoid tissue and by ex vivo IL-21 
and HMB-PP stimulated tonsillar Vγ9Vδ2 T cells. 
 
















Peripheral blood obtained from healthy adult donors by venous puncture was collected into 
a tube containing anti-coagulation buffer (PBS containing 20 U/ml Heparin and 15 mM 
EDTA), a 1:5 dilution of anti-coagulation buffer to venous blood was used.  Peripheral 
blood mononuclear cells (PBMCs) were isolated from donor blood by density gradient 
centrifugation using LymphoprepTM (Axis-Shield).  LymphoprepTM is a ready made sterile 
and endotoxin tested solution for the isolation of pure mononuclear cells, which contains 
sodium diatrizoate 9.1% (w/v) and polysaccharide 5.7% (w/v).  Peripheral blood was 
diluted with an equal volume of sterile phosphate buffered saline (PBS) solution (deionised 
H2O containing 1 X PBS).  20 mls of LymphoprepTM was added to a 50 ml Falcon tube and 
30 mls of diluted blood was carefully layered on top, avoiding any disruption of the two 
layers.  Tubes were centrifuged in a swing-out rotor, at room temperature (approximately 
20°C) for 25 minutes at 1500 rpm (450 x g) with no brake.  After centrifugation the cloudy 
layer of mononuclear cells formed at the sample/ LymphoprepTM interface were carefully 
harvested using a Pasteur pipette.  The harvested mononuclear fraction was washed twice by 
diluting cells in either PBMC wash buffer (PBS containing 2% foetal calf serum (FCS) and 
2 mM EDTA) or in RPMI-1640 medium and centrifuged at 1300 rpm (300 x g, 4°C, for 10 
minutes).  Supernatants from wash steps were discarded and cells were re-suspended in 






In order to study cells from secondary lymphoid tissues, mononuclear cells were freshly 
isolated from the following tissues: fresh tonsils (palatine tonsils) of patients undergoing 
tonsillectomy; fresh appendix tissue of patients undergoing appendectomy; or from biopsy 
specimens of the gastrointestinal tract of patients undergoing diagnostic colonoscopy.  
Performed under sterile conditions, simple mechanical disaggregation was used to obtain 
single cell suspensions from primary tissue such as tonsils, appendix and colon biopsies.   
To preserve maximum cell viability and avoid any enzymatic manipulation/destruction of 
cell surface proteins I chose not to use any enzymatic disaggregation methods.  To remove 
any blood, tissue samples were washed with PBS before being placed in a dish containing 
RPMI-1640 medium (without supplements).  Tissue was cut with scissors into small pieces 
and then mashed through a stainless steel mesh cell filter.  To separate the mechanically 
released cells from any tissue fragments homogenised tissue was re-suspended in RPMI-
1640 medium and passed through a 70 μM cell strainer followed by a 40 μM cell strainer 
(BD Biosciences). The resulting single cell suspension was washed twice by pelleting the 
cells by centrifugation (300 x g, 4°C, 10 minutes) and re-suspending in RPMI-1640 
medium.  Mononuclear cells were isolated from tissue derived cell suspensions by density 




Patients on continuous ambulatory peritoneal dialysis (CAPD) for ≤5 years were recruited 
from the Peritoneal Dialysis Unit, University Hospital of Wales, Cardiff.  Diagnosis of 
CAPD-associated peritonitis was based on the presence of abdominal pain, a cloudy 
peritoneal effluent with a leukocyte count >105 per ml, and a positive microbiological 
culture (data not shown).  Two litres of overnight dwell effluent bags were collected on ice 




peritoneal effluents by centrifugation at 1,200 g and 4°C for 25-30 minutes by Chan-Yu Lin 




All cell sorting was carried out under aseptic conditions in a Class II laminar airflow unit, 
cells and reagents were kept on ice throughout the cell sorting procedure.   
 
Single cell suspensions were sorted by magnetic activated cell sorting (MACS) using 
MACS® column technology (Miltenyi Biotech).  MACS® column technology is based on 
the use of MACS microbeads, MACS columns and MACS separators.  Cells are directly or 
indirectly labelled with magnetic beads and are separated over a MACS column placed in 
the magnetic field of a MACS separator (a strong permanent magnet).  Magnetically 
labelled cells are retained on the column, while unlabelled cells pass through. The retained 
cells are eluted from the MACS column after removal from the magnet.   
 
In cases where high purities could not be achieved by magnetic cell sorting using MACS®, 
cells were further sorted to higher purities using a MoFlo cell sorter (Dako cytomation), 
which was operated by a core facility (Central Biotechnology Services; CBS) technician.  
The MoFlo cell sorter is a high-speed cell sorter flow cytometer (8-color, 3-laser system) 




For co-culture experiments, cells were isolated by magnetic cell sorting using MACS® 




PE (B6.1; BD Biosciences) or V9-PE-Cy5 (Immu360; Beckman-Coulter) antibodies and 
anti-PE microbeads, followed by isolation of peripheral B cells or monocytes (as feeder 
cells) by positive selection using anti-CD19 microbeads (>98%) or anti-CD14 microbeads 
(>96%), respectively, as described below. 
 
Sample preparation for γδ T cell isolation.  Pellet from PBMC isolation was re-suspended 
in 1 ml MACS buffer (PBS containing 5 mM EDTA and 2% FCS) in a 15 ml falcon tube.  
Before staining, Fc receptors on cells were blocked for 10 minutes at 4°C (on ice) using 
human Ig serum (1:100; Kiovig, Baxter).  For γδ surface labelling, Vδ2-PE or V9-PE-Cy5 
antibodies were added to cell suspension at appropriate concentrations (see Table 2.1) and 
mixed by pipetting, then incubated in the dark at 4°C (on ice) for 30 minutes. To remove 
excess unbound antibody, cells were washed once in MACS buffer (300 x g, 4°C, 10 
minutes), the supernatant was discarded.  Cells were magnetically labelled with microbeads 
by re-suspending pellet in 1 part anti-PE microbeads to 4 parts MACS buffer (i.e. 10 µl 
beads + 40 µl MACS buffer was added per 107 total cells) and incubated in the dark at 4-
8°C (in the fridge) for 15 minutes.  To remove excess unbound microbeads, cells were 
washed once in MACS buffer (300 x g, 4°C, 10 minutes).  The supernatant was discarded 
and cells were re-suspended in 2 ml MACS buffer.  
 
Magnetic separation of γδ T cells.  A LS MACS column was placed in the magnetic field 
of a MACS separator.  The column was rinsed by adding 2 ml of MACS buffer before 
proceeding to magnetic separation.  The cell suspension was applied to the column and the 
unlabelled fraction of cells that passed through the column (flow through) was collected into 
a 15 ml Falcon tube.  The column was washed with 2 ml MACS buffer; this was also 
collected into the same 15 ml Falcon tube.  The flow through containing the unlabelled 
fraction of cells was kept aside on ice for B cell or monocyte isolation.  To get rid of any 
unlabelled cells, the column was further washed by adding 2 ml of MACS buffer.  Wash 
step was repeated three times and the buffer collected from wash steps was discarded.  The 




tube.  5 ml of MACS buffer was pipetted onto the column and the magnetically labelled γδ 
T cells were flushed out by firmly pushing the plunger into the column. 
Sample preparation for B cell or monocyte isolation.  For feeder cells, B cells or 
monocytes were positively isolated from the γδ T cell depleted population.  The unlabelled 
fraction of cells were centrifuged (300 x g, 4°C, 10 minutes), the supernatant was discarded 
and the cell pellet was re-suspended in 1 part anti-CD19 microbeads (for B cell isolation) or 
in 1 part anti-CD14 microbeads (for monocyte isolation) to 4 parts MACS buffer (100 µl 
beads + 400 µl MACS buffer), cells were incubated in the dark at 4-8°C (in the fridge) for 
15 minutes.  To remove excess unbound microbeads, cells were washed once in MACS 
buffer (300 x g, 4°C, 10 minutes).  The supernatant was discarded and cells were re-
suspended in 2 ml MACS buffer.  
 
Magnetic separation of B cells or monocytes.  A LS MACS column was placed in the 
magnetic field of a MACS separator.  The column was rinsed by adding 2 ml of MACS 
buffer before proceeding to magnetic separation.  The cell suspension was applied to the 
column and the unlabelled fraction of cells that passed through the column was collected 
into a 15 ml Falcon tube.  The column was washed with 2 ml MACS buffer; this was also 
collected into the same 15 ml Falcon tube.  To get rid of any unlabelled cells, the column 
was further washed by adding 2 ml of MACS buffer.  Wash step was repeated three times 
and the buffer collected from wash steps was discarded.  The column was removed from the 
magnetic separator and placed on a 15 ml Falcon collection tube.  5 ml of MACS buffer was 
pipetted onto the column and the magnetically labelled cells were flushed out by firmly 
pushing the plunger into the column.  For use as feeder cells in co-culture experiments, 
isolated peripheral monocytes or B cells were irradiated at 30 Gy (3000 rad).  Purities of 
cell populations obtained were determined by flow cytometry and total cell numbers 






Functional assays for investigating B cell help were carried out using cells purified from 
either freshly isolated PBMCs or tonsillar mononuclear cells or both.  Using MACS® 
technology peripheral V9V2 T cells (>97%) were isolated using Vδ2-PE antibodies and 
anti-PE microbeads, as feeder cells peripheral B cells (>98%) were purified from Vγ9Vδ2 T 
cell depleted PBMC using anti-CD19 microbeads (as described above) or for antibody 
production by using the untouched B cell isolation kit (>95%) (as described below).  
  
Tonsillar Tfh cells (CXCR5+ CD4+ T cells; >85%) and tonsillar CXCR5+ B cells (>95%) 
were purified by magnetic cell sorting, tonsillar Vγ9Vδ2 T cells (>95%) were purified by 
MACS® technology followed by a MoFlo cell sorter, as follows:   
 
Tonsillar Tfh cell isolation.  Pellet from PBMC isolation was re-suspended in 1 ml MACS 
buffer (PBS containing 5 mM EDTA and 2% FCS) in a 15 ml falcon tube.  Before staining, 
Fc receptors on cells were blocked for 10 minutes at 4°C (on ice) using human Ig serum 
(1:100).  For CD4 T cell surface labelling, anti-CD4-FITC labelled antibodies were added to 
cell suspension at appropriate concentrations (see Table 2.1) and mixed by pipetting, then 
incubated in the dark at 4°C (on ice) for 30 minutes.  To remove excess unbound antibody, 
cells were washed once in MACS buffer (300 x g, 4°C, 10 minutes).  FITC labelled CD4+ T 
cells were magnetically labelled by re-suspending pellet in 90 µl of buffer and 10 µl of anti-
FITC multisort microbeads per 107 total cells and incubated in the dark at 4-8°C (in the 
fridge) for 15 minutes.  To remove excess unbound microbeads, cells were washed once in 
MACS buffer (300 x g, 4°C, 10 minutes).  The supernatant was discarded and cells were re-
suspended in 2 ml MACS buffer.  CD4+ T cells were magnetically separated by positive 
selection using an LS column.  A LS MACS column was placed in the magnetic field of a 
MACS separator.  The column was rinsed by adding 2 ml of MACS buffer before 
proceeding to magnetic separation.  The cell suspension was applied to the column and the 




Falcon tube.  The column was washed with 2 ml MACS buffer; this was also collected into 
the same 15 ml Falcon tube.  The flow through containing the unlabelled fraction of cells 
was kept aside on ice for γδ and B cell isolation.  To get rid of any unlabelled cells, the 
column was further washed by adding 2 ml of MACS buffer.  Wash step was repeated three 
times and the buffer collected from wash steps was discarded.  The column was removed 
from the magnetic separator and placed on a 15 ml Falcon collection tube.  5 ml of MACS 
buffer was pipetted onto the column and the magnetically labelled CD4+ T cells were 
flushed out by firmly pushing the plunger into the column.  Following positive CD4+ T cell 
selection (>98 %) the magnetic particles were removed from the cells by adding 20 µl of 
multisort Release Reagent per 1 ml cell suspension, cells were incubated for 10 minutes at 
4-8°C (in the fridge) .  To remove any residual magnetically labelled cells, magnetic 
separation was repeated over a new column.   
 
To isolate tonsillar Tfh cells, purified tonsillar CD4+ T cells were stained with anti-CXCR5-
PE labelled antibodies (incubated in the dark at 4°C on ice for 30 minutes).  To remove 
excess unbound antibody, cells were washed once in MACS buffer (300 x g, 4°C, 10 
minutes).  PE labelled CXCR5+ CD4+ T cells were magnetically labelled by re-suspending 
pellet in 1 part anti-PE microbeads to 4 parts MACS buffer (100 µl beads + 400 µl MACS 
buffer) and incubated in the dark at 4-8°C (in the fridge) for 15 minutes.  To remove excess 
unbound microbeads, cells were washed once in MACS buffer (300 x g, 4°C, 10 minutes).  
The supernatant was discarded and cells were re-suspended in 2 ml MACS buffer.  CXCR5+ 
CD4+ T cells (Tfh cells) were magnetically separated by positive selection using an LS 
column.  A LS MACS column was placed in the magnetic field of a MACS separator.  The 
column was rinsed by adding 2 ml of MACS buffer before proceeding to magnetic 
separation.  The cell suspension was applied to the column and the unlabelled fraction of 
cells that passed through the column was collected into a 15 ml Falcon tube.  The column 
was washed with 2 ml MACS buffer; this was also collected into the same 15 ml Falcon 
tube.  To get rid of any unlabelled cells, the column was further washed by adding 2 ml of 
MACS buffer.  Wash step was repeated three times and the buffer collected from wash steps 
was discarded.  The column was removed from the magnetic separator and placed on a 15 




magnetically labelled CXCR5+ CD4+ T cells were flushed out by firmly pushing the plunger 
into the column. 
 
Tonsillar Vγ9Vδ2 T cell isolation.  Tonsillar Vγ9Vδ2 T cells were positively isolated from 
the CD4 T cell depleted population by magnetic cell sorting using Vδ2-PE antibodies and 
anti-PE microbeads (as described above for peripheral V9V2 T cell isolation), resulting in 
20-24% purity.  For a higher purity Vγ9Vδ2 positive cells were further purified by flow 
cytometry using a MoFlo cell sorter as follows.  For selection of CD3+ V9V2 T cells and 
exclusion of B cells (and any remaining CD4-FITC labelled cells) the enriched Vδ2 
population (already stained with anti-Vδ2-PE) was stained with anti-CD3-APC, Vg9-PeCy5 
and CD19-FITC (incubated in the dark on 4°C for 30 minutes).  To remove excess unbound 
antibody, cells were washed once in MACS buffer (300 x g, 4°C, 10 minutes).  Cells were 
re-suspended in MACs buffer to a concentration of 10 million/ml for moflo sorting.  
Vγ9Vδ2 T cells were sorted as V9+ Vδ2+ CD3+ CD4− CD19− lymphocytes, unstained and 
single stained controls were used for compensation.  Sorted Vγ9Vδ2 T cells were collected 
in a tube containing 1 ml of FCS. 
 
Tonsillar CXCR5+ B cell isolation.  Tonsillar B cells were isolated from the CD4 and 
Vγ9Vδ2 T cell depleted population using the untouched B cell isolation kit from Miltenyi 
Biotech.  The B cell isolation kit consists of two components, a biotin-antibody cocktail 
(containing biotin-conjugated monoclonal antibodies against CD2, CD14, CD16, CD36, 
CD43 and CD235a) and anti-biotin microbeads.  Cells were centrifuged (300 x g, 4°C, 10 
minutes), the supernatant was discarded and the cell pellet was re-suspended in 200 µl of 
MACS buffer and 50 µl of biotin-antibody cocktail per 107 cells.  After 10 minutes of 
incubation in the dark at 4-8°C (in the fridge), 30 µl of MACS buffer and 20 µl of anti-
biotin microbeads per 107 cells, were added and left to incubate for a further 15 minutes in 
the dark at 4-8°C (in the fridge).  To remove excess unbound microbeads, cells were washed 
once in MACS buffer (300 x g, 4°C, 10 minutes).  The supernatant was discarded and cells 
were re-suspended in 2 ml MACS buffer.  A LS MACS column was placed in the magnetic 




proceeding to magnetic separation.  The cell suspension was applied to the column and the 
unlabelled fraction of cells (purified CD19 positive B cells) that passed through the column 
was collected into a 15 ml Falcon tube.  The column was washed with 2 ml MACS buffer, 
this was also collected into the same 15 ml Falcon tube.  The column was removed from the 
magnetic separator and placed on a 15 ml Falcon collection tube.  5 ml of MACS buffer was 
pipetted onto the column and the magnetically labelled cells (non-B cells) were flushed out 
by firmly pushing the plunger into the column.   
 
To isolate tonsillar CXCR5+ B cells, purified unlabelled CD19+ B cells were stained with 
anti-CXCR5-PE labelled antibodies (incubated in the dark at 4°C on ice for 30 minutes).  To 
remove excess unbound antibody, cells were washed once in MACS buffer (300 x g, 4°C, 
10 minutes).  PE labelled CXCR5+ CD19+ B cells were magnetically labelled by re-
suspending pellet in 1 part anti-PE microbeads to 4 parts MACS buffer (100 µl beads + 400 
µl MACS buffer) and incubated in the dark at 4-8°C (in the fridge) for 15 minutes.  To 
remove excess unbound microbeads, cells were washed once in MACS buffer (300 x g, 
4°C, 10 minutes).  The supernatant was discarded and cells were re-suspended in 2 ml 
MACS buffer.  CXCR5+ CD19+ B cells were magnetically separated by positive selection 
using an LS column.  A LS MACS column was placed in the magnetic field of a MACS 
separator.  The column was rinsed by adding 2 ml of MACS buffer before proceeding to 
magnetic separation.  The cell suspension was applied to the column and the unlabelled 
fraction of cells that passed through the column was collected into a 15 ml Falcon tube.  The 
column was washed with 2 ml MACS buffer; this was also collected into the same 15 ml 
Falcon tube.  To get rid of any unlabelled cells, the column was further washed by adding 2 
ml of MACS buffer.  Wash step was repeated three times and the buffer collected from 
wash steps was discarded.  The column was removed from the magnetic separator and 
placed on a 15 ml Falcon collection tube.  5 ml of MACS buffer was pipetted onto the 
column and the magnetically labelled CXCR5+ CD19+ B cells were flushed out by firmly 
pushing the plunger into the column.  Purities of cell populations obtained were determined 
by flow cytometry and total cell numbers obtained were determined by manual cell counting 






To determine the number of cells per ml, manual cells counts were performed using a 
haemocytometer.  A 15 μl aliquot of evenly suspended cells was applied to the 
haemocytometer chamber and allowed to settle for 20 seconds.  The main divisions separate 
the grid into 9 large squares; each large square has surface area of 1 mm-squared and a 
depth of 0.1 mm, giving it a volume of 0.1 mm-cubed.  Each large corner square is divided 
into 16 squares, the number of cells in one set of 16 corner squares is equivalent to the 
number of cells x 104/ml (Experimental Biosciences) (Figure 2.1).  Cells were counted in 
each of the four large corner squares by focusing on the grid lines of the haemocytometer 
using the 10X objective of the microscope.  Cell count was determined using the following 
formula: 
 









Figure 2.1. Schematic diagram showing gridlines on a haemocytometer grid. 






The cell culture medium used throughout this study was RPMI-1640 medium supplemented 
with 2 mM L-glutamine, 1% non-essential amino acids, 1% sodium pyruvate, 50 µg/ml 
penicillin/streptomycin, 50 μM β-mercaptoethanol, and 10% FCS (Invitrogen).  FCS added 
to medium was first heat inactivated (56°C for 30 minutes) in order to inactivate 
complement components and aliquated (50 ml) for storage at -20°C.  All cells were cultured 
in U-round bottomed 96 well plates (Sigma-Aldrich, Kent, UK) at 37°C in a humidified 
incubator with 5% CO2.  All cultures procedures were carried out under aseptic conditions 




Surface marker expression on freshly isolated and stimulated Vγ9Vδ2 T cells, CD4+ T cells 
and B cells was studied as follows.  Total PBMC or tonsillar mononuclear cells or sorted γδ 
T cells (co-cultured with sorted B cells) were plated at 0.1 to 0.3x106 cells per well of a 96-
well round bottom plate and cultured for up to 7 days in the presence of 0.1-100 nM 
HMB-PP (synthetic, LPS-free; kindly provided by Dr Hassan Jomaa, University Hospital 
Giessen and Marburg, Giessen, Germany) with or without 0.1-100 U/ml IL-2 or 0.1-100 
ng/ml IL-21 (kindly provided by Dr Donald Foster, Zymogenetics, Seattle, USA).  As 
controls, cells were stimulated with 0.1-100 U/ml IL-2 or 0.1-100 ng/ml IL-21 alone, or 
with 1 g/ml phytohemagglutinin (PHA; Sigma) or with 10 ng/ml phorbol-12-myristate-13-
acetate (PMA; Sigma) and 1 g/ml ionomycin (Sigma) or in medium alone.  After 0, 1, 2, 3, 
4, 5, 6, and 7 days in culture cells were harvested and stained with fluorochrome-conjugated 







For analysis of CXCL13 and cytokine production by peripheral  T cells, purified 
peripheral  T cells were co-cultured with feeder cells (purified peripheral irradiated 
monocytes or irradiated B cells).  Cells were plated at 105 cells of each T and feeder cell, 
per well of a 96-well round bottom plate and cultured in medium alone, or in the presence of 
0.1-100 nM HMB-PP with or without 0.1-100 U/ml IL-2 or 0.1-100 ng/ml IL-21.  After 2-3 
days culture supernatants were harvested and concentration of CXCL13 and IL-17 was 
measurement by enzyme-linked immunosorbent assay (ELISA).  Cells were stained and 
analysed for intracellular detection of CXCL13 (by flow cytometry and 
immunofluorescence microscopy) and cytokines (by flow cytometry).  
 
For analysis of intracellular CXCL13 and cytokine expression in tonsillar  and CD4+ 
T cells, isolated tonsillar mononuclear cells were plated at 0.3x106 cells per well of a 96-
well round bottom plate.  To induce robust cell activation and stimulate cytokine production 
cells were treated with PMA (10 ng/ml) and ionomycin (1 µg/ml) in the presence of 
brefeldin A (20 ug/ml).  After 3 hours, cells were harvested and stained with fluorochrome-




Tonsillar B cell help (Part i). The ability of pre-stimulated peripheral Vγ9Vδ2 T cells to 
induce antibody production by tonsillar B cells was studied using a non-autologous system 
as follows.  To induce acquisition of a Tfh-like phenotype purified peripheral blood 
Vγ9Vδ2 T cells were pre-activated in vitro with 10 nM HMB-PP or in medium alone in the 
presence of purified irradiated autologous peripheral B cells.  After 42 hours, HMB-PP 
stimulated cultures were treated with or without 50 ng/ml IL-21 or 20 U/ml IL-2.  Non-




further 24 hours, stimulated and non-stimulated γδ T cells were harvested and washed 
several times to ensure removal of any residual HMB-PP, IL-21 and IL-2, thus minimising 
direct action of IL-21 or IL-2 on B cells.  For antibody production CXCR5+ B cells and Tfh 
cells were purified from tonsillar mononuclear cells of the same donor.  Non-stimulated 
(medium), HMB-PP, IL-2+HMB-PP or IL-21+HMB-PP pre-stimulated peripheral γδ T 
cells were co-cultured with an equal number of purified tonsillar CXCR5+ B cells, unless 
otherwise indicated.  Cells were plated at 105 cells of each γδ T and B cell per well of a 96-
well round bottom plate in the absence or presence of either 10 nM HMB-PP or with an 
equal number of tonsillar Tfh cells to B cells.  As controls, tonsillar CXCR5+ B cells (105 
cells/well) were cultured in medium alone, or with an equal number of Tfh cells or in the 
presence of 0.1-50 ng/ml of IL-21 alone.  After 10 days of culture, total IgM, IgG and IgA 
levels in culture supernatants were measured by ELISA. 
 
Tonsillar B cell help (Part ii). The ability of tonsillar Vγ9Vδ2 T cells to induce antibody 
production by tonsillar B cells was studied using an autologous system as follows.  
Mononuclear cells were freshly isolated from inflamed tonsils.   All three cell types, 
Vγ9Vδ2 T cells, CXCR5+ B cells and Tfh cells were purified from tonsillar mononuclear 
cells of the same donor.  In co-culture experiments B cells were cultured with an equal 
number of γδ T cells or Tfh cells.  In triple cultures Vγ9Vδ2 T cells, B cells and Tfh cells 
were cultured at a ratio of 1:1:1, unless otherwise indicated, i.e. in experiments involving 
titration of γδ T cells the number of Vγ9Vδ2 T cells to B cells was decreased, but the 
number of Tfh cells to B cells remained equal.  Cells were plated at 5 x 104 cells of each T 
and B cell per well of a 96-well round bottom plate in medium alone, or in the presence of 
10 nM HMB-PP with or without 20 U/ml IL-2 or 50 ng/ml IL-21, or with 50 ng/ml IL-21 
alone.  As controls tonsillar B cells (5 x 104 cells/well) were cultured in medium alone, or 
stimulated with 0.01% Staphylococcus aureus Cowan 1 (SAC) (PANSORBIN cells, 
Calbiochem) in the presence of 100 U/ml IL-2, or with 10 nM HMB-PP in the presence or 
absence of 20 U/ml IL-2 or 50 ng/ml IL-21, or with 50 ng/ml IL-21 alone.  To prevent 
occurrence and carry over of fungal contamination from tonsillar tissue, all cultures and 




(Invitrogen).  After 10 days of culture, total IgM, IgG, IgA and IgE levels in culture 
supernatants were measured by ELISA. 
 
Peripheral B cell help. The ability of peripheral Vγ9Vδ2 T cells to induce peripheral B cell 
activation, APC marker expression, differentiation and antibody production was studied 
using an autologous system as follows.  Purified peripheral B cells were co-cultured with an 
equal number of purified peripheral γδ T cells (obtained from the same donor), unless 
otherwise indicated.  In experiments involving titration of γδ T cells the number of Vγ9Vδ2 
T cells to B cells was decreased 4-fold from a 1:1 ratio to a 1:64 ratio.  Cells were plated at 
105 or 8 x 104 cells of each γδ T and B cell per well of a 96-well round bottom plate, in 
medium alone, or in the presence of 10 nM HMB-PP with or without 20 U/ml IL-2 or 50 
ng/ml IL-21, or with 20 U/ml IL-2 alone or 50 ng/ml IL-21 alone.  As controls B cells (105 
or 8 x 104 cells) were cultured in medium alone or with 0.01% SAC and 100 U/ml IL-2, in 
the presence of 10 nM HMB-PP with or without 20 U/ml IL-2 or 50 ng/ml IL-21, or with 20 
U/ml IL-2 alone or 50 ng/ml IL-21 alone.  After 3 days, cells were harvested and stained for 
activation (CD69 and CD25), APC (CD86, CD40 and HLA-DR) and naïve/memory (IgD 
and CD27) markers in combination with CD3, CD19 and Vδ2 or Vγ9 surface markers 
before being analysed by flow cytometry.  After 10 days of culture, total IgM, IgG, IgA and 









Anti-human antibodies together with appropriate isotype controls and secondary reagents 
used for flow cytometric analysis are described in the table below (Table 2.1).  The correct 
dilutions of the antibodies to give efficient staining were established by titration of the 
antibodies by different members of our lab group.  All cell staining was performed in U-
round bottomed 96 well plates (Sigma-Aldrich, Kent,UK) and all wash steps were carried 
out by re-suspending cells in FACS buffer and by centrifugation at 300 x g, (4°C, 3 
minutes).  For antibody staining, depending on the total number of cells per well of a 96-
well plate, antibody cocktails were made up in a final volume of 30-50 µl of staining buffer 
per well/sample.  For example, a total volume of 50 µl was used per 1 x 106 cells/well. 
 
Cell staining for surface phenotyping.  To eliminate dead cells from flow cytometric 
analysis a fixable Live/Dead Aqua viability stain (LIVE/DEAD® Aqua; Invitrogen) was 
used prior to antibody staining.  For this, cells were washed twice in PBS and 3 to 6 μl of 
diluted (1:10; in PBS) live/dead aqua was added directly to the cell pellet. Cells were left to 
stain at room temperature for 15 minutes in the dark then washed twice in FACS buffer.  
Before antibody staining, Fc receptors on cells were blocked to reduce non-specific 
background staining using 10 mg/ml of purified human Igs diluted in FACS buffer (PBS 
containing 5 mM EDTA and 2% FCS) for 10 minutes at 4°C.  For staining of surface 
markers, 30 μl to 50 μl of diluted (in FACS buffer) antibody along with isotype-matched 
controls were added to the cells and incubated for 20 minutes at 4°C in the dark.  To remove 
unbound antibodies cells were washed twice in FACS buffer. Cells stained with unlabelled 
antibodies were further incubated for 20 minutes in 30 to 50 μl of diluted (in FACS buffer) 
biotinylated or fluorochrome labelled secondary antibody and washed twice in FACS buffer 




additionally incubated for 20 minutes in 30 to 50 μl of conjugated streptavidin diluted in 
FACS buffer and washed twice in FACS buffer to remove unbound streptavidin.  Cells were 
re-suspended in 200 to 400 µl of FACS buffer and immediately acquired/analysed by flow 
cytometery. 
 
Intracellular staining for CXCL13 and cytokines.  For intracellular detection of CXCL13 
and cytokines brefeldin A (Sigma) was added to cultures at 10 g/ml 4 hours prior to 
harvesting.  To remove brefeldin A, cells were washed twice in PBS (300 x g, 4°C, 3 
minutes) and then stained with LIVE/DEAD® fixable aqua stain.  Cells were washed twice 
in PBS before being fixed and permeabilized using the Fix&Perm kit (eBioscience).  
Subsequent washes and incubations were performed using permeabilization buffer 
(eBioscience).  Prior to staining cells were washed once and Fc receptors were blocked for 
10 minutes at 4°C in the dark using 10 mg/ml of purified human Igs diluted in 
permeabilization buffer.  Cells were incubated with mouse anti-CXCL13 or with an isotype 
control antibody (mouse IgG1; MR9) for 30 minutes at room temperature.  Cells were 
washed twice and incubated (in dark, 20 minutes at RT) with an Alexa fluor488-conjugated 
goat anti-mouse secondary antibody (Dako).  Cells were washed twice and incubated for 15 
minutes at RT in the dark with 10 mg/ml of purified mouse Igs diluted in Permeabilization 
buffer.  Cells were further incubated with antibodies targeting specific surface markers or 
intracellular cytokines, along with isotype-matched controls and left for 20 minutes at 4°C 
in the dark.  Cells were re-suspended in 200 to 400 µl of FACS buffer and immediately 










Vδ1 FITC TS8.2 mouse IgG1 Endogen 1:10             
Vδ2 PE B6.1 mouse IgG1 BD Biosciences 1:60 
Vδ2 FITC B6.1 mouse IgG1 BD Biosciences 1:60 
Vγ9 PE-Cy5 Immu360 mouse IgG1 Beckman Coulter 1:400 
CD3 APC HIT3a mouse IgG2a BD Biosciences 1:20 
CD3 APC-H7 SK7 mouse IgG1 BD Biosciences 1:80 
CD3 Pacific Blue UCHT1 mouse IgG1 BD Biosciences 1:100 
CD4 FITC RPA-T4 mouse IgG1 BD Biosciences 1:20 
CD4 ECD SFCI12T4D11 mouse IgG1 Beckman Coulter 1:100 
CD8 PeCy7 SK1 mouse IgG1 BD Biosciences 1:600 
CD14 FITC MOP9 mouse IgG2b BD Biosciences 1:20 
CD14 Pacific Blue M5E2 mouse IgG1 BD Biosciences 1:40 
CD19 FITC HD37 mouse IgG1 DAKO 1:50 
CD19 APC SJ25C1 mouse IgG1 eBioscience 1:800 
CD25 APC-H7 M-A251 mouse IgG1 BD Biosciences 1:50 
CD25 PE-Cy5 M-A251 mouse IgG1 BD Biosciences 1:40 
CD25 Pe-Cy7 M-A251 mouse IgG1 BD Biosciences 1:40 
CD27 FITC M-T271 mouse IgG1 BD Biosciences 1:40 
CD27 PE-Cy5 1A4CD27 mouse IgG1 Beckman Coulter 1:40 
CD28 PE-Cy5 CD28.2 mouse IgG1 BD Biosciences 1:20 
CD40 PE mAB89  mouse IgG1 Beckman Coulter 1:20 
CD45RA  APC HI100 mouse IgG2b eBioscience 1:40 
CD45RA  FITC HI100 mouse IgG2b BD Biosciences 1:20 
CD69 FITC FN50 mouse IgG1 BD Biosciences 1:20 
CD70 FITC Ki-24 mouse IgG3 BD Biosciences 1:5 
CD86 FITC 2331 mouse IgG1 BD Biosciences 1:40 
CD134/OX40  FITC ACT35 mouse IgG1 BD Biosciences 1:5 
CD154/CD40L Pacific Blue 24-31 mouse IgG1 BD Biosciences 1:100 
CD278/ICOS  PE DX29 mouse IgG1 BD Biosciences 1:4 
CXCR5 PE 51505.111 mouse IgG2b R&D Systems 1:16 
CXCR5 Biotin 51505.111 mouse IgG2b R&D Systems  
CCR7  unlabelled 3D12 Rat IgG2a kindly provided by 
Dr Martin Lipp, Max 




HLA-DR APC-H7 L243 mouse IgG2a BD Biosciences 1:40 
IgD  PE IA6-2 mouse IgG2a BD Biosciences 1:75 
IL-21R unlabelled 9N1.1  kindly provided by 










Table 2.1 continued….. 
 







unlabelled 53610.11 mouse IgG1 R&D Systems 1:25 
IL-4  PE 8D4 mouse IgG1 BD Biosciences 1:10 
IFN-γ Pacific Blue 4S.B3 mouse IgG1 eBioscience 1:5 
TNF-α APC 6401.1111 mouse IgG1 BD Biosciences 1:20 
      
Isotypes 
mouse IgG1  FITC — — BD Biosciences — 
mouse IgG1  PE — — BD Biosciences — 
mouse IgG1 PeCy5 — — BD Biosciences — 
mouse IgG1  PeCy7 — — BD Biosciences — 
mouse IgG1  Pacific Blue — — BD Biosciences — 
mouse IgG1  APC — — BD Biosciences — 
mouse IgG1 APC-H7 — — BD Biosciences — 
mouse IgG2a  PE — — eBiosciences — 
mouse IgG2a  FITC — — BD Biosciences — 
mouse IgG2a APC-H7 G155-178 — BD Biosciences — 
mouse IgG2b  FITC — — BD Biosciences — 
mouse IgG2b  PE — — BD Biosciences — 
mouse IgG2b  APC — — eBiosciences — 
mouse IgG2b  Biotin — — BD Biosciences — 
mouse IgG1  unlabelled MR9 — A gift from Patrick — 
Rat IgG2a  unlabelled — — BD Biosciences — 
      
Secondary 
α-mouse Ig PE — goat Ig DAKO 1:80 
α-mouse Ig FITC — goat Ig DAKO 1:100 
α-mouse-IgG1 Alexa fluor488 — goat Ig Molecular Probes 1:1000 
α-rat IgG  Biotin — Rabbit Ig DAKO 1:100 
      
Conjugates 
Strepavidin  PeCy7 — — eBioscience 1:1000 
Strepavidin APC — — DAKO 1:80 
Strepavidin PE — — DAKO 1:80 
Strepavidin FITC — — DAKO 1:80 
 
Table 2.1 Antibodies used for flow cytometry. 
A list of antibodies used in this study including fluorescence label, species and clone, 








For flow cytometric analysis cells were acquired using either a four-color FACSCalibur 
(BD Biosciences) or a nine-colour CyAn ADP (Beckman Coulter) flow cytometer and were 
analysed using FloJo 7.5 software (TreeStar).  To correct multiple parametric flow 
cytometry data for spectral overlap, compensation was performed for each individual 
experiment using a series of single-colour stained cells, each stained with a single 




For analysis of each sample the same gating strategy was adopted.  Firstly, the lymphocyte 
population was gated based on typical lymphocyte forward scatter (FSC) and side scatter 
(SSC) patterns (Figure 2.2 step A).  Next, dead cells were gated out as these can bind 
antibodies non-specifically, a fixable dye (LIVE/DEAD® Aqua) was used for this purpose.  
Cells with compromised membranes readily stain with the dye and therefore have higher 
fluorescence intensity than cells with intact cell membranes (Figure 2.2 step B).  To 
exclude doublets or cell aggregates (which would appear as a distinct population above the 
single cells) a gate was set on the single population of cells (singlets) (Figure 2.2 step C).  
The Vγ9+ or Vδ2+ T cell populations were gated from the live lymphocyte, singlets 
population based on fluorescent intensity levels from Vγ9 or Vδ2 and CD3 specific 
antibody staining (Figure 2.2 step D).  The percentages Vγ9 or Vδ2, CD3 positive cells 
expressing the different surface or intracellular markers of interest were determined by 
comparison with the appropriate isotype controls, as shown in the example for CD25 and 



























Figure 2.2. Example of gating strategy for identifying CD25 and OX40 positive 
Vγ9Vδ2 T cell populations.   
Following 3 days in culture, HMB-PP stimulated PBMCs were harvested for phenotypic 
analysis.  Cells were stained with Live/Dead Aqua viability stain and subsequently with 
flow cytometry with anti-CD3-APC-H7, anti-Vγ9-PE-Cy5, anti-CD25- PE-Cy7 and anti-
OX40-FITC.  Lymphocytes were defined according to their FSC and SSC (step A). Live 
lymphocytes were identified as those with low fluorescence levels of Live/Dead (step B).  
Doublets were gated out by gating on single cells (C)  γδ T cells were identified by gating 
on CD3+ lymphocytes and Vγ9+ (or Vδ2+) lymphocytes (step D). The percentage of 
CD3+Vγ9+ T cells expressing CD25 and OX40 (E) was determined by setting quadrants in 
dot plots using isotype-matched control antibodies (F).  Numbers in dot plots represent the 











































Cells were prepared for detection of intracellular CXCL13 by immunofluorescence 
microscopy as follows.  Following 3 days of culture, cells were treated with brefeldin A (10 
g/ml) 4 hours prior to harvesting.  Staining for CXCL13 was carried out in U-round 
bottomed 96 well plates as described for flow cytometry, briefly; cells were fixed, 
permeabilized, blocked and stained with mouse anti-CXCL13, followed by Alexa Fluor488-
conjugated goat anti-mouse IgG1 (green) and anti-Vδ2-PE (red) antibodies.  Cells were 
counterstained with 0.5 µg/ml of DAPI (a blue fluorescent nuclear stain; Sigma) for 10 
minutes at RT in the dark.  Around 40,000 cells re-suspended in PBS were transferred onto 
poly-Lysine coated slides and allowed to settle for 30 minutes in the dark before being 
coversliped with prolong® gold anti-fade reagent (Invitrogen).  Slides were analysed by 
Immunofluorescence microscopy using a Nikon microscope (Eclipse 80i, Nikon).  Images 
were captured with a Nikon digital camera (DXM1200F) controlled by ACT-1 2.70 imaging 




Cell culture supernatants were analyzed using ELISA kits for CXCL13 and IL-17 according 
to the manufacturer’s protocols (R&D Systems).  Antibody levels were determined using 
the human IgM, IgG, IgA, and IgE quantitation kits (Universal Biologicals).  All samples 







All practical work was undertaken in the laboratories of Cardiff University.  All chemicals 
and reagents used were COSHH assessed.  Reagents were prepared, stored and disposed 
correctly according to the departmental policy and appropriate protective clothing was 
worn. 
 
Ethical approval for this study was obtained from the South East Wales Local Ethics 
Committee (04WSE04/27 and 08/WSE04/17) and conducted according to the principles 





All statistical analysis was carried out using GraphPad Prism 4.0 for Windows, GraphPad 
Software, San Diego California USA.  Firstly, data were analysed using the normality test to 
assess if distribution of data points was normal.  To analyse the significance of differences 
between two groups with normal distribution the two-tailed Student’s t tests was used.  In 
cases where normality of data could not be determined (i.e. sample size too small to 
determine normality) or if data failed to pass the normality test, two groups of data were 
compared using the non-parametric Mann-Whitney two-tailed test.  Differences considered 
significant were indicated with P values in the figures and text and significance was defined 














The overall objective of this chapter was to induce and examine markers associated with 
follicular B cell help on peripheral blood Vγ9Vδ2 T cells.  I hypothesised that IL-21 
regulates expression of IL-21 receptor (IL-21R), CXCL13, CXCR5 and co-stimulatory 
molecules on in vitro HMB-PP activated peripheral Vγ9Vδ2 T cells. 
 
Aims of this chapter were to investigate the effects of IL-21 and HMB-PP stimulation on 
peripheral Vγ9Vδ2 T cell expression of:  
 
1. IL-21R 
2. CXCL13  
3. CXCR5  
4. Co-stimulatory molecules involved in B cell help 










In order to examine the effects of IL-21 stimulation on peripheral Vγ9Vδ2 T cells, surface 
expression of a functional IL-21R would be essential.  Previous studies have found 
expression of the IL-21R on Vγ9Vδ2 T cells at the mRNA level (Vermijlen et al. 2007) 
whereas expression at the protein level has not been documented to date.  Therefore I began 
by addressing the question whether freshly isolated peripheral Vγ9Vδ2 T cells would 
express surface IL-21R. 
 
PBMCs were freshly isolated from normal healthy donors.  Cells were stained with an 
unconjugated mouse anti-human monoclonal antibody against IL-21R, followed by a 
secondary α-mouse Ig-PE antibody.  Cells were also stained with fluorochrome-conjugated 
antibodies specific for CD4, CD19, CD14, Vδ2 or Vγ9 together with CD3.  Cells were 
analysed by flow cytometry and assessed for IL21R expression by gating on live cells and 
on Vγ9+CD3+ T cells, CD4+CD3+ T cells, CD19+CD3− B cells or CD14+CD3− monocytes.  
IL-21R expression was detected on freshly isolated peripheral Vγ9Vδ2 T cells (Figure 
3.1A), CD4+ T cells (Figure 3.1B) CD19+ B cells (Figure 3.1C) but not on CD14+ 
monocytes (Figure 3.1D).  Highest expression was found on B cells (geometric mean 
fluorescence intensity (GMFI) fold increase of 5.8 ± 2.16), followed by CD4+ T cells 
(GMFI fold increase of 2.9 ± 0.85) and Vγ9Vδ2 T cells (GMFI fold increase of 1.8 ± 0.16).  
Monocytes served as a negative control and consistent with published data expression of IL-
21R was not found on resting monocytes (Parrish-Novak et al. 2000; Strengell et al. 2006; 
























Figure 3.1. Freshly isolated peripheral blood Vγ9Vδ2 T cells express the receptor for 
IL-21.   
PBMCs were freshly isolated and stained with unlabelled mouse anti-human mAb against 
IL-21R (black-outlined histogram) or with an isotype matched control mAb (solid gray 
histogram) followed by detection with anti-mouse Ig-PE.  IL-21R expression was measured 
by flow cytometry.  Cells were analysed by gating on live cells and on (A) Vγ9+CD3+ T 
cells, (B) CD4+CD3+ T cells (C) CD19+CD3− B cells or (D) CD14+ monocytes.  Flow 
cytometry histograms represent one of 4 independent experiments.  The values shown 
within histograms represent mean fold change in GMFI, calculated as (geometric MFI of 
IL-21R)/(geometric MFI of isotype control).  Results are expressed as mean ± standard 
deviation (SD) from four individual donors. 
 





























































The microbial metabolite HMB-PP has been described as the most potent and specific 
activator of Vγ9Vδ2 T cells.  Recognition of HMB-PP during many pathogenic infections 
leads to rapid activation and expansion of Vγ9Vδ2 T cells to very high numbers.  Previous 
in vitro studies have demonstrated HMB-PP to stimulate uniform activation of human 
Vγ9Vδ2 T cells (Brandes et al. 2009; Davey et al. 2011; Eberl et al. 2009; Vermijlen et al. 
2007).  Whilst others have shown enhanced expression of activation markers on in vitro 
stimulated peripheral Vγ9Vδ2 T cells in the presence of cytokines (Eberl et al. 2002a; Eberl 
et al. 2002b; Vermijlen et al. 2007).   
 
IL-21 is a Tfh signatory cytokine which plays a central role in B cell help.  Here I examined 
the effects of IL-21 and HMB-PP stimulation on peripheral Vγ9Vδ2 T cell IL-21R surface 
expression.  Freshly isolated PBMCs were treated with medium alone, or with HMB-PP (10 
nM) in the absence or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  Cells 
were kept in culture for 1, 2, 3, 4 and 5 days.  Every 24 hours cells were harvested and 
assessed for IL-21R expression by flow cytometry. 
 
Cumulative IL-21R data from 4 different healthy donors, taken on day 0 (freshly isolated) 
and over a 5 day time course are shown in Figure 3.2.  Here, as a measurement of IL-21R 
surface expression, the geometric MFI of IL-21R fluorescence is displayed on the y-axis.  
IL-21R surface expression was analysed on Vγ9Vδ2 T cells, CD4+ T cells and B cells in 
response to each culture condition (Figure 3.2).   
 
The most striking observations where made on day 2, were IL-21R expression on HMB-PP 
stimulated Vγ9Vδ2 T cells had peaked and was significantly (P=0.028, Mann-Whitney two-




expression (cells cultured in medium alone; GMFI 5 ± 0.58).  This up-regulation of IL-21R 
observed in response to HMB-PP stimulation was short-lived, as on day 3 IL-21R 
expression levels had dramatically decreased (GMFI 9 ± 1.9).  On day 5, IL-21R expression 
levels were similar to those observed on day 1 (GMFI 6.6 ± 1.3) (Figure 3.2A).  This effect 
was specific to Vγ9Vδ2 T cells as HMB-PP stimulation of PBMCs had no effect on IL-21R 
expression on CD4+ T cells (Figure 3.2B) or on B cells (Figure 3.2C).  
 
In contrast, after 1 day of culturing PBMCs with HMB-PP in the presence of IL-21 co-
stimulation, an initial down-regulation of IL-21R on Vγ9Vδ2 T cells was observed, which 
returned to baseline expression on days 2 and 3.  More interestingly after long-term culture 
of 5 days, IL-21R expression levels had increased (GMFI 8 ± 0.7) to levels which were 
higher to those at baseline expression (GMFI 5.3 ± 0.3).  Again, this pattern of IL-21R 
expression and response to co-stimulation with IL-21 in the presence of HMB-PP was 
unique to Vγ9Vδ2 T cells (Figure 3.2A), as it was not observed on CD4+ T cells (Figure 
3.2B). 
 
Stimulation of PBMCs with IL-21 alone resulted in a more long-lived down-regulation of 
the IL-21R on both Vγ9Vδ2 and CD4+ T cells.   Throughout the 5 day culture, IL-21R 
expression levels had been down-regulated to levels lower than those seen in the medium 
control.  In contrast to cells stimulated with both HMB-PP and IL-21, stimulation with IL-
21 alone did not allow recovery of IL-21R expression on both Vγ9Vδ2 and CD4+ T cells 
(Figure 3.2A and B).  Similarly, IL-21R expression on B cells was also significantly down-
regulated after 1 day with IL-21 stimulation (with or without HMB-PP) (P=0.028, Mann-
Whitney two-tailed test), except here a gradual recovery of IL-21R expression levels was 




































































Figure 3.2. HMB-PP induced up-regulation of IL-21R expression on peripheral blood 
Vγ9Vδ2 T cells.   
Freshly isolated PBMCs were cultured in medium (control, represents baseline IL-21R 
expression), or with HMB-PP (10 nM) in the absence or presence of IL-21 (50 ng/ml), or 
with IL-21 alone (50 ng/ml).  Freshly isolated PBMCs (Day 0) and PBMCs after 1, 2, 3, 4 
and 5 days in culture were stained for flow cytometry (as described in Figure 3.1)  Cells 
were analysed for IL-21R expression by gating on live cells, lymphocytes and on (A) 
Vδ2+CD3+ cells, (B) CD4+CD3+ T cells or (C) CD19+CD3− B cells.  IL-21R expression is 
shown as GMFI.  Results are expressed as mean ± SEM from four independently assessed 
donors.  A statistically significant difference on Vδ2+ T cell day 2 data between medium and 
HMB-PP treated cells/cultures was found (P=0.028).  A statistically significant difference 





Furthermore, after one day, HMB-PP stimulation induced the early activation marker CD25, 
which was significantly (P=0.028, Mann-Whitney two-tailed test) up-regulated on 25% of 
the Vγ9Vδ2 T cells and was further enhanced to 58% with co-treatment with IL-21.  In 
response to HMB-PP stimulation, activated Vγ9Vδ2 T cells continuously maintained 
surface expression of CD25 throughout the 5 days of culture (Figure 3.3A). 
 
Vγ9Vδ2 T cells cultured with IL-21 alone and in medium alone served as negative controls, 
under these conditions CD25 expression was absent on Vγ9Vδ2 T cells (Figure 3.3A).  
Similarly, CD25 was not up-regulated on CD4+ T cells (Figure 3.3B) under any of the 
indicated culture conditions, thus indicating a γδ T cell specific response to HMB-PP.  A 
small and short-lived up-regulation of CD25 after 1 day, was seen on B cells in response to 
IL-21 alone (Figure 3.3C).  Notably, co-staining with CD25 or CD69 revealed that IL-21R 
expression was primarily up-regulated on HMB-PP activated CD25 positive (Figure 3.4) 
and CD69 positive (data not shown) Vγ9Vδ2 T cells.   
 
Taken together, these data indicated that not only do γδ T cells become highly activated 
after 2 days with HMB-PP stimulation but also up-regulate surface IL-21R expression to 
peak levels, thus allowing Vγ9Vδ2 T cells to become highly responsive in vitro to 
exogenously added IL-21 and in vivo to IL-21 released from neighbouring cells in the 

























Figure 3.3. Sustained CD25 expression on HMB-PP activated peripheral blood 
Vγ9Vδ2 T cells.   
Freshly isolated PBMCs were cultured in medium, or with HMB-PP (10 nM) in the absence 
or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  Freshly isolated PBMCs 
(Day 0) and PBMCs after 1, 2, 3, 4 and 5 days in culture were stained for flow cytometry 
with anti-CD25-PE-Cy5, anti-CD3-APC and anti-Vδ2-FITC or anti-CD4-FITC or anti-
CD19-FITC.  Cells were analysed for CD25 expression, by gating on live cells lymphocytes 
and on (A) Vδ2+CD3+ cells, (B) CD4+CD3+ T cells or (C) CD19+CD3− B cells.  Results are 
expressed as mean percentage ± SEM from four independently assessed donors.  A 
statistically significant difference on Vδ2+ T cell day 1 data between medium and HMB-PP 
treated; and between medium and IL-21+HMB-PP treated cells/cultures was found 
(P=0.028). 















































































Figure 3.4. IL-21R expression is up-regulated on HMB-PP activated CD25+ Vγ9Vδ2 T 
cells.   
Freshly isolated PBMCs were cultured in medium, or with HMB-PP (10 nM) in the absence 
or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  After 2 days, cells were 
harvested and stained for flow cytometry, with unlabelled mouse anti-IL-21R followed by 
detection with anti-mouse Ig-PE, anti-CD25-PE-Cy5, anti-Vδ2-FITC and anti-CD3-APC.  
Cells were analysed for CD25 and IL-21R expression, by gating on live cells, lymphocytes 
and on Vδ2+CD3+ cells, quadrants were set using isotype-matched control antibodies.  
Numbers in dot plots represent the percentage of Vδ2+ T cells positive for CD25 and IL-


























I and others have demonstrated that Vγ9Vδ2 T cells in PBMCs can be successfully 
activated in response to HMB-PP and cytokine co-stimulation (Vermijlen et al. 2007).  Here 
the aim was to establish optimal conditions for γδ T cell activation in both PBMCS and in 
γδ T-B cell co-cultures.  Thus, I here examined the effects of IL-21 and HMB-PP 
stimulation on peripheral Vγ9Vδ2 T cells in PBMCs alongside Vγ9Vδ2 T cells in γδ T-B 
cell co-cultures. 
 
Vγ9Vδ2 T cells were positively isolated from freshly isolated PBMCs using the magnetic 
cell sorting system from Miltenyi Biotec, resulting in >97% purity (Figure 3.5A).  For 
optimum in vitro Vγ9Vδ2 T cell stimulation with HMB-PP, the presence of accessory 
(feeder) cells is required.  As feeder cells, peripheral B cells or (Figure 3.5B) peripheral 
monocytes (Figure 3.5C)  were isolated from Vγ9Vδ2 T cell depleted PBMC using anti-
CD19 or anti-CD14 microbeads, resulting in >98% and >96% purity, respectively.   
 
For supporting HMB-PP activation of purified γδ T cells, monocytes have already been well 
established as ‘feeder’ cells (Eberl et al. 2009), thus as initial control experiments, HMB-PP 
treated co-cultures were set-up using irradiated purified monocytes.  For comparison, at the 
same time, purified Vγ9Vδ2 T cells were co-cultured with purified irradiated B cells, in the 
presence of HMB-PP stimulation.  Flow cytometry analysis of activation markers showed 
that in comparison to monocytes, irradiated peripheral B cells were equally as effective at 
providing ‘feeder’ qualities.  Here, irradiated B cells had successfully supported HMB-PP 
activation of purified γδ T cells.  Furthermore, reducing the number of B cells co-cultured 
with γδ T cells from a 1:1 to a 1:2 ratio, did not affect the ability of irradiated B cells to 






























Figure 3.5. Flow cytometric purity analysis of freshly isolated Vγ9Vδ2 T cells, B cells 
and monocytes.   
Freshly isolated PBMCs were blocked with human Igs and stained with anti-Vγ9-PE-Cy5 
antibodies followed with anti-PE microbeads.  (A) Vγ9Vδ2 T cells were positively isolated 
from PBMCs using the magnetic cell sorting system from Miltenyi Biotec, resulting in 
>97% purity.  (B) B cells or (C) Monocytes were isolated from Vγ9Vδ2 T cell depleted 
PBMC using anti-CD19 or anti-CD14 microbeads, resulting in >98% and >96% purity, 
respectively.  Results are representative of 10 or more experiments performed. 
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Next, I established optimal conditions for γδ T cell activation in the presence of IL-21 and 
HMB-PP stimulation, in PBMCs and in γδ T-B cell co-cultures.  PBMCs alongside purified 
Vγ9Vδ2 T cells co-cultured with purified irradiated B cells (at a ratio of 1:1), were cultured 
with medium alone, with HMB-PP (10 nM) and in the presence of IL-21 (50 ng/ml).  After 
24 hours cells were harvested, stained with fluorochrome-conjugated antibodies and 
analysed by flow cytometry for CD25 and CD69 expression.   
 
Representative flow cytometry dotplots of CD25 and CD69 expression on Vγ9Vδ2 T cells 
in both PBMCS and in co-cultures is shown in Figure 3.6.  In PBMCs, stimulation of 
Vγ9Vδ2 T cells with HMB-PP alone induced co-expression of CD25 and CD69 in 38% of 
Vγ9Vδ2 T cells, which was further enhanced (48%) with co-treatment with IL-21.  In 
comparison, stimulation of Vγ9Vδ2 T cells in co-cultures with HMB-PP alone induced co-
expression of CD25 and CD69 in only 18% of Vγ9Vδ2 T cells, which was further enhanced 
(25%) with co-treatment with IL-21 (Figure 3.6).  Thus, in agreement with previous studies 
(Vermijlen et al. 2007), the presence of cytokines, such as IL-21 does enhance expression of 
activation markers on in vitro HMB-PP stimulated peripheral Vγ9Vδ2 T cells.   
 
Furthermore, in PBMCs the percentage of Vγ9Vδ2 T cells expressing CD25 or CD69 was 
dose-dependent on the concentration of HMB-PP.  As the concentration of HMB-PP was 
decreased 10 fold from 10 nM to 1 and 0.1 nM, the percentage of Vγ9Vδ2 T cells 
expressing either CD25 or CD69 had also decreased accordingly.  CD25 or CD69 
expression induced on Vγ9Vδ2 T cells was not influenced by the high concentrations of IL-
21 (50-100 ng/ml) used here (Figure 3.7).  However, as previously reported, much lower 
concentrations of IL-21 (0.1-10 ng/ml), become less potent at providing co-stimulation for 



















Figure 3.6. HMB-PP activated Vγ9Vδ2 T cells in both PBMCs and in co-cultures co-
express CD25 and CD69.   
Freshly isolated PBMCs (top three dot plots) and co-cultures of γδ T cells with B cells at a 
1:1 ratio (bottom three dot plots) were cultured in medium, or with HMB-PP (10 nM) in the 
absence or presence of IL-21 (50 ng/ml).  After 24 hours, cells were harvested and stained 
for flow cytometry, with anti-Vγ9-PE-Cy5, anti-CD3-APC and anti-CD25-PE and anti-
CD69-FITC.  Cells were analysed for CD25 and CD69 expression, gating on live cells, 
lymphocytes and on Vγ9+CD3+ T cells, quadrants were set using isotype-matched control 
antibodies.  Numbers in dot plots represent the percentage of Vγ9+ T cells positive for CD25 
and CD69.  Results are representative of four independently assessed donors. 
 


















































Figure 3.7. CD25 and CD69 expression on Vγ9Vδ2 T cells is dependent on the 
concentration of HMB-PP.   
Freshly isolated PBMCs were cultured in medium with 0.1, 1 or 10 nM of HMB-PP and in 
the presence of 50 or 100 ng/ml of IL-21.  After 24 hours, cells were harvested and stained 
for flow cytometry with anti-Vγ9-PE-Cy5, anti-CD3-APC and anti-CD25-PE and anti-
CD69-FITC.  Cells were analysed for CD25 and CD69 expression, by gating on live cells, 
lymphocytes and on Vγ9+CD3+ cells, isotype-matched antibodies were used as controls.  
Graphs show percentage of (A) CD25 and (B) CD69 positive, Vγ9+CD3+ T cells.  Results 

































































Migration and positioning of B and Tfh cells to B cell follicles are tightly controlled by the 
chemokine CXCL13 and its receptor CXCR5 (King 2009; King et al. 2008).  CXCL13 is 
constitutively secreted by FDCs and Tfh cells in GCs, which attracts B and T cells bearing 
the CXCR5 receptor (Allen and Cyster 2008; Elgueta et al. 2010; Förster et al. 1994; Kim et 
al. 2004; Moser and Loetscher 2001; Moser et al. 2002; Rasheed et al. 2006).  In order for 
γδ T cells to induce B cell activation and provide potent B cell help direct cell-to-cell 
contact between the two cell types would be required.  Therefore, cell proximity would be a 
prerequisite for such cell-to-cell contact to occur.  Here, I propose IL-21 induced secretion 
of CXCL13 by HMB-PP activated γδ T cells, as a possible mechanism of attracting 
circulating CXCR5+ B cells and Tfh cells towards CXCL13 producing γδ T cells (Vermijlen 
et al. 2007).   
 
It has previously been shown that V9V2 T cells stimulated with HMB-PP in the presence 
of IL-21 but not in the presence of IL-2 or IL-4 expressed mRNA levels of CXCL13.  
Furthermore, secretion of CXCL13 protein into the supernatants of PBMC stimulated with 
HMB-PP and IL-21 depended on the presence of V9V2 T cells (Vermijlen et al. 2007).  
Here, the aim was to establish optimal in vitro conditions for detection of CXCL13 in 
V9V2 T cells stimulated with HMB-PP in the presence of IL-21 and to directly confirm 
 T cells as the source of CXCL13 on the protein level.   
 
In order to achieve this, preliminary experiments were designed to establish optimal 
conditions for detection of CXCL13, which began by examining the effects of using various 
HMB-PP and IL-21 concentrations on Vγ9Vδ2 T cell secretion of CXCL13.  For a more 
precise analysis of CXCL13 expression, I utilised purified peripheral Vγ9Vδ2 T cells 




within PBMCs.  Peripheral blood Vγ9Vδ2 T cells and B cells (as feeder cells) were isolated 
to high purities as previously described in Figure 3.5.  Purified peripheral γδ T cells were 
co-cultured with purified irradiated peripheral B cells (at a ratio of 1:1), with various 
concentrations of HMB-PP (1 and 10 nM), IL-21 (0.1, 1, 10, and 100 ng/ml) or IL-2 (0.1, 1, 
10, and 100 units/ml).  After, 3 days total CXCL13 levels in culture supernatants were 
measured by using a well established ELISA method. 
 
In co-cultures stimulated with 10 nM of HMB-PP, IL-21 induced a clear dose-dependent 
effect on CXCL13 secretion, in contrast IL-2 was dose-dependent in inhibiting CXCL13 
secretion (Figure 3.8A).  In comparison, the effects of IL-21 co-stimulation in the presence 
of a lower concentration of HMB-PP (1 nM) was less prominent on CXCL13 secretion 
(Figure 3.8A).  IL-21 alone, in the absence of HMB-PP stimulation did not induce secretion 
of CXCL13 into cultures supernatants (data not shown).  These results identified 10 nM of 
HMP-PP along with 10-100 ng/ml of IL-21 as optimum concentrations for inducing 
CXCL13 secretion by Vγ9Vδ2 T cells in co-cultures.  Furthermore, noticeably higher levels 
of CXCL13 protein were detected in culture supernatants harvested following 3 days of 
incubation in comparison to supernatants harvested after 2 days (data not shown).  Thus, 
indicating a 3 day culture period to be optimal for detecting higher levels of secreted 
CXCL13. 
 
After having established the above optimum culture conditions, experiments were repeated 
using peripheral blood γδ and B cells from four different donors.  Vγ9Vδ2 T cells and 
irradiated B cells were co-cultured in medium, or with HMB-PP (10 nM) in the absence or 
presence of IL-21 (100 ng/ml), or with IL-21 alone (100 ng/ml).  After 3 days culture 
supernatants were harvested and concentration of secreted CXCL13 was measurement by 
ELISA (Figure 3.8B).  Here, HMB-PP alone had induced production of CXCL13 (460 
pg/ml), this was substantially increased four-fold (1950 pg/ml) with co-treatment with IL-
21(Figure 3.8A and B).  Secretion of CXCL13, induced by HMB-PP+IL-21 stimulation 
was significantly (P=0.016, Mann-Whitney two-tailed test) higher when compared to the 




blocking antibodies, to block of any IL-4 and IFN-γ which may be inhibiting γδ T cell 
response to IL-21 and in turn inhibiting CXCL13 expression, blocking of these cytokines 
did not effect CXCL13 expression.  The possibility of IL-21 inducing production of IL-17 
by γδ T cells was also ruled out, as IL-17 in culture supernatants was not detected by ELISA 


























Figure 3.8. IL-21 induces secretion of CXCL13 by HMB-PP activated Vγ9Vδ2 T cells.   
Peripheral Vγ9Vδ2 T cells and peripheral B cells were freshly isolated (as described in 
Figure 3.5) and co-cultured at a ratio of 1:1 under the indicated conditions, after 3 days 
culture supernatants were harvested and concentration of CXCL13 was measurement by 
ELISA.  (A) Vγ9Vδ2 T cells and irradiated B cells were co-cultured in medium with 1 nM 
or 10 nM HMB-PP and in the absence or presence of various concentrations (0.1, 1, 10, and 
100) of IL-21 (ng/ml) or IL-2 (U/ml).  Results are representative of two experiments 
performed.  (B) Vγ9Vδ2 T cells and irradiated B cells were co-cultured in medium, or with 
HMB-PP (10 nM) in the absence or presence of IL-21 (100 ng/ml), or with IL-21 alone (100 
ng/ml).  After 3 days culture supernatants were harvested and concentration of CXCL13 
was measurement by ELISA.  Results are expressed as mean + SEM of three or four 
experiments.  Statistical difference between medium and IL-21 + HMB-PP treated was 
found to be significant (P= 0.016).  
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 To confirm  T cells as source of CXCL13 on the protein level, I established a unique and 
novel method to detect intracellular CXCL13.  Vγ9Vδ2 T cells and irradiated B cells were 
co-cultured in medium, or with HMB-PP (10 nM) in the absence or presence of IL-21 (100 
ng/ml), or with IL-21 alone (100 ng/ml).  After 2 days, to block the secretion of intracellular 
CXCL13 cells were treated with brefeldin A.  After 4 hours, cells were harvested, fixed and 
permeabilised.  Cells were stained with fluorochrome-conjugated antibodies specific for 
CXCL13, CD25, CD3 and Vγ9.  Flow cytometry analysis revealed that intracellular 
CXCL13 was expressed by 0.8% of HMB-PP stimulated CD25+ Vγ9Vδ2 T cells, which 
was further enhanced (2%) with co-treatment with IL-21 (Figure 3.9).  This clear shift in 
CXCL13 positive population was evident only on gated Vγ9Vδ2 T cells but not on gated B 
cells (data not shown).   
 
These findings were further confirmed by immunofluorescence microscopy.  Co-cultures 
were set up as above.  After 3 days cells were treated with brefeldin and after 4 hours, cells 
were harvested, fixed and permeabilised.  Cells were stained for intracellular CXCL13 
(conjugated to a green- fluorescent dye), surface Vδ2 (conjugated to a red- fluorescent dye) 
and counterstained with a blue fluorescent nuclear stain called DAPI.  Cells were mounted 
on to microscope slides and viewed under a fluorescence microscope.  Intracellular 
CXCL13 was clearly observed in Vδ2 positive cells stimulated with IL-21+HMB-PP 
(Figure 3.10D) but not in cells incubated in medium alone (Figure 3.10A).  Vδ2 negative 
cells identified as B cells, stained negative for intracellular CXCL13 (Figure 3.10C).  An 
isotope-matched antibody was used as control staining for CXCL13 which was also 
negative for intracellular CXCL13 (Figure 3.10B).   
 
Cytokines such as IL-4 and IFN-γ are also known to regulate B cell differentiation and 
antibody production (Crotty 2011; King 2009).  Previous studies have shown activated 
human  T cells to provide help to B cells via soluble factors such as IL-4 and IL-10 
(Caccamo et al. 2006a).  Thus, Vγ9Vδ2 T cells in co-cultures were also simultaneously 
stained for intracellular IL-4 and IFN-γ and TNF-α.  HMB-PP stimulation induced 




cells, respectively.   The percentage of IL-4 (12.5%) positive and IFN-γ (18%) positive 
Vγ9Vδ2 T cells, was further increased with co-treatment with IL-21 (Figure. 3.11), there 
was no change in TNF-α positive Vγ9Vδ2 T cells (data not shown).  Intracellular cytokine 
expression of IL-4, IFN-γ and TNF-α was not found in Vγ9Vδ2 T cells treated with medium 
or with IL-21 alone (data not shown).  Noticeably, CXCL13+ CD25+ Vγ9Vδ2 T cells also 























Figure 3.9. Detection of intracellular CXCL13 in Vγ9Vδ2 T cells by flow cytometry.  
Vγ9Vδ2 T cells and B cells were freshly isolated (as described in Figure 3.5) and co-
cultured at a ratio of 1:1 in medium, or with HMB-PP (10 nM) in the absence or presence of 
IL-21 (100 ng/ml).  After 2 days, cultures were treated with brefeldin A (20 ug/ml).  After 4 
hours, cells were harvested, fixed and permeabilised.  Cells were stained for flow cytometry 
with mouse anti-CXCL13, followed by detection with an Alexa fluor488-conjugated goat 
anti-mouse-secondary antibody, anti-Vγ9-PE-Cy5, anti-CD3-APC and anti-CD25-PE-Cy7.  
Quadrants in dot plots were set using isotype-matched control antibodies.  Numbers in dot 
plots represent the percentages of Vγ9+CD3+ T cells positive for CXCL13 and CD25.  Data 




































































Figure 3.10. Detection of intracellular CXCL13 in Vγ9Vδ2 T cells by 
immunofluorescence microscopy.   
Vγ9Vδ2 T cells and B cells were freshly isolated (as described in Figure 3.5) and co-
cultured at a ratio of 1:1 in (A) medium, or (B-D) with HMB-PP (10 nM) in the presence of 
IL-21 (100 ng/ml).  After 3 days cultures were treated with brefeldin A (20 ug/ml).  After 4 
hours, cells were harvested, fixed and permeabilised.  Cells were stained with mouse anti-
CXCL13, followed by detection with an Alexa fluor488-conjugated goat anti-mouse IgG1-
secondary antibody (green), anti-Vδ2-PE (red), and counterstaining with DAPI for nuclear 
staining (blue).  (B) Isotope-matched antibody was used as control staining for CXCL13 
antibody staining.  Cells were analysed by immunofluorescence microscopy.  Data are 


































Figure 3.11. CXCL13 positive Vγ9Vδ2 T cells express IL-4 and IFN-γ.   
Vγ9Vδ2 T cells and B cells were freshly isolated (as described in Figure 3.5) and co-
cultured at a ratio of 1:1 in medium, or with HMB-PP (10 nM) in the absence or presence of 
IL-21 (100 ng/ml).  After 2 days, cultures were treated with brefeldin A (20 ug/ml).  After 4 
hours, cells were harvested, fixed and permeabilised.   Cells were stained for flow 
cytometry for intracellular CXCL13, IL-4 and IFN-γ.  Dot plots show data from HMB-PP 
treated cultures, in the absence and presence of IL-21.  Numbers in dot plots represent the 
percentages of Vγ9+CD3+ T cells positive for (A) IL-4 and CXCL13 and (B) IFN-γ and 
CXCL13.  Quadrants in dot plots were set using isotype-matched control antibodies.  Data 

































Expression of the chemokine receptor CXCR5 allows activated T cells to migrate into 
CXCL13-rich B cell follicles of secondary lymphoid tissues, where they provide 
instructions for B cell differentiation into plasma cells (King 2009; King et al. 2008).  Here, 
I examined surface expression of CXCR5 on freshly isolated and in vitro HMB-PP and IL-
21 activated peripheral blood Vγ9Vδ2 T cells.  CXCR5 was absent on freshly isolated 
peripheral Vγ9Vδ2 T cells (Figure 3.12A) but present on 7% of freshly isolated peripheral 
CD4+ T cells (Figure 3.12B).  
 
To study the expression of CXCR5 on HMB-PP and IL-21 in vitro stimulated peripheral 
Vγ9Vδ2 T cells, freshly isolated PBMCs from normal healthy donors were cultured in 
medium, with HMB-PP (10 nM) in the absence or presence of IL-21 (50 ng/ml) or with IL-
21 alone.  After 2 days cells were harvested and stained with fluorochrome-conjugated 
antibodies specific for CXCR5.  Cells were analysed by flow cytometry and assessed for 
CXCR5 expression by gating on lymphocytes, gating out dead cells and doublets, and 
gating on Vγ9+CD3+ T cells or CD4+ CD3+ T cells.   
 
Representative flow cytometry dotplots of CXCR5 expression on HMB-PP and IL-21 in 
vitro stimulated Vγ9+CD3+ T cells is shown in Figure 3.13A.  Surface expression of 
CXCR5 was not detected on HMB-PP stimulated Vγ9Vδ2 T cells and the addition of IL-21 
did not induce expression of CXCR5.  Similarly, stimulation with IL-21 alone (100 and 50 
ng/ml) did not induce expression of CXCR5 on Vγ9Vδ2 T cells (data not shown). 
 
Expression of CXCR5 is known to be rapid and transient, therefore I further examined for 




timepoints (day 1, 3, 4, 5, 6).  Pre-stimulation of Vγ9Vδ2 T cells with HMB-PP for 42 hours 
before the addition of IL-21, or co-treatment with higher concentrations of IL-21 
(100ng/ml) did not induce CXCR5 expression (data not shown).  In addition, experiments 
where repeated using peripheral blood from several individual donors.  Here, CXCR5 was 
found to be absent and not detected on any of the timepoints or donors tested (data not 
shown). 
 
Previously Schaerli et al. (2001) showed induction of CXCR5 on peripheral blood naïve and 
CXCR5-negative memory CD4+ T cells with PHA stimulation.  Therefore similarly, to 
induce CXCR5 surface expression, I cultured PBMCs with PHA (1µg/ml).  After 2 days 
cells were harvested, stained for CXCR5 and analysed by flow cytometry.  Although PHA 
stimulation did not induce CXCR5 expression on peripheral Vγ9Vδ2 T cells (Figure 
3.13B), however, the percentage of CD4+ T cells expressing CXCR5 had increased from 7% 
(day 0) to 22% (day 2) (Figure 3.12B and 3.13B). 
 
As a source of obtaining and stimulating naïve γδ T cells, human cord blood mononuclear 
cells were stimulated with HMB-PP in the presence of various concentrations of IL-21 or 
IL-2.  CXCR5 was not detected on the very small population of γδ T cells present in cord 



























Figure 3.12. Freshly isolated peripheral Vγ9Vδ2 T cells do not express CXCR5.  
Freshly isolated PBMCs from a single donor were stained with anti-CXCR5-PE, anti-Vγ9-
E-Cy5, anti-CD4-FITC and anti-CD3-APC.  Cells were analysed by flow cytometry for 
CXCR5 expression by gating on lymphocytes, gating out dead cells and doublets, and 
gating on, (A) Vγ9+CD3+ cells or (B) CD4+CD3+ T cells (positive control).  Gates were set 
using isotype-matched control antibodies.  Numbers in dot plots represent the percentage of 













































Figure 3.13. IL-21, HMB-PP or PHA stimulation does not induces CXCR5 expression 
in peripheral Vγ9Vδ2 T cells.    
Freshly isolated PBMCs from a single donor were cultured in medium, with HMB-PP (10 
nM) in the absence or presence of IL-21 (50 ng/ml) or with PHA (1µg/ml).  After 2 days in 
culture, stimulated PBMCs were stained with anti-CXCR5-PE, anti-Vγ9-PE-Cy5, anti-CD4-
FITC and anti-CD3-APC.  Cells were analysed by flow cytometry for CXCR5 expression, 
by gating on lymphocytes, gating out dead cells and doublets, and gating on Vγ9+CD3+ cells 
or CD4+CD3+ T cells (positive control).  Gates were set using isotype-matched control 
antibodies.  Numbers in dot plots represent the percentage of CXCR5 positive cells.  Data 







































Numerous co-stimulatory molecules have been identified playing a role in the initiation of 
T-dependent B cell responses.  Successful γδ-induced B cell activation and response would 
require physical interaction via presentation of co-stimulatory molecules.  Earlier studies 
involving the use of a weaker Vγ9Vδ2 T cell activator (IPP) in the absence of cytokine 
stimulation have shown up-regulation of some co-stimulatory molecules (CD40L, OX40, 
ICOS and CD70) involved in B cell help (Brandes et al. 2003).  Here, by using IL-21 in the 
presence of HMB-PP, I use a more physiologically relevant and novel way of inducing 
Vγ9Vδ2 T cell expression of co-stimulatory molecules.  Furthermore, I utilise 9-colour flow 
cytometry, which not only allows gating out of dead cells and doublets but also allows 
several markers to be studied at the same time.  This approach not only allows expression of 
several markers to be studied on Vγ9Vδ2 T cells but also simultaneously (as a control) on 
CD4+ T cells.  Here, I examined surface expression of co-stimulatory molecules CD40L, 
ICOS, OX40, CD70, CD28 and CD27 on freshly isolated and in vitro HMB-PP and IL-21 
stimulated peripheral blood Vγ9Vδ2 T cells.   
 
Surface expression of the early co-stimulatory molecule CD40L is transient and is usually 
only expressed by activated T cells (Daoussis et al. 2004).  Here, surface CD40L was not 
detected on freshly isolated peripheral Vγ9Vδ2 T cells or on CD4+ T cells (Figure 3.14).  
Similarly, the late co-stimulatory molecules ICOS and OX40 were both found to be absent 
on freshly isolated peripheral Vγ9Vδ2 T cells (Figure 3.15A).  Although, ICOS (6.6%) and 
OX40 (7.2%) was detected on a small percentage of freshly isolated peripheral CD4+ T cells 
(Figure 3.15B).  CD70, another important co-stimulatory molecule involved in B cell help 
was also found to be absent on freshly isolated peripheral Vγ9Vδ2 T cells (data not shown).  




and 92% of freshly isolated Vγ9Vδ2 T cells, respectively (Figure 3.16).  Similarly, the 






































Figure 3.14. Freshly isolated peripheral Vγ9Vδ2 T cells do not express CD40L.  Freshly 
isolated PBMCs from a single donor were stained with anti-CD40L-Pacific Blue, anti-
CD25- Pe-Cy7, anti-Vγ9-PE-Cy5, anti-CD4-ECD and anti-CD3-APC-H7.  Cells were 
analysed by flow cytometry by gating on lymphocytes, gating out dead cells and doublets, 
and gating on (A) Vγ9+CD3+ cells or (B) CD4+CD3+ T cells.  Gates were set using isotype-
matched control antibodies.  Numbers in dot plots represent the percentage of CD25 and 




































































Figure 3.15. Freshly isolated peripheral Vγ9Vδ2 T cells do not express ICOS or OX40.   
Freshly isolated PBMCs from a single donor were stained with anti-ICOS-PE, anti-OX40-
FITC, anti-Vγ9-PE-Cy5, anti-CD4-ECD and anti-CD3-APC.  Cells were analysed by flow 
cytometry by gating on lymphocytes, gating out dead cells and doublets, and gating on (A) 
Vγ9+CD3+ cells or (B) CD4+CD3+ T cells (positive control).  Gates were set using isotype-
matched control antibodies.  Numbers in dot plots represent the percentage of ICOS and 








































































Figure 3.16. Freshly isolated peripheral Vγ9Vδ2 T cells express CD28 and CD27.  
Freshly isolated PBMCs from a single donor were stained with anti-CD28-PE-Cy5, anti-
CD27-FITC, anti-Vγ9-PE-Cy5 or FITC conjugated and anti-CD3-APC.  Cells were 
analysed by flow cytometry by gating on lymphocytes, gating out dead cells and doublets, 
and gating on Vγ9+CD3+ T cells.  Gates were set using isotype-matched control antibodies.  
Numbers in dot plots represent the percentage of (A) CD28 and (B) CD27 positive cells.  
























To study surface expression of CD40L, ICOS and OX40 co-stimulatory molecules on 
HMB-PP and IL-21 stimulated peripheral Vγ9Vδ2 T cells, freshly isolated PBMCs were 
cultured in medium with or without HMB-PP.  After 42 hours of HMB-PP pre-stimulation, 
HMB-PP stimulated and non HMB-PP stimulated cultures (medium alone) were treated 
with or without IL-21.  After 2, 3, 4, 5 and 6 days in culture, cells were harvested and 
stained with fluorochrome-conjugated antibodies specific for CD40L, ICOS, OX40 and 
CD25.  Cells were analysed by flow cytometry and assessed for CD40L, ICOS, OX40 and 
CD25 surface expression by gating on lymphocytes, gating out dead cells and doublets, and 
gating on Vγ9+CD3+ or CD4+CD3+ T cells. 
 
Representative flow cytometry dotplots of CD40L expression on Vγ9+CD3+ and CD4+CD3+ 
T cells is shown in Figure 3.17.  Expression of the early co-stimulatory marker CD40L was 
not detected on HMB-PP-stimulated or on non-stimulated (medium control) Vγ9Vδ2 T cells 
(Figure 3.17A).  CD4+ T cells are known to rapidly up-regulated CD40L when cultured for 
6 hours with PMA and ionomycin.  To test methodology used and the binding potential of 
the CD40L antibody, I examined induction of CD40L expression on CD4+ T cells.  Here, 





































Figure 3.17. IL-21 does not induce CD40L expression by HMB-PP activated 
peripheral Vγ9Vδ2 T cells.   
(A) Freshly isolated PBMCs were cultured in medium with or without HMB-PP (10 nM).  
After 42 hours, HMB-PP stimulated and non HMB-PP stimulated cultures (medium alone) 
were treated with or without IL-21 (50 ng/ml).  After 2 days (6 hours post IL-21 
stimulation) cells were harvested and stained with anti-CD40L-Pacific Blue, anti-CD25- Pe-
Cy7, anti-Vγ9-PE-Cy5 and anti-CD3-APC-H7.  Cells were analysed by flow cytometry by 
gating on lymphocytes, gating out dead cells and doublets, and gating on Vγ9+CD3+ cells.  
Gates were set using isotype-matched control antibodies.  Numbers in dot plots represent 
the percentage of CD25 and CD40L positive cells.  (B) As a positive control PBMCs were 
also cultured with PMA (10 ng/ml) and ionomycin (1 µg/ml).  After 6 hours, cells were 
harvested and analysed by flow cytometry by gating on lymphocytes, live single cells and 
CD4+CD3+ cells.  Numbers in dot plots represent the percentage of CD40L positive cells. 

































Vγ9Vδ2 T cell surface expression of the late co-stimulatory molecules OX40 and ICOS was 
analysed over a 6 day culture period.  Cumulative data from 3 different healthy donors is 
shown in Figure 3.18A.  On day 2, in the presence of HMB-PP stimulation (with and 
without IL-21 co-stimulation), a substantial up-regulation of OX40 was observed, with 43% 
of Vγ9Vδ2 T cells expressing OX40.  Similar levels of OX40 expression was maintained 
for a further 1 day in response to HMB-PP, and a further 2 days with co-stimulation with 
IL-21.  OX40 expression on Vγ9Vδ2 T cells induced by HMB-PP alone declined 
considerably after 3 days in culture and after 4 days in the presence of IL-21 co-stimulation 
(Figure 3.18A).  
 
In contrast, up-regulation of ICOS expression on Vγ9Vδ2 T cells was more gradual.  On 
day 2, in response to HMB-PP stimulation alone 12.7% (± 3.8%) of Vγ9Vδ2 T cells 
expressed ICOS increasing to 21% (± 7.7%) on day 3.  Percentage of ICOS positive 
Vγ9Vδ2 T cells did not increase further with HMB-PP stimulation alone.  Strikingly, the 
addition of IL-21 co-stimulation induced and maintained a higher percentage of ICOS 
positive Vγ9Vδ2 T cells.  Over the 6 day culture period, levels of ICOS expression 
remained constant in response to HMB-PP stimulation, whereas co-treatment with IL-21 
resulted in a steady increase in percentage of ICOS positive Vγ9Vδ2 T cells.  On day 3, 
26% (± 6%) of Vγ9Vδ2 T cells expressed ICOS this was increased to 40% (± 8.5%) on day 
4, and similar levels were maintained after 5 and 6 days (44% ± 3%) in culture.  Thus, 
revealing an IL-21 dependent response in maintenance of a higher percentage of ICOS 
positive Vγ9Vδ2 T cells (Figure 3.18A).  Stimulation of PBMCs with HMB-PP and IL-21 
had no effect on ICOS or OX40 expression on CD4+ T cells, indicating a Vγ9Vδ2 T cell 
specific response (Figure 3.18B).  Representative flow cytometry dotplots of ICOS and 
OX40 expressingVγ9Vδ2 T cells, after 4 days in culture is shown in Figure 3.19.  Notably, 
co-stimulation with IL-21 resulted in 16% of Vγ9Vδ2 T cells co-expressing ICOS and 


























Figure 3.18. IL-21 maintains higher expression of OX40 and ICOS on HMB-PP 
activated peripheral Vγ9Vδ2 T cells.   
Freshly isolated PBMCs were cultured in medium with or without HMB-PP (10 nM).  After 
42 hours, HMB-PP stimulated and non HMB-PP stimulated cultures (medium alone) were 
treated with or without IL-21 (50 ng/ml).  Freshly isolated PBMCs (Day 0) and PBMCs 
after 2, 3, 4, 5 and 6 days in culture, were stained for flow cytometry with anti-ICOS-PE, 
anti-OX40-FITC, anti-Vγ9-PE-Cy5, anti-CD4-ECD and anti-CD3-APC.  Isotope-matched 
antibodies were used as control staining.  Cells were analysed for percentage of OX40 and 
ICOS positive (A) Vγ9+CD3+cells, and (B) CD4+CD3+ cells.  Results are expressed as mean 
± SEM of three independently assessed donors.  
























































































































































Figure 3.19. IL-21 induces co-expression of ICOS and OX40 on HMB-PP activated 
peripheral Vγ9Vδ2 T cells.   
Freshly isolated PBMCs were cultured in medium with or without HMB-PP (10 nM).  After 
42 hours, HMB-PP stimulated and non HMB-PP stimulated cultures (medium alone) were 
treated with or without IL-21 (50 ng/ml).  After 4 days cells were harvested and stained with 
anti-ICOS-PE, anti-OX40-FITC, anti-Vγ9-PE-Cy5 and anti-CD3-APC.  Cells were 
analysed by flow cytometry by gating on lymphocytes, gating out dead cells and doublets, 
and gating on Vγ9+CD3+ cells.  Gates were set using isotype-matched control antibodies.  
Numbers in dot plots represent the percentage of ICOS and OX40 positive cells.  Data are 




















Surface expression of other co-stimulatory molecules such as CD70, CD28 and CD27 was 
also studied on HMB-PP and IL-21 stimulated peripheral Vγ9Vδ2 T cells.  Here, freshly 
isolated PBMCs were cultured in medium, or with HMB-PP (10 nM) in the absence or 
presence of IL-21 (50 ng/ml).  Freshly isolated PBMCs (Day 0) and PBMCs after 1, 2  3 
and 4 days in culture were harvested and stained with fluorochrome-conjugated antibodies 
specific for CD70, CD28 and CD27.  Cells were analysed by flow cytometry and assessed 
for CD70, CD28 and CD27 surface expression by gating on live cells lymphocytes and on 
Vδ2+CD3+ or Vγ9+CD3+ cells.  Data from 1 to 4 different healthy donors is shown in 
Figure 3.20. 
 
On day 2, in the presence of HMB-PP stimulation expression of CD70 was detected on 14% 
(± 3.5%) of Vγ9Vδ2 T cells, which peaked to 39% (± 4%) on day 3, expression was not 
maintained long-term, as a dramatic decrease was observed on day 4.  The addition of IL-21 
to HMB-PP stimulated Vγ9Vδ2 T cells resulted in suppression of surface CD70, as only 9% 
(± 3.7%) and 14% (± 5%) of Vγ9Vδ2 T cells expressed CD70 on day 2 and day 3, 
respectively (Figure 3.20A). 
 
The majority of freshly isolated peripheral Vγ9Vδ2 T cells expressed both CD28 and CD27 
(Figure 3.20).  Culturing of PBMCs over 3 days in medium alone (regardless of culture 
condition) resulted in a remarkable loss of CD28 expressing Vγ9Vδ2 T cells (Figure 3.20B) 




































Figure 3.20. CD70, CD28 and CD27 co-stimulatory molecule expression on non-
activated and HMB-PP activated peripheral Vγ9Vδ2 T cells.   
Freshly isolated PBMCs were cultured in medium, or with HMB-PP (10 nM) in the absence 
or presence of IL-21 (50 ng/ml).  Freshly isolated PBMCs (Day 0) and PBMCs after 1, 2, 3 
and 4 days in culture were stained and analysed by flow cytometry for (A) CD70 (B) CD28 
and (C) CD27 expression, by gating on live cells, lymphocytes and on Vδ2+CD3+ or 
Vγ9+CD3+ cells.  Gates were set using isotype-matched control antibodies.  CD28 day 0 and 
day 3 data representative of one donor, all other results are expressed as mean percentage ± 
SEM of two or four donors. 




























































































3.2.7.  HMB‐PP  stimulation  induces  expression  of  CCR7,  CD40, 
CD86 and HLA‐DR on peripheral Vγ9Vδ2 T cells 
 
After infection, antigen-presenting cells (APCs) initiate T cell immunity by the capture and 
presentation of foreign antigens to circulating T cells within secondary lymphoid organs.  
Expression of the chemokine receptor CCR7 allows migration and continuous recirculation 
of peripheral T and B cells into secondary lymphoid tissues.  Circulating T cells become 
activated by APCs after presentation of cognate antigen and APC markers (Moser and Eberl 
2007).  
 
As shown by previous studies, activated γδ T cells have the ability to differentiate into 
professional antigen presenting cells (γδ T-APCs) and present antigen, thus enabling γδ T 
cells to induce CD4+ and CD8+ T cell responses (Brandes et al. 2009; Brandes et al. 2005; 
Meuter et al. 2010).  As an additional and alternative mechanism of γδ T cell in providing B 
cell help, I propose HMB-PP activated γδ T cells to differentiate into γδ T-APCs allowing 
interaction of γδ T cells as APCs with CD4+ T cells in secondary lymphoid tissue.  In this 
working model, expression of CCR7 would allow migration of peripheral γδ T cells into 
secondary lymphoid tissues, where γδ T cell secretion of CXCL13 would attracts CXCR5-
positive CD4+ T and B cells.  CD4+ T cells become activated via co-localization and 
presentation of microbial antigen and APC markers by γδ T-APCs.  In turn, activated CD4+ 
T cells (as Tfh cells) along with activated γδ T cells work in synergy to provide B cell help 
(Moser and Eberl 2007; Vermijlen et al. 2007).  Thus, here I examined the expression of 
APC markers on freshly isolated and in vitro HMB-PP and IL-21 stimulated peripheral 
blood Vγ9Vδ2 T cells. 
 
To study the expression of APC markers on Vγ9Vδ2 T cells, freshly isolated PBMCs were 
cultured in medium with or without HMB-PP (10 nM).  After 42 hours, HMB-PP stimulated 
and non HMB-PP stimulated cultures (medium alone) were treated with or without IL-21 




were stained with fluorochrome-conjugated antibodies specific for CCR7, CD40, CD86 and 
HLA-DR APC markers.  Cells were analysed by flow cytometry and assessed for surface 
APC marker expression by gating on lymphocytes, gating out dead cells and doublets, and 
gating on Vγ9+CD3+ T cells. 
 
Cumulative data from 2 and 3 different healthy donors over a 6 day culture period is shown 
in Figure 3.21.  Freshly isolated peripheral blood Vγ9Vδ2 T cells lack surface expression of 
CCR7, CD86 and HLA-DR, however around 20% express surface CD40.  Culturing of 
PBMCs with HMB-PP alone, for 2 days (in the presence or absence of IL-21) induced 
Vγ9Vδ2 T cell surface expression of CCR7 (7.8 % ± 1.3%), CD86 (6.5 % ± 1.5%) and 
HLA-DR (26 % ± 5.6%) and further enhanced expression of CD40 (70 % ± 3.7%).  In 
response to HMB-PP, the percentage of CCR7 and HLA-DR expressing cells increased 
from day 2 to day 3 in culure whereas the percentage of CD40 and CD86 expressing cells 
remained the same. 
 
Co-treatment with IL-21 did not further enhance expression of CD40, CD86 or HLA-DR.  
However, 3 day with IL-21 co-stimulation (in the presence of HMB-PP) did somewhat 
increase the percentage of CCR7 positive Vγ9Vδ2 T cells (18% ± 4.6%) compared to 
culturing with HMB-PP alone (14% ± 4.2%), however, this was not found to be significant 
(Figure 3.21). 
 
Furthermore, HMB-PP stimulated Vγ9Vδ2 T cells co-expressed CCR7, CD40 and HLA-
DR.  Representative flow cytometry dotplots from a single donor display co-expression of 
CD40 and HLA-DR (Figure 3.22A), CD40 and CCR7 (Figure 3.22B), HLA-DR and CCR7 

































Figure 3.21. HMB-PP stimulation up-regulates CCR7, CD40, CD86 and HLA-DR 
expression on peripheral Vγ9Vδ2 T cells.   
Freshly isolated PBMCs were cultured in medium with or without HMB-PP (10 nM).  After 
42 hours, HMB-PP stimulated and non HMB-PP stimulated cultures (medium alone) were 
treated with or without IL-21 (50 ng/ml).  Freshly isolated PBMCs (Day 0) and PBMCs 
after 2 and 3 days in culture were stained with anti-CCR7, anti-CD40-PE, anti-CD86-FITC, 
HLA-DR-APC-H7, anti-CD3-APC-H7 and anti-Vγ9-Pe-Cy5.  Cells were analysed by flow 
cytometry for (A) CCR7, (B) CD40, (C) CD86 and (D) HLA-DR expression by gating on 
lymphocytes, gating out dead cells and doublets, and gating on Vγ9+CD3+ cells.  Gates were 
set using isotype-matched control antibodies.  Results are expressed as mean percentage ± 

































































































Figure 3.22. HMB-PP stimulation induces co-expression of CCR7, CD40 and HLA-DR 
on peripheral Vγ9Vδ2 T cells.   
PBMCs were cultured in medium with or without HMB-PP (10 nM).  After 42 hours, 
HMB-PP stimulated and non HMB-PP stimulated cultures (medium alone) were treated 
with or without IL-21 (50 ng/ml).   After 3 days cells were harvested and stained for flow 
cytometry as described in Figure 3.21.  Cells were analysed by gating on live, single, CD3+ 
Vγ9+ cells.  Numbers in dot plots represent the percentage of (A) CD40 and HLA-DR, (B) 
CD40 and CCR7, (C) HLA-DR and CCR7 positive Vγ9Vδ2 T cells.  Gates were set using 

























































































Similar to circulating peripheral CD4+ T cells, peripheral Vγ9Vδ2 T cells are heterogeneous 
and comprise of distinct memory populations, that can be distinguished on the basis of 
either CD45RA/CCR7 or CD45RA/CD27 surface marker expression (Dieli et al. 2003; 
Moser and Eberl 2007; Sallusto et al. 2004).  Here, using these two different methods of 
identifying Vγ9Vδ2 T cell memory populations, I investigated the differentiation and 
proliferation of Vγ9Vδ2 T cell naïve/memory subsets in response to in vitro IL-21 and 
HMB-PP stimulation. 
 
Freshly isolated PBMCs were cultured in medium or with HMB-PP, in the absence or 
presence of IL-21 or with IL-21 alone.  Freshly isolated PBMCs and PBMCs after 1, 2, and 
3 days in culture were harvested and stained with fluorochrome-conjugated antibodies 
specific for memory markers CD45RA and CCR7 or CD27, in combination with Vδ2 or 
Vγ9 and CD3 surface markers.  Cells were analysed by flow cytometry by gating on 
lymphocytes, gating out dead cells and doublets, and gating on Vγ9+CD3+ or Vδ2+CD3+ T 
cells.  On the gated Vγ9Vδ2 T cells a dot plot with CCR7 or CD27 along the y-axis and 
CD45RA on the x-axis was created.  Quadrants in dot plots were set using isotype-matched 
control antibodies.  Vγ9Vδ2 T cell memory subsets were identified based on 
CD45RA/CCR7 expression as follows: CD45RA+CCR7+ (Naïve), CD45RA–CCR7+ (T 
central memory; TCM), CD45RA–CCR7– (T effector memory; TEM) and CD45RA+CCR7– 
(terminally differentiated effector memory T cell; TEMRA) (Figure 3.23E).  Here, in freshly 
isolated PBMCs 1% of total Vγ9Vδ2 T cells were naïve (± 0.6 [SEM] n = 3), 1% TCM (± 
1.3%), 61% TEM (± 9%) and 35% TEMRA (± 9%).  Thus majority of peripheral Vγ9Vδ2 T 
cells were TEM, whilst the naïve and the TCM subset represented a minor or absent population 
(Figure 3.23).  The distribution of Vγ9Vδ2 T cell naïve/memory subsets differed form 





Culturing of PBMCs over 3 days in medium alone had not maintained Vγ9Vδ2 T cell 
naïve/memory pools.  Pattern of responsiveness of Vγ9Vδ2 T cell TEM and TEMRA subsets 
cultured in medium alone was comparable to cultures stimulated with HMB-PP and IL21.  
Hence, HMB-PP or IL-21 stimulation had no major additional effects on Vγ9Vδ2 T cell 
TEM and TEMRA populations.  After 1 day of culturing in medium alone, the percentage of 
Vγ9Vδ2 T cells in the TEM pool increased from 60 to 88% (Figure 3.23C), reciprocally the 
percentage of cell in the TEMRA pool decreased from 38% to 6% (Figure 3.23D).  After 3 
days the percentage of cells in the TEM pool had gradually returned back to similar levels as 
that seen on day 0 (Figure 3.23C).   
 
However, stimulation with HMB-PP and IL-21 did have additional effects on Vγ9Vδ2 T 
naïve and TCM populations.  Culturing of PBMCs in medium alone resulted in a loss of 
naïve Vγ9Vδ2 T cells.  Whereas in the presence of HMB-PP stimulation loss of naïve 
Vγ9Vδ2 T cells was somewhat rescued and levels were maintained throughout the 3 day 
culture (Figure 3.23 A).  Furthermore, an increase in the TCM population (9% ± 3%) was 
observed after 3 days in response to HMB-PP stimulation, which was further enhanced in 

































Figure 3.23. The effects of IL-21 and HMB-PP stimulation on Vγ9Vδ2 T cell memory 
subsets, based on CCR7 expression.   
Freshly isolated PBMCs were cultured in medium, or with HMB-PP (10 nM) in the absence 
or presence of IL-21 (50 ng/ml).  Freshly isolated PBMCs (0 hours) and PBMCs after 1, 2, 
and 3 days in culture were harvested and stained for memory markers CCR7 and CD45RA 
in combination with Vδ2 or Vγ9 and CD3 surface markers.  Cells were analysed by flow 
cytometry by gating on lymphocytes, gating out dead cells and doublets, and gating on 
Vγ9+CD3+ or Vδ2+CD3+ T cells.  Memory subsets were classified as follows: (A) Naïve = 
CD45RA+CCR7+, (B) T central memory (TCM) = CD45RA–CCR7+, (C) T effector memory 
(TEM) = CD45RA–CCR7– and (D) terminally differentiated effector memory T cell (TEMRA) 
= CD45RA+CCR7–.  (E) A representative dot plot showing percentage of freshly isolated 
Vδ2+ T cells expressing CCR7 and CD45RA.  Quadrants were set using isotype-matched 
control antibodies.  Results are expressed as mean percentage ± SEM of three (day 0, 2 and 
3 data) and one (day 1 data) healthy donor(s).   























































































Vγ9Vδ2 T cell memory subsets were also identified based on CD45RA/CD27 expression as 
follows: CD45RA+CD27+ (Naïve), CD45RA–CD27+ (TCM), CD45RA–/CD27– (TEM) and 
CD45RA+CD27– (TEMRA) (Figure 3.24E).  Cumulative data from 3 different healthy donors 
over a 3 day culture period is shown in Figure 3.24.  Here, approximately 50% of freshly 
isolated peripheral Vγ9Vδ2 T cells were TCM, 25% TEM, 16% TEMRA and 8% naïve.  
Noticeably, Vγ9Vδ2 T cell memory subsets identified based on CD45RA/CD27 expression 
differed to those identified based on CD45RA/CCR7 expression (Figure 3.24 and Figure 
3.23).   
 
Similar to the above findings based on CD45RA/CCR7 expression, culturing in medium 
alone had not maintained naïve/memory pools.  Over the three day culture period and 
regardless of culture condition, there was a gradual decrease in the percentage of naïve 
(Figure 3.24A) and TCM (Figure 3.24B) Vγ9Vδ2 T cells, whilst a gradual increase in the 
percentage of TEM (Figure 3.24C) and TEMRA (Figure 3.24D) Vγ9Vδ2 T cells.  Here, HMB-
PP or IL-21 stimulation had no major additional effect on the percentage of naïve/memory 

































Figure 3.24. The effects of IL-21 and HMB-PP stimulation on Vγ9Vδ2 T cell memory 
subsets, based on CD27 expression.   
Freshly isolated PBMCs were cultured in medium, or with HMB-PP (10 nM) in the absence 
or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  Freshly isolated PBMCs 
(0 hours) and PBMCs after 1, 2, and 3 days in culture were harvested and stained for 
memory markers CD27 and CD45RA in combination with Vδ2 or Vγ9 and CD3 surface 
markers.  Cells were analysed by flow cytometry by gating on lymphocytes, gating out dead 
cells and doublets, and gating on Vγ9+CD3+ or Vδ2+CD3+ T cells.  Memory subsets were 
classified as follows: (A) Naïve = CD45RA+CD27+, (B) TCM = CD45RA–CD27+, (C) TEM = 
CD45RA–CD27–  and (D) TEMRA = CD45RA+CD27– (E) A representative dot plot showing 
percentage of freshly isolated Vδ2+ T cells expressing CD27 and CD45RA.  Quadrants were 
set using isotype-matched control antibodies.  Results are expressed as mean percentage ± 
SEM of two to six healthy donors.   
 
 














































































Finally, the proliferative capacity of Vγ9Vδ2 T cell in PBMCs in response to IL-21 and 
HMB-PP stimulation was also examined.  Cumulative data from 3 different healthy donors, 
over a 7 day culture period is shown in Figure 3.25.  In freshly isolated PBMCs, Vγ9Vδ2 T 
cells represented 4% (± 0.2) of total CD3 positive cells.  In response to HMB-PP 
stimulation, Vγ9Vδ2 T cells began proliferating after 5 days in culture, increasing to 13.5% 
(± 4.8) after 7 days.  The addition of IL-21 in the presence of HMB-PP enhanced 
proliferation of Vγ9Vδ2 T cell.  After 7 days of culture Vγ9Vδ2 T cells represented 28.5% 
(± 8.6) of total CD3 positive cells.  The error bars displayed in Figure 3.25, account for 
donor-to-donor variability between the three donors, in the expansion potential of peripheral 



























Figure 3.25. Peripheral blood Vγ9Vδ2 T cells proliferate in response to IL-21+HMB-
PP stimulation.   
Freshly isolated PBMCs were cultured in medium with or without HMB-PP (10 nM).  After 
42 hours, HMB-PP stimulated and non HMB-PP stimulated cultures (medium alone) were 
treated with or without IL-21 (50 ng/ml).  Freshly isolated PBMCs (Day 0) and PBMCs 
after 3, 5 and 7 days in culture were stained for flow cytometry with anti-CD3-APC-H7 and 
anti-Vγ9-PE-Cy5.  The percentage of Vγ9+ CD3+ cells was determined by gating on 
lymphocytes, gating out dead cells and doublets, and gating on Vγ9+ CD3+ cells.  Data are 
shown as mean ± SEM from 3 individual donors. 
 













































After having established conditions that favour the acquisition of a B helper-Tfh-like 
phenotype on peripheral blood Vγ9Vδ2 T cells, the objective of this chapter was to similarly 
examine for markers associated with follicular B cell help on Vγ9Vδ2 T cells from 
secondary lymphoid tissue.  I hypothesised that Vγ9Vδ2 T cells found in inflamed tonsils 
readily express markers associated with follicular B cell help, which can be further up-
regulated in vitro by HMB-PP and IL-21 stimulation. 
 
Aims of this chapter were to investigate expression of the following markers on freshly 
isolated and on in vitro IL-21 and HMB-PP stimulated tonsillar Vγ9Vδ2 T cells: 
 
1. IL-21R 
2. CXCL13  
3. CXCR5  
4. Co-stimulatory molecules involved in B cell help 















Although Vγ9Vδ2 T cells represent only a minor subset of the peripheral lymphocyte 
population (0.5 to 5%), Vγ9Vδ2 T cells can expand dramatically following infection by 
pathogens that produce the microbial metabolite HMB-PP (Eberl et al. 2003; Holtmeier and 
Kabelitz 2005; Vermijlen et al. 2007).  Resting peripheral blood Vγ9Vδ2 T cells exhibit an 
inflammatory migration profile, which guides Vγ9Vδ2 T cells to sites of microbial 
infection.  Activation of Vγ9Vδ2 T cells in response to certain pathogens induces a rapid 
switch from inflammatory to lymph node homing phenotype, whereby expression of CCR7 
permits migration to secondary lymphoid tissue (Brandes et al. 2003).   
 
Increasing evidence shows γδ T cells to be present in several secondary lymphoid organs 
such as the draining lymph node, spleen, Peyer’s patches, tonsils, inflamed appendix and 
gastrointestinal mucosa (Brandes et al. 2003; Dieli et al. 2003; Groh et al. 1989).  One 
particular study showed increased number of γδ T cells, to be found in secondary follicles of 
infection related lymph nodes compared to lymph nodes from healthy individuals.  More so, 
γδ T cells in infection related lymph nodes were detected within GCs of B cell follicles co-
localised with CXCL13-producing cells (Brandes et al. 2003).  Collectively, these findings 
strongly indicate an involvement of γδ T cells in humoral immune responses (Brandes et al. 
2003; Caccamo et al. 2006a; Soo et al. 1995; Vermijlen et al. 2007).   
 
In my aim to investigate B helper-Tfh-like phenotype on Vγ9Vδ2 T cells in secondary 
lymphoid tissue, primarily I set out to identify the most easily available source of 
inflamed/infection related human lymphoid tissue that would provide a good source and 
yield of Vγ9Vδ2 T cells.  Here, I proposed the presence of activated/pre-activated Vγ9Vδ2 





Tonsillectomies, appendectomies and biopsies of the lower gastrointestinal tract, are 
routinely performed surgical procedures, which result in removal of inflamed lymphoid 
tissue.  Surgical removal of tonsils is not a treatment for the acute condition, but it is aimed 
at reducing the incidence of recurrent infections (Callery 2011; Crayford 2007).  Thus, a 
tonsillectomy is not performed during an episode of tonsillitis but after a response to 
infection is over.  However, tonsils similar to lymph nodes have large active GCs, that have 
been developed due to the constant exposure to antigens from the throat and upper 
respiratory tract, which makes tonsils an ideal organ for studying B cell responses (Crotty 
2011). 
 
In contrast, appendectomies are performed immediately after the onset of an acute infection. 
Hence, because the inflamed appendix is completely removed during the infection (Humes 
and Simpson 2006), this makes the appendix more ideal for examining an inflammatory 
immune response to a recent local acute infection.    
 
Mucosal surfaces of the gastrointestinal tract (i.e. intestines and colon) are colonised by 
lymphocytes that can be found in distinct aggregations (Peyer’s patches) or in loosely 
organized lymphoid follicles.  These lymphocytes are constantly exposed to extreme 
amounts of potentially pathogenic ingested and inhaled microorganisms (Nagler-Anderson 
2001; Pistoia and Cocco 2009).  Clusters of γδ T cells have been found to be present in 
gastrointestinal lymphoid tissues (Brandes et al. 2003).  Thus, mucosal biopsy specimens of 
the gastrointestinal tract, taken from patients undergoing diagnostic colonoscopy (i.e. for 
inflammatory bowel disease), could provide as an ideal source of γδ T cells from both 
inflamed and non-inflamed lymphoid tissue. 
 
Acute peritonitis is a sudden localised inflammation of the peritoneum, which usually 
occurs due to bacterial infection (Johnson et al. 1997).  For early diagnosis, cloudy 




peritoneal dialysis patients suffering from an episode of acute bacterial infection.  Thus, 
cloudy peritoneal effluents provide a ready source of immune cells including γδ T cells 
which have recently been involved in an immune response to acute infection (Davey et al. 
2011). 
 
Here, mononuclear cells were isolated from inflamed tonsils, inflamed appendices, from 
colon biopsies (inflamed and non-inflamed) taken from various parts of the large intestine 
(caecum, colon, sigmoid and rectum), and from peritoneal effluents taken from patients 
suffering from acute peritonitis.  Mononuclear cells were analysed for the percentage of 
Vδ2+ T cells amongst the CD3+ T cell population.  Cumulative data from several 
independent donors showed that Vδ2+ T cells represented 0.7% (± 0.1), 1% (± 0.6), 1% (± 
0.7) and 1% (± 0.2) of the total CD3+ T cell population, isolated from inflamed tonsils, 
inflamed appendices, colon biopsies and peritoneal effluents, respectively (Figure 4.1A). 
 
For comparison, mononuclear cells isolated from inflamed tonsils, inflamed appendices, 
colon biopsies were also analysed for Vδ1, CD4, and CD8 T cell populations.  CD4+ T cells 
represented the majority of total CD3+ T cells isolated from inflamed tonsils, inflamed 
appendices and colon biopsies, followed by a lower percentage of CD8+ T cells and a minor 
population of Vδ1+ T cells.  Vδ1+ T cells represented 7% (± 2.2%) and 1.3 % (± 0.3%) of 
total CD3+ T cells in colon biopsies and tonsils, respectively, which was higher than the 
percentage of Vδ2+ T cells.  Here, percentages of Vδ1+ T cells isolated from the appendix 
could not be confirmed, this was mainly due to the unavailability of a reliable clone of anti-
Vδ1 antibody, the original clone of antibody used was no longer commercially available 























Figure 4.1. Vγ9Vδ2 T cells are detectable in a variety of human lymphoid tissue.  
Mononuclear cells were isolated from inflamed tonsils, inflamed appendices and colon 
biopsies.  Peritoneal cells were harvested from peritoneal effluents obtained from peritoneal 
dialysis patients suffering from an episode of acute bacterial infection.  Cells were stained 
for surface CD3, CD4, CD8, Vδ1 and Vδ2 expression.  Cells were analysed by flow 
cytometry by gating on lymphocytes, live cells, singlets, and CD3 positive cells.  (A) 
Percentage of Vδ2+ T cells in various human tissues expressed as a percentage of CD3 
positive cells.  Percentage of CD4+, CD8+ and γδ T cell expressed as a percentage of CD3 
positive cells in human (B) colon biopsies, (C) appendix and (D) tonsils.  Data are shown as 
mean percentage + SEM from three to twelve independently assessed donors.  Peritoneal 
data was kindly provided by Chan-Yu Lin, Institute of Infection & Immunity, School of 
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To examine for in vivo activation of Vγ9Vδ2 T cells, mononuclear cells isolated from colon 
biopsies, inflamed appendices and inflamed tonsils were analysed for the early activation 
markers CD69 and CD25.  Interestingly, in colon biopsies a similar percentage (around 60 
%) of Vδ2+, Vδ1+, CD8+, and CD4+ T cells expressed the activation marker CD69 (Figure 
4.2A).  Similarly CD69 was also expressed on a large proportion of Vδ2+ T cells (44% ± 
9%), CD8+ (19% ± 5%) and CD4+ T cells (37% ± 4%) isolated from the appendix (Figure 
4.2B), whereas in tonsils CD69 was expressed on a smaller percentage of Vδ2+ T cells (5% 
± 1.8%), CD8+ T cells (12% ± 2.5%) and CD4+ T cells (28% ± 4%) (Figure 4.2C).   
 
The activation marker CD25 was consistently found to be expressed by a small population 
of CD4+ T cells (10-20%), but only by < 5% of Vδ2+ and CD8+ T cells in colon biopsies, 
appendices and tonsils (Figure 4.2).  Thus, in contrast to the absent expression of surface 
CD69 and CD25 on peripheral blood Vδ2+, CD8+, and CD4+ T cells, both CD69 and to a 
lesser extent CD25, was clearly found to be expressed on a distinct population of tissue 
derived Vδ2+, CD8+ and CD4+ T cells. 
 
Notably, although CD69 and CD25 were only expressed by a minority of tonsillar Vγ9Vδ2 
T cells, this differed to expressions found on peripheral blood Vγ9Vδ2 T cells (Figure 4.3).  
The presence of CD69/CD25 activated CD4+, CD8+ and Vγ9Vδ2 T cells within the same 
pool of tonsillar mononuclear cells strongly suggests in vivo activation of all three subsets of 
T lymphocytes, possibly in response to recent or chronic infection. 
 
Next, I wanted to find out if pre-activated tonsillar Vγ9Vδ2 T cells could be re-activated 
upon in vitro re-stimulation.  Here, to induce activation of tonsillar Vγ9Vδ2 and CD4+ T 
cells, mononuclear cells isolated from tonsils were stimulated with phorbol myristate acetate 
(PMA; 10ng/ml) and ionomycin (1 µg/ml).  Expression of CD25 was significantly (35% (± 
4.7%) vs 1.8% (± 0.5%), P=0.0028, Mann-Whitney two-tailed test) up-regulated on 
tonsillar Vδ2 T cells upon 3 hours of in vitro PMA and ionomycin stimulation.  Similarly 
CD25 expression on freshly isolated CD4+ T cells was also up-regulated (54% (± 9.4%) vs 




pre-activated Vγ9Vδ2 T cells and CD4+ T cells, from inflamed tonsils, can be rapidly re-
activated upon in vitro re-stimulation, thus have the capacity to respond to antigen re-
challenge. 
 
In conclusion, activated Vγ9Vδ2 T cells along side activated CD4+ and CD8+ T cells are 
detectable in infection related lymphoid tissues such as the inflamed tonsils and inflamed 
appendix.  Moreover, for several reasons, I found the inflamed tonsil as the most reliable 
and most accessible source of human secondary lymphoid tissue.  Tonsils, in comparison to 
colon biopsies and the appendix, provided a much better yield of not only Vγ9Vδ2 T cells 
but of total mononuclear cells (data not shown).  Therefore, from this point on, the rest of 




























Figure 4.2. Vγ9Vδ2 T cells from colon biopsies, appendix and tonsils express surface 
CD69.   
Mononuclear cells were isolated from human tonsils, appendix tissue and colon biopsies.  
Peritoneal cells were harvested from peritoneal effluents obtained from individuals on 
continuous ambulatory peritoneal dialysis.  Cells were stained for surface CD3, CD4, CD8, 
Vδ1, Vδ2, CD25 and CD69 expression.  Cells were analysed by flow cytometry by gating 
on lymphocytes, live cells, singlets and CD3 positive cells.  CD25 (white bars) and CD69 
(black bars) surface expression was analysed on CD4+, CD8+ and γδ T cell subsets from 
human (A) colon biopsies, (B) appendix and (C) tonsils.  Gates were set using isotype-
matched control antibodies.  Data are shown as mean percentage + SEM from three to 































































































Figure 4.3. Comparison of CD69 and CD25 expression on peripheral blood and 
tonsillar Vγ9Vδ2 T cells.   
Freshly isolated PBMCs and tonsillar mononuclear cells were stained for surface CD25 and 
CD69 expression.  Cells were analysed by flow cytometry by gating on lymphocytes, live 
cells, singlets, Vδ2+CD3+ cells.  Gates were set using isotype-matched control antibodies.  











Figure 4.4. CD25 expression on tonsillar Vγ9Vδ2 T cells is up-regulated upon in vitro 
PMA and ionomycin stimulation.   
Mononuclear cells isolated from human tonsils were cultured in medium.  After 1 hour 
PMA (10ng/ml), ionomycin (1 µg/ml) and brefeldin A (20 ug/ml) was added to the cultured 
cells.  After 3 hours cultured cells and freshly isolated tonsillar mononuclear were stained 
for surface CD3, CD4, Vδ2 and CD25 expression.  Cells were analysed for CD25 
expression by gating on lymphocytes, live cells, singlets, CD4+CD3+ cells and Vδ2+CD3+ 
cells.  Gates were set using isotype-matched control antibodies.  Data are shown as mean 
percentage + SEM from four to nine independent donors.  A statistically significant 
difference on Vδ2+ T cells between freshly isolated and PMA/ionomycin treated 




































































CXCL13 is a homeostatic chemokine constitutively expressed in follicles of secondary 
lymphoid tissue, selectively attracts B and Tfh cells via binding to its receptor CXCR5.  Tfh 
cells provide B cell help via presentation of a range of co-stimulatory molecules and by 
secretion of cytokines (King et al. 2008).  Tfh cells express helper cytokines such as IL-21, 
IL-2, IL-4 and IL-10 and limited amounts of IFN-γ, that influence B cell differentiation and 
antibody production (Crotty 2011; King 2009; King et al. 2008).  Some of these cytokines 
are also important in mediating function of Tfh cells (Crotty 2011; Reinhardt et al. 2009). 
 
Here, I proposed secretion of CXCL13 by tonsillar γδ T cells, as a possible mechanism of 
attracting circulating CXCR5+ B cells towards CXCL13 producing γδ T cells in tonsils.  γδ 
T cells have been well established as producers of pro-inflammatory  (IFN-γ and TNF-α) 
and anti-inflammatory cytokines (IL-4 and IL-10) (Caccamo et al. 2006a; Caccamo et al. 
2011; Hayday 2000; Vermijlen et al. 2007).  Secretion of cytokines by Vγ9Vδ2 T cells, 
within secondary lymphoid tissues, may modulate Tfh and B cell antibody responses.  Thus, 
here I examined tonsillar Vγ9Vδ2 T cells alongside tonsillar CD4+ T cells, for intracellular 
expression of CXCL13, IL-4, TNF-α and IFN-γ. 
 
Non-stimulated T lymphocytes produce cytokines and chemokines at levels which are too 
low for detection by flow cytometry.  Therefore, appropriate in vitro stimulation is required 
for detection of cytokines and chemokines.  PMA a protein kinase C activator is a potent T 
cell mitogen commonly used in conjunction with ionomycin (a calcium ionophore) to 
stimulate intracellular production of cytokines (Baran et al. 2001).  To inhibit secretion of 
cytokines from the cells, a protein transport inhibitor such as brefeldin A (BFA) is added to 
cell cultures (Nylander and Kalies 1999).  Here, to induce robust cell activation and potent 




PMA (10ng/ml) and ionomycin (1 µg/ml) in the presence of brefeldin A (20 ug/ml).  After 3 
hours, cells were harvested, fixed, permeabilised and stained with fluorochrome conjugated 
antibodies specific for CXCL13, IL-4, IFN-γ TNF-α and CD3, CD4 and Vγ9, before being 
analysed by flow cytometry. 
 
Expression of intracellular CXCL13 was not detected in tonsillar Vγ9Vδ2 T cells, but was 
clearly expressed by a distinct population of tonsillar CD25+ CD4+ T lymphocytes (9 % ± 
1.4%) (Figure 4.5).  Unlike CD4+ T cells, Vγ9Vδ2 T cells represent a very small population 
amongst tonsillar mononuclear cells.  Here, I failed to detect CXCL13 producing Vγ9Vδ2 T 
cells mainly due to the very small percentage of Vγ9Vδ2 T cells amongst mononuclear cells 
and also due to the methodology used.  The lengthy stimulation and staining procedure for 
the detection of CXCL13, resulted in lose of the very few Vγ9Vδ2 cells present.  This also 
made analysis and interpretation of flow cytometry data very difficult.  For a more reliable 
analysis of CXCL13 in tonsillar Vγ9Vδ2 T cells, it would be more ideal to work with highly 
purified tonsillar Vγ9Vδ2 T cells co-cultured with feeder cells.  I was unable to carry out 
such experiments, due to the restricted availability of fresh tonsils and also due to the 
challenges of isolating such a small population of Vγ9Vδ2 T cells at high purities.  
 
In response to PMA and ionomycin stimulation a small percentage of tonsillar Vγ9Vδ2 T 
cells (6% ± 3%) and CD4+ T cells (14% ± 0.5%) expressed IL-4.  Similar percentages of 
Vγ9Vδ2 T cells (34 % ± 8%) and CD4+ T cells (46% ± 5%) expressed the pro-inflammatory 
cytokine TNF-α.  Expression of IFN-γ was significantly higher in Vγ9Vδ2 T cells (58% ± 
10%) in comparison to CD4+ T cells (8% ± 1.5%) (P=0.0286, Mann-Whitney two-tailed 
test) (Figure 4.6).  IFN-γ producing Vγ9Vδ2 T cells and CD4+ T cells did not co-express 
IL-4 but co-expressed TNF-α (data not shown).  Levels of cytokines secreted by Tfh cells 
within GCs, is thought to be dependent on environmental conditions (Crotty 2011).  
Inflammatory conditions such as tonsillitis may favour secretion of IFN-γ by Vγ9Vδ2 T 
cells but not by CD4+ T cells.  Secretion of IFN-γ by Vγ9Vδ2 T cells may be a way of 















Figure 4.5. Tonsillar CD4+ T cells express intracellular CXCL13.   
Mononuclear cells isolated from human tonsils were cultured in medium.  After 1 hour 
PMA (10ng/ml), ionomycin (1 µg/ml) and brefeldin A (20 ug/ml) was added to the cultured 
cells.  After 3 hours cultured cells were harvested, fixed and permeabilized.  Cells were 
stained for flow cytometry with mouse anti-CXCL13, followed by detection with an Alexa 
fluor488-conjugated goat anti-mouse-secondary antibody, anti-CD4-ECD, anti-CD3-APC 
and anti-CD25-PE-Cy7.  Cells were analysed by gating on lymphocytes, live cells, singlets, 
CD4+CD3+ cells. (A) Numbers in dot plots represent the percentages of CD4+ T cells 
positive for CXCL13 and CD25.  Quadrants in dot plots were set using isotype-matched 
control antibodies.  Data are representative of four independently assessed donors.  (B) Data 


























































Figure 4.6. Tonsillar γδ and CD4+ T cells express IFN-γ, TNF-α and IL-4.   
Mononuclear cells isolated from human tonsils were cultured in medium.  After 1 hour 
PMA (10ng/ml), ionomycin (1 µg/ml) and brefeldin A (20 ug/ml) was added to the cultured 
cells.  After 3 hours cultured cells were harvested, fixed and permeabilized.  Cells were 
stained for flow cytometry for intracellular IFN-γ, TNF-α and IL-4.  Cells were analysed by 
gating on lymphocytes, live cells, singlets, CD4+CD3+ cells (white bars) and Vγ9+CD3+ 
cells (black bars).  Gates were set using isotype-matched control antibodies.  Data are 
shown as mean percentage + SEM from four independent donors.  A statistically significant 
difference between the percentage of IFN-γ expressing Vγ9Vδ2 T cells and CD4+ T cells 































In chapter 3, I failed to detect expression of CXCR5 and CD40L on freshly isolated and on 
HMB-PP and IL-21 stimulated peripheral Vγ9Vδ2 T cells.  However, expression of the co-
stimulatory molecules ICOS, OX40 and CD70 were detected on HMB-PP and IL-21 
stimulated peripheral Vγ9Vδ2 T cells.  Here, I proposed expression of CXCR5 and co-
stimulatory molecules on freshly isolated tonsillar γδ T cells.  In my model, expression of 
CXCR5 on tonsillar Vγ9Vδ2 T cells would allow migration into CXCL13-rich B cell 
follicles, where they would provide instructions for B cell activation, differentiation and 
antibody production via presentation of co-stimulatory molecules and secretion of cytokines 
(Vermijlen et al. 2007). 
 
To study the expression of CXCR5, and the co-stimulatory molecules ICOS, OX40 and 
CD40L on tonsillar Vγ9Vδ2 T cells, mononuclear cells freshly isolated from inflamed 
tonsils were stimulated with PMA (10ng/ml) and ionomycin (1 µg/ml) in the presence of 
brefeldin A (20 ug/ml).  Freshly isolated and PMA and ionomycin stimulated mononuclear 
cells were stained with fluorochrome-conjugated antibodies specific for CXCR5, ICOS, 
OX40, CD40L, CD4, CD3 and Vγ9, before being analysed by flow cytometry.  For 
comparison, expression of co-stimulatory molecules on Vγ9Vδ2 T cells was studied 
alongside CD4+ T cells. 
 
Here, a small population of freshly isolated tonsillar Vγ9Vδ2 T cells expressed CXCR5 (4 
% ± 1%), ICOS (6 % ± 1%) and OX40 (3 % ± 1%).  CD40L was found to be absent on 
freshly isolated tonsillar Vγ9Vδ2 T cells, but was significantly up-regulated (24% ± 5%) 
upon 3 hours with PMA/ionomycin stimulation (P=0.0167, Mann-Whitney two-tailed test).  
In contrast, stimulation with PMA/ionomycin did not further up-regulate expression of 




decreased and expression of OX40 was completely lost upon PMA/ionomycin stimulation 
(Figure 4.7A).   
 
Freshly isolated tonsillar CD4+ T cells expressed CXCR5 (22 % ± 4%), ICOS (59 % ± 7%) 
and OX40 (28 % ± 4%), at higher levels compared to freshly isolated tonsillar Vγ9Vδ2 T 
cells.  Similar to tonsillar Vγ9Vδ2 T cells, CD40L was found to be absent on freshly 
isolated tonsillar CD4+ T cells, but was significantly up-regulated (54% ± 6%) with 
PMA/ionomycin stimulation (P=0.0040, Mann-Whitney two-tailed test).  In contrast, there 
was a drop in the percentage of CXCR5 and ICOS positive CD4+ T cells.  Similar to 
Vγ9Vδ2 T cells, expression of OX40 was also completely lost on CD4+ T cells after 
PMA/ionomycin stimulation (Figure 4.7B).   
 
Representative flow cytometry dot plots are shown demonstrating CD40L positive tonsillar 
Vγ9Vδ2 T cells (Figure 4.7C) and CD4+ T cells (Figure 4.7D) after PMA/ionomycin 
stimulation.  Interestingly, co-staining with intracellular CXCL13 revealed that within the 





























Figure 4.7. CD40L expression on tonsillar Vγ9Vδ2 and CD4+ T cells is up-regulated 
upon in vitro PMA and ionomycin stimulation.   
Mononuclear cells isolated from inflamed tonsils were cultured in medium.  After 1 hour 
PMA (10ng/ml), ionomycin (1 µg/ml) and brefeldin A (20 ug/ml) was added to the cultured 
cells.  After 3 hours cultured cells were harvested, fixed and permeabilized.  Cultured cells 
and freshly isolated tonsillar mononuclear were stained for surface CD3, CD4, Vγ9, 
CXCR5, ICOS, OX40 CD40L and intracellular CXCL13.  Cells were analysed by gating on 
lymphocytes, live cells, singlets, (A) Vγ9+CD3+ cells and (B) CD4+CD3+ cells.  Data are 
shown as mean percentage + SEM from four to nine independent donors.  Numbers in flow 
cytometry dot plot represent the percentages of (C) Vγ9+CD3+ cells positive for CD40L and 
(D) the percentage of CD4+CD3+ cells positive for CD40L and CXCL13.  Gates were set 
using isotype-matched control antibodies.  Data is representative of three to four 
independent donors.  A statistically significant difference in the expression of CD40L 
between freshly isolated and PMA/ionomycin treated cells/cultures was found. 


































































































In Chapter 3, I proposed a possible interaction of γδ T cells as APCs with CD4+ T cells and 
studied the expression of APC markers on freshly isolated peripheral Vγ9Vδ2 T cells.  
Here, I examined for APC marker expression on freshly isolated tonsillar γδ T cells. 
 
To examine for APC marker expression on freshly isolated tonsillar Vγ9Vδ2 T cells, 
mononuclear cells freshly isolated from inflamed tonsils, were stained with fluorochrome-
conjugated antibodies specific for CCR7, CD40, CD86 and HLA-DR.  Cells were analysed 
by flow cytometry and assessed for surface marker expression by gating on Vγ9+CD3+ or 
CD4+ CD3+ T cells. 
 
Freshly isolated tonsillar Vγ9Vδ2 T cells expressed CCR7 (8 % ± 2%), CD40 (34 % ± 6%) 
and HLA-DR (16 % ± 3%).  Similarly, CCR7 (36 % ± 5%), CD40 (45 % ± 12%) and HLA-
DR (51% ± 6%) was also expressed on freshly isolated tonsillar CD4+ T cells.  CD68 was 
found to be absent on both tonsillar Vγ9Vδ2 and CD4+ T cells (Figure 4.8).  Furthermore, 
in tonsils a higher percentage of Vγ9Vδ2 T cells expressed CCR7, CD40 and HLA-DR in 














Figure 4.8. Tonsillar Vγ9Vδ2 and CD4+ T cells express CCR7, CD40 and HLA-DR.  
Mononuclear cells were freshly isolated from human tonsils.  Cells were stained for surface 
CD3, CD4, Vγ9, CCR7, CD40, HLA-DR and CD86 expression.  Cells were analysed by 
flow cytometry by gating on lymphocytes, live cells, singlets, and CD4+CD3+ cells (white 
bars) and Vγ9+CD3+ cells (black bars).  Gates were set using isotype-matched control 

















Figure 4.9. Higher percentage of Vγ9Vδ2 T cells express CCR7, CD40 and HLA-DR in 
tonsils in comparison to peripheral blood.   
Freshly isolated PBMCs and tonsillar mononuclear cells were stained for surface CD3, Vγ9, 
CCR7, CD40, HLA-DR and CD86 expression.  Cells were analysed by flow cytometry by 
gating on lymphocytes, live cells, singlets and Vγ9+CD3+ cells.  Gates were set using 
isotype-matched control antibodies.  Data are shown as mean percentage + SEM from three 
(PBMCs) and nine (tonsils) independent donors.   

























































Expression of the chemokine receptor CCR7 allows migration and continuous recirculation 
of peripheral T and B cells into secondary lymphoid tissues.  CCR7 is mainly found to be 
expressed by circulating naive and central memory T cells (Sallusto et al. 2004).  Here, 
based on CD45RA/CCR7 surface marker expression I identified Vγ9Vδ2 T cell memory 
populations in tonsils. 
 
Mononuclear cells were freshly isolated from inflamed tonsils and stained with 
fluorochrome-conjugated antibodies specific for memory markers CD45RA and CCR7 in 
combination with Vδ2 and CD3 surface markers.  Cells were analysed by flow cytometry by 
gating on Vδ2+CD3+ T cells and memory subsets were identified based on CD45RA/CCR7 
expression (CD45RA+CCR7+ (Naïve), CD45RA–CCR7+ (TCM), CD45RA–CCR7– (TEM) and 
CD45RA+CCR7– (TEMRA)).  In comparison, CD4+ T cells from tonsils were also analysed 
for memory subsets. 
 
In inflamed tonsils 6% (± 1.6%) of total Vγ9Vδ2 T cells were naïve, 2% (± 0.7%) TCM, 34% 
(± 6%) TEM and the majority were TEMRA (57% ± 5%).  In comparison, tonsillar CD4+ T 
cells constituted of 18% (± 3.5%) naïve, 13% (± 3.4%) TCM, 51% (± 7%) TEM and 18% (± 
7%) TEMRA.  Thus the majority of Vγ9Vδ2 T cells found in tonsils belonged to the TEM and 
TEMRA pools, whilst the majority of CD4+ T cells belonged to the TCM pool (Figure 4.10).  
Subpopulations of Vγ9Vδ2 T cells found in tonsils differed to those found in peripheral 
blood.  In tonsils the majority of Vγ9Vδ2 T cells were TEMRA (57% ± 5%), whereas in 
peripheral blood the majority of Vγ9Vδ2 T cells were TEM (61% ± 9%).  Furthermore, a 
noticeably higher percentage of naïve Vγ9Vδ2 T cells were found in tonsils in comparison 














Figure 4.10. Vγ9Vδ2 and CD4+ T cell memory subsets in tonsils.   
Freshly isolated tonsillar mononuclear cells were stained for memory markers CCR7 and 
CD45RA in combination with CD3, CD4 and Vδ2 surface markers.  Memory subsets were 
classified as follows: Naïve = CD45RA+CCR7+, T central memory (TCM) = CD45RA–
CCR7+, T effector memory (TEM) = CD45RA–CCR7– and terminally differentiated effector 
memory T cell (TEMRA) = CD45RA+CCR7–.  Cells were analysed by flow cytometry by 
gating on lymphocytes, live cells, singlets, CD4+CD3+ cells (white bars) and Vδ2+CD3+ 
cells (black bars).  Gates were set using isotype-matched control antibodies.  Data are 












Figure 4.11. Tonsillar memory Vγ9Vδ2 T cell populations differ from peripheral 
blood.  
Freshly isolated PBMCs and tonsillar mononuclear cells were stained and analysed for 
surface memory markers as described above in Figure 4.10.  Cells were analysed by flow 
cytometry by gating on lymphocytes, live cells, singlets, and Vδ2+CD3+ cells.  Gates were 
set using isotype-matched control antibodies.  Data are shown as mean percentage + SEM 
from three (PBMCs) and nine (tonsils) independent donors. 


















































































After having found expression of markers associated with follicular B cell help on only a 
small population of freshly isolated tonsillar Vγ9Vδ2 T cells, here, I proposed up-regulation 
of B cell helper markers on tonsillar Vγ9Vδ2 T cells upon in vitro stimulation with IL-21 
and HMB-PP.  Primarily, in order to examine the effects of IL-21 stimulation on tonsillar 
Vγ9Vδ2 T cells, surface expression of a functional IL-21R would be essential.  In chapter 3, 
I showed expression of IL-21R on peripheral blood Vγ9Vδ2 T cells.  Similarly, here I 
examined for surface expression of IL-21R on Vγ9Vδ2 and CD4+ T cells from inflamed 
tonsils. 
 
Mononuclear cells were freshly isolated from inflamed tonsils and stained with 
unconjugated mouse anti-human monoclonal antibody against IL-21R, followed by a 
secondary α-mouse Ig-PE antibody.  Cells were also stained with fluorochrome-conjugated 
antibodies specific for Vγ9, CD4 and CD3.  Cells were analysed by flow cytometry and 
assessed for IL-21R expression by gating on live single cells and on Vγ9+CD3+ T cells or 
CD4+CD3+ T cells. 
 
Surface IL-21R expression was found to be uniformly expressed on both freshly isolated 
tonsillar Vγ9Vδ2 T cells and CD4+ T cells.  However, the GMFI of IL-21R was found to be 
significantly lower on tonsillar Vγ9Vδ2 T cells in comparison to peripheral blood (GMFI 
1.5 (± 0.08) vs GMFI 1.8 (± 0.16), P=0.0145 Mann-Whitney two-tailed test).  Similarly the 
GMFI of IL-21R was also found to be lower on tonsillar CD4+ T cells in comparison to 
peripheral blood, however this was found to be non-significant (GMFI 2.0 (± 1.5) vs GMFI 





















Figure 4.12. Freshly isolated tonsillar Vγ9Vδ2 T cells express the receptor for IL-21.  
Tonsillar mononuclear cells and PBMCs were freshly isolated and stained with mouse anti-
human mAb against IL-21R (black-outlined histogram) or with an isotype matched control 
mAb (solid gray histogram) followed by detection with α-mouse Ig-PE.  IL-21R expression 
was measured by flow cytometry.  Cells were analysed for IL-21R expression by gating on 
live cells, singlets, Vγ9+CD3+ T cells and on CD4+CD3+ T cells.  Flow cytometry 
histograms represent one of 4 independent experiments.  The values represent mean fold 
change in GMFI, calculated as (geometric MFI of IL-21R)/(geometric MFI of isotype 
control).  Data are shown as mean ± SD from four individual donors.  A statistically 
significant difference on Vγ9Vδ2+ T cells between tonsillar and peripheral blood was found 
(P=0.0145). 


























































In the previous chapter, resting peripheral Vγ9Vδ2 T cells were rapidly activated upon in 
vitro HMB-PP stimulation.  Here, I proposed up-regulation of activation markers CD25 and 
CD69 on tonsillar Vγ9Vδ2 T cells upon in vitro stimulation with IL-21 and HMB-PP. 
 
Freshly isolated tonsillar mononuclear cells were cultured in medium, or with HMB-PP (10 
nM) in the absence or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  
Freshly isolated tonsillar mononuclear cells (day 0) and cells after 1, 2 and 3 days in culture 
were stained with fluorochrome-conjugated antibodies specific for CD25, CD69, CD4, CD3 
and Vδ2, before being analysed by flow cytometry. 
 
Here, a minority of freshly isolated tonsillar Vγ9Vδ2 T cells readily expressed CD25 (3% ± 
1.5%) and CD69 (11% ± 2.9%).  Following 1 day of culture, surprisingly, CD25 (22% ± 
9.5%) and CD69 (54% ± 10%) was up-regulated on tonsillar Vγ9Vδ2 T cells cultured in 
medium alone.  The addition of IL-21 alone had no effect on the expression of CD25 or 
CD69 on tonsillar Vγ9Vδ2 T cells (Figure 4.13A).   
 
However, one day stimulation with HMB-PP alone, lead to enhanced expression of both 
CD25 and CD69 on tonsillar Vγ9Vδ2 T cells.  In response to HMB-PP, CD69 expression 
peaked after just 1 day (86% ± 2.3%) but then declined considerably after 3 days (23% ± 
6%).  Similarly CD25 was also substantially up-regulated after one day with HMB-PP 
stimulation, but in contrast to CD69, the percentage of CD25 expressing tonsillar Vγ9Vδ2 T 





The addition of IL-21 to HMB-PP stimulated cultures did not further enhance expression of 
CD25 or CD69 on tonsillar Vγ9Vδ2 T cells (Figure 4.13A).  Furthermore, the response to 
HMB-PP stimulation was specific to Vγ9Vδ2 T cells, as culturing of freshly isolated 
tonsillar mononuclear cells with HMB-PP in the absence or presence of IL-21, did not effect 





































Figure 4.13. HMB-PP induces up-regulation of CD25 and CD69 activation markers on 
tonsillar Vγ9Vδ2 T cells.   
Freshly isolated tonsillar mononuclear cells were cultured in medium, or with HMB-PP (10 
nM) in the absence or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  
Freshly isolated tonsillar mononuclear cells (day 0) and cells after 1, 2 and 3 days in culture 
were stained for flow cytometry with anti-CD25-PE-Cy7, anti-CD69-PE-Cy5, anti-CD3-
APC-H7, anti-CD4-ECD and anti-Vδ2-FITC.  Cells were analysed for CD25 and CD69 
expression, by gating on lymphocytes, live cells, singlets, (A) Vδ2+CD3+ cells and (B) 
CD4+CD3+ cells.  Gates were set using isotype-matched control antibodies.  Data are shown 
as mean ± SEM from three individual donors. 
  




























































































In chapter 3, I failed to detect CXCR5 on resting or HMB-PP and IL-21 in vitro stimulated 
peripheral V9V2 T cells, but here showed expression of CXCR5 on a small percentage of 
tonsillar V9V2 T cells.  Here, I proposed up-regulation of surface CXCR5 on tonsillar 
Vγ9Vδ2 T cells upon in vitro stimulation with IL-21 and HMB-PP. 
 
Freshly isolated tonsillar mononuclear cells were cultured in medium, or with HMB-PP (10 
nM) in the absence or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  
Freshly isolated tonsillar mononuclear cells (day 0) and cells after 1, 2 and 3 days in culture 
were stained with fluorochrome-conjugated antibodies specific for CXCR5, CD25, CD3 and 
Vδ2, before being analysed by flow cytometry. 
 
Culturing of tonsillar mononuclear cells in medium or IL21 alone, up-regulated expression 
of CD25 but not CXCR5 on tonsillar V9V2 T cells (Figure 4.14A).  Surprisingly, one 
day stimulation with HMB-PP induced up-regulation of CXCR5 (13% ± 0.8%), which was 
further enhanced with IL-21 co-stimulation (20% ± 3.5%) (Figure 4.14A and B).  CXCR5 
was predominantly found on activated tonsillar V9V2 T cells that co-expressed CD25 
(Figure 4.14A).  Over the 3 day culture period, expression of CXCR5 reached peak levels 
after one day in culture and declined gradually between 2 and 3 days in culture.  This 
pattern of expression was seen in cultures treated with HMB-PP alone and in cultures co-
treated with both HMB-PP and IL-21.  However, higher levels of CXCR5 were induced 
only in the presence of both HMB-PP and IL-21 stimulation, thus indicating a strong co-




































Figure 4.14. IL-21 enhances expression of CXCR5 on HMB-PP stimulated tonsillar 
Vγ9Vδ2 T cells.   
Freshly isolated tonsillar mononuclear cells were cultured in medium, or with HMB-PP (10 
nM) in the absence or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  
Freshly isolated tonsillar mononuclear cells (day 0) and cells after 1, 2 and 3 days in culture 
were stained for flow cytometry with anti-CXCR5-PE, anti-CD25-PE-Cy7, anti-CD3-APC-
H7 and anti-Vδ2-FITC.  Cells were analysed for surface CXCR5 and CD25 expression, by 
gating on lymphocytes, live cells, singlets and Vδ2+CD3+ cells.  Gates were set using 
isotype-matched control antibodies.  (A) Flow cytometry FACs plots showing expression of 
CXCR5 and CD25 on freshly isolated tonsillar Vδ2+ T cells and after 1 day in culture, 
under the indicated conditions, data representative of three donors. (B) Percentage of Vδ2+ 
expressing CXCR5 over 3 days in culture.  Data are shown as mean percentage ± SEM of 
three donors.  
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In the previous chapter, I showed up-regulation of co-stimulatory molecules ICOS, OX40, 
CD70 but not CD40L on IL-21 and HMB-PP stimulated peripheral Vγ9Vδ2 T cells.  Here, I 
proposed up-regulation of co-stimulatory molecules on tonsillar Vγ9Vδ2 T cells upon in 
vitro stimulation with IL-21 and HMB-PP.  At the same time, CD4+ T cells from tonsils 
were also analysed for the same co-stimulatory molecules.  
 
Freshly isolated tonsillar mononuclear cells were cultured in medium, or with HMB-PP (10 
nM) in the absence or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  
Freshly isolated tonsillar mononuclear cells (day 0) and cells after 1, 2 and 3 days in culture 
were stained with fluorochrome-conjugated antibodies specific for ICOS, OX40, CD70, 
CD28, CD40L, CD4, CD3 and Vδ2 or Vγ9, before being analysed by flow cytometry. 
 
Freshly isolated tonsillar Vγ9Vδ2 T cells did not express, ICOS, OX40, CD70, CD28 
(Figure 4.15) or CD40L (data not shown).  Surprisingly, culturing of tonsillar mononuclear 
cells over 3 days in medium alone somewhat up-regulated expression of ICOS, OX40, 
CD70 and CD28 (Figure 4.15) but not CD40L (data not shown).  The addition of IL-21 
alone did not further enhance expression of co-stimulatory molecules on tonsillar Vγ9Vδ2 T 
cells cultured in medium alone (Figure 4.15).   
 
Stimulation with HMB-PP alone led to further up-regulation of ICOS, OX40, CD70, CD28 
(Figure 4.15), but not CD40L (data not shown) on tonsillar Vγ9Vδ2 T cells.  Over the 3 day 
culture period, highest expression of OX40 (17% ± 1.4%) and CD28 (21% ± 5%) was found 
on day 2 of culture.  Expression of both OX40 and CD28 was transient, as on day 3 of 




CD28 was completely lost.  In contrast, HMB-PP induced a continuous up-regulation of 
both ICOS and CD70 expression, on tonsillar Vγ9Vδ2 T cells.  Highest expression of ICOS 
(75% ± 5.5%) and CD70 (17% ± 3%) was found after 3 days in culture (Figure 4.15).  
 
The addition of IL-21 to HMB-PP stimulated cultures had no effect on ICOS or CD28 
expression.  In contrast, co-stimulation with IL-21 resulted in a considerable but steady 
down-regulation of OX40 in >50 % of HMB-PP stimulated Vγ9Vδ2 T cells (7% ± 0.6% vs 




































Figure 4.15. HMB-PP induces up-regulation of ICOS, OX40, CD70 and CD28 co-
stimulatory molecules on tonsillar Vγ9Vδ2 T cells.   
Freshly isolated tonsillar mononuclear cells were cultured in medium, or with HMB-PP (10 
nM) in the absence or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  
Freshly isolated tonsillar mononuclear cells (day 0) and cells after 1, 2 and 3 days in culture 
were stained for flow cytometry with anti-ICOS-PE, anti-OX40-FITC, anti-CD70-FITC, 
anti-CD28-PE-Cy5, anti-CD3-pacific blue ( or anti-CD3-APC-H7), and anti-Vγ9-PE-Cy5 or 
Vδ2-PE.  Cells were analysed for ICOS, OX40, CD70 and CD28 expression, by gating on 
lymphocytes, live cells, singlets and Vγ9+CD3+ or Vδ2+CD3+ cells.  Gates were set using 














































































































In the same cultures, I also examined co-stimulatory molecule expression on tonsillar CD4+ 
T cells.  Here I found ICOS (64% ± 9%), OX40 (33% ± 4%), CD70 (8% ± 2%) and CD28 
(17% ± 1.4%) to be expressed on freshly isolated tonsillar CD4+ T cells (Figure 4.16).  
Similar to tonsillar Vγ9Vδ2 T cells, CD40L was not detected on freshly isolated CD4+ T 
cells (data not shown).  
 
After one day of culturing tonsillar mononuclear cells in medium alone, expression of ICOS 
(32% ± 10%), OX40 (15% ± 1.4%), CD70 (1% ± 0.6%) and CD28 (4% ± 0.3%) was 
considerably lost on 50% of CD4+ T cells.  OX40 and CD70 returned to baseline after 3 
days in culture.  In contrast, expression of ICOS did not return to baseline, but was 
continuously expressed by a lower percentage of CD4+ T cells throughout the 3 day of 
culture.  The percentage of CD28 positive CD4+ T cells had declined over 2 days in culture 
and by day 3, CD28 was found to be absent on all tonsillar CD4+ T cells (Figure 4.16).  
Furthermore, the addition of HMB-PP or IL-21 to tonsillar mononuclear cell cultures did 
not change expression of ICOS, OX40, CD70 or CD28 on tonsillar CD4+ T cells.  Thus, the 


































Figure 4.16. HMB-PP or IL21 does not induce up-regulation of ICOS, OX40, CD70 or 
CD28 co-stimulatory molecules on tonsillar CD4+ T cells.   
Freshly isolated tonsillar mononuclear cells were cultured in medium, or with HMB-PP (10 
nM) in the absence or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  
Freshly isolated tonsillar mononuclear cells (day 0) and cells after 1, 2 and 3 days in culture 
were stained for flow cytometry with anti-ICOS-PE, anti-OX40-FITC, anti-CD70-FITC, 
anti-CD28-PE-Cy5, anti-CD3-pacific blue ( or anti-CD3-APC-H7) and anti-CD4-ECD.  
Cells were analysed for ICOS, OX40, CD70 and CD28 expression, by gating on 
lymphocytes, live cells, singlets and CD4+CD3+ cells.  Gates were set using isotype-























































































































In the previous chapter, I showed up-regulation of APC markers CCR7, CD40, CD86 and 
HLA-DR on HMB-PP stimulated peripheral Vγ9Vδ2 T cells.  Here, I proposed up-
regulation of APC markers on tonsillar Vγ9Vδ2 T cells upon in vitro stimulation with IL-21 
and HMB-PP.  In comparison, tonsillar CD4+ T cells were also analysed for APC marker 
expression. 
 
Freshly isolated tonsillar mononuclear cells were cultured in medium, or with HMB-PP (10 
nM) in the absence or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  
Freshly isolated tonsillar mononuclear cells (day 0) and cells after 1, 2 and 3 days in culture 
were stained with fluorochrome-conjugated antibodies specific for CCR7, CD40, CD86 and 
HLA-DR, CD3, CD4 and Vγ9, before being analysed by flow cytometry.   
 
Expression of CCR7 was analysed on freshly isolated tonsillar mononuclear cells and cells 
after 1 day in culture.  CCR7 was expressed on a minority of freshly isolated tonsillar 
Vγ9Vδ2 T cells (3% ± 0.2%), which was found to be  up-regulated (19% ± 1.5%) after just 
1 day of culturing tonsillar mononuclear cells in medium alone (Figure 4.17).  This was not 
due to activation of cells but due to receptor recycling.  T cells within secondary lymphoid 
tissues such as tonsils undergo receptor internalization of surface CCR7 as one way of 
rendering cells unresponsive to the ligands CCL19/CCL21.  Removing cells from the 
CCL19/CCL21 rich tissue environment and culturing them in medium alone may allow 
receptors to recycle back to the plasma membrane (Otero et al. 2006).  The addition of 
HMB-PP (25% ± 4.5%), or IL-21 in the absence (23% ± 1%) or presence of HMB-PP (24% 






In contrast to CCR7, CD40 was found to be readily expressed by a large proportion of 
freshly isolated tonsillar Vγ9Vδ2 T cells (67% ± 5%), which was further up-regulated in 
response to HMB-PP stimulation, with highest expression found on day 3 (88% ± 3%).  
Furthermore, HMB-PP stimulation maintained expression of CD40, as in the absence of 
HMB-PP stimulation, the percentage of CD40 positive Vγ9Vδ2 T cells had decreased after 
1 day in culture (54% ± 3%) (Figure 4.17).  
 
Expression of CD86 was found to be absent on freshly isolated tonsillar Vγ9Vδ2 T cells.  
On day 3, in medium alone CD86 was up-regulated by a small percentage of Vγ9Vδ2 T 
cells (6% ± 1.5%), which was further up-regulated in response to HMB-PP stimulation 
(24% ± 1.4%).  Similar to CCR7, expression of CD40 and CD86 was not affected by the 
presence of IL-21 stimulation (with or without HMB-PP stimulation) (Figure 4.17).  
 
HLA-DR expressed on a minority of freshly isolated tonsillar Vγ9Vδ2 T cells (12% ± 1.8%) 
was found to be up-regulated in response to all four culture conditions.  On day 3, HLA-DR 
was found to be up-regulated on Vγ9Vδ2 T cells cultured in medium alone (20% ± 5%), IL-
21 alone (31% ± 7%), HMB-PP alone (58% ± 2%), with highest expression found in 
response to both HMB-PP and IL-21 stimulation (71% ± 2.4%).  Hence the co-stimulatory 
effect of IL-21 did not enhance surface expression of CCR7, CD40 or CD86 but did 



































Figure 4.17. HMB-PP induces up-regulation of CCR7, CD40, CD86 and HLA-DR on 
tonsillar Vγ9Vδ2 T cells.   
Freshly isolated tonsillar mononuclear cells were cultured in medium, or with HMB-PP (10 
nM) in the absence or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  
Freshly isolated tonsillar mononuclear cells (day 0) and cells after 1, 2 and 3 days in culture 
were stained for flow cytometry with unlabelled rat anti-CCR7, followed by anti-rat-biotin -
secondary antibody and detection with streptavidin-PeCy7.  Cells were also stained with 
anti-CD40-PE, anti-CD86-FITC, anti-HLA-DR-APC-H7, anti-CD3-pacific blue, anti-CD4-
ECD and anti-Vγ9-PE-Cy5.  Vγ9+CD3+ cells were analysed for CCR7, CD40, CD86 and 
HLA-DR surface expression by gating on lymphocytes, live cells and singlets.  Gates were 
set using isotype-matched control antibodies.  Data are shown as mean ± SEM from three 
individual donors. 
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In the same cultures, I also examined expression of CCR7, CD40, CD86 and HLA-DR on 
tonsillar CD4+ T cells.  Similar to tonsillar Vγ9Vδ2 T cells, CCR7 on freshly isolated 
tonsillar CD4+ T cells (18% ± 7.5%) was found to be up-regulated after 1 day of culturing 
tonsillar mononuclear cells in medium alone (63% ± 13%) (Figure 4.18).   
 
CD40 (71% ± 4.5%) and HLA-DR (57% ± 6%) was readily expressed by a large proportion 
of freshly isolated tonsillar CD4+ T cells. Both CD40 (41% ± 3%) and HLA-DR (23% ± 
2.5%) were considerably down-regulated after 2 day of culturing in medium alone (Figure 
4.18).  In contrast, CD86 was expressed by a minority of freshly isolated tonsillar CD4+ T 
cells (3% ± 6%). After one day of culturing tonsillar mononuclear cells in medium alone, 
expression of CD86 was lost but returned to levels above baseline after 3 days in culture 
(6% ± 0.7%) (Figure 4.18).  Furthermore, the addition of HMB-PP or IL-21 to tonsillar 
mononuclear cell cultures did not change expression of CCR7, CD40, CD86 or HLA-DR on 
tonsillar CD4+ T cells.  Thus, the response to HMB-PP and IL-21 stimulation was specific 































Figure 4.18. HMB-PP and IL-21 does not induce up-regulation of CCR7, CD40, CD86 
or HLA-DR on tonsillar CD4+ T cells.   
Freshly isolated tonsillar mononuclear cells were cultured in medium, or with HMB-PP (10 
nM) in the absence or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  
Freshly isolated tonsillar mononuclear cells (day 0) and cells after 1, 2 and 3 days in culture 
were stained for flow cytometry with unlabelled rat anti-CCR7, followed by anti-rat-biotin -
secondary antibody and detection with streptavidin- PeCy7.  Cells were also stained with 
anti-CD40-PE, anti-CD86-FITC, anti-HLA-DR-APC-H7, anti-CD3-pacific blue, anti-CD4-
ECD and anti-Vγ9- PE-Cy5.  CD4+CD3+ cells were analysed for CCR7, CD40, CD86 and 
HLA-DR surface expression by gating on lymphocytes, live cells and singlets.  Gates were 
set using isotype-matched control antibodies.  Data are shown as mean ± SEM from three 
individual donors. 
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In chapter 3, I showed HMB-PP and IL-21 induced proliferation of peripheral blood 
Vγ9Vδ2 T cells in PBMCs.  Here, I examined the proliferative capacity of tonsillar Vγ9Vδ2 
T cells alongside CD4+ T cells in response to in vitro HMB-PP and IL-21 stimulation.   
 
Freshly isolated tonsillar mononuclear cells taken from 3 different donors were cultured in 
medium, or with HMB-PP (10 nM) in the absence or presence of IL-21 (50 ng/ml), or with 
IL-21 alone (50 ng/ml).  Freshly isolated tonsillar mononuclear cells (day 0) and cells after 
3, 5, 7 and 10 days in culture were stained with fluorochrome-conjugated antibodies specific 
for CD3, CD4 and Vδ2.  Cells were analysed by flow cytometry for the total percentage of 
Vδ2+ positive T cells amongst the CD3 positive population (Figure 4.19A).   
 
In freshly isolated tonsillar mononuclear cells, Vγ9Vδ2 T cells represented 2 % (± 0.5%) of 
total CD3 positive cells.  In response to HMB-PP stimulation, the percentage of Vγ9Vδ2 T 
cells amongst the CD3 positive population increased from day 3 (2 % ± 0.8%) to day 7 (23 
% ± 5.7%) and declined on day 10 of culture (16% ± 8.6%).  Co-stimulation with IL-21 
suppressed proliferation of tonsillar Vγ9Vδ2 T cells to 15% (± 8%) on day 7 and to 12% on 
day 10 (± 6%).  Culturing of tonsillar mononuclear cells in medium or IL-21 alone did not 
induce proliferation of tonsillar Vγ9Vδ2 T cells.  Thus, stimulation with HMB-PP alone for 
up to 7 days provided the best conditions for in vitro proliferation of tonsillar Vγ9Vδ2 T 
cells (Figure 4.19A).  The error bars displayed in Figure 4.19A, account for donor-to-donor 
variability between the three donors, in the expansion potential of tonsillar Vγ9Vδ2 T cells. 
 
In the same cultures, I also examined proliferation of tonsillar CD4+ T cells.  In freshly 
isolated tonsillar mononuclear cells, CD4+ T cells represented 52 % (± 9.5%) of total CD3 




percentage of CD4+ T cells amongst the CD3 positive population increased from day 0 (52 
% ± 9.5%) to day 7 (89 % ± 1.5%) and declined by day 10 (83 % ± 6%) in culture (Figure 
4.19B).  In contrast to Vγ9Vδ2 T cells, proliferation of tonsillar CD4+ T cells was not 
specific to HMB-PP or IL-21 stimulation.  Instead, the addition of HMB-PP or IL-21 to 
tonsillar mononuclear cell cultures, somewhat suppressed proliferation of tonsillar CD4+ T 







































Figure 4.19. Tonsillar Vγ9Vδ2 T cells proliferate in response to HMB-PP stimulation.   
Freshly isolated tonsillar mononuclear cells were cultured in medium, or with HMB-PP (10 
nM) in the absence or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  
Freshly isolated tonsillar mononuclear cells (Day 0) and cells after 1, 3, 7 and 10 days in 
culture, cells were stained for flow cytometry with anti-CD3-pacific blue, anti-CD4-ECD 
and anti-Vδ2-PE.  The percentage of (A) Vδ2+ CD3+ cells and (B) CD4+ CD3+ cells was 
determined by gating on lymphocytes, live cells and singlets.  Data are shown as mean ± 
SEM from three individual donors. 
 








































































Human γδ T cells have previously been shown to induce antibody production during co-
culture with B cells (Brandes et al. 2003; Caccamo et al. 2006a).  Brandes et al. (2003) 
demonstrated peripheral blood γδ T cells stimulated with an anti-TCR antibody, in the 
absence of cytokines to induce tonsillar B cell IgM, IgA and IgG antibody production.  
Similarly, Caccamo et al. (2006) also showed peripheral blood and tonsillar Vγ9Vδ2 T cells 
to help autologous tonsillar B cells in antibody production, however, this was shown in the 
presence of a weak synthetic γδ T cell activator (bromohydrin pyrophosphate) (Morita et al. 
2007) and also in the absence of cytokines.  Here, by using the microbial metabolite HMB-
PP and the Tfh-derived cytokine IL-21, my study uses a more physiologically relevant and 
novel method of investigating Vγ9Vδ2 T cell ability to induce antibody production during 
co-culture with B cells.  Thus, after having established conditions that favour the acquisition 
of a B helper-Tfh-like phenotype on peripheral blood Vγ9Vδ2 T cells, as well as having 
identified Tfh-like phenotypes on tonsillar Vγ9Vδ2 T cells, the objective of this chapter was 
to investigate whether Vγ9Vδ2 T cells were able to provide B cell help using an in vitro co-
culture model.   
 
Here, I hypothesised that the IL-21 induced acquisition of a Tfh-like phenotype on HMB-PP 
activated Vγ9Vδ2 T cells equips Vγ9Vδ2 T cells to support B cell activation, 





Aims of this chapter were to:  
 
1. Phenotype B cells from peripheral blood and tonsils. 
2. Investigate the effects of HMB-PP and IL-21 on the ability of peripheral Vγ9Vδ2 T 
cells to induce antibody production by tonsillar B cells. 
3. Investigate the effects of HMB-PP and IL-21 on the ability of tonsillar Vγ9Vδ2 T 
cells to induce antibody production by tonsillar B cells. 
4. Investigate the effects of HMB-PP and IL-21 on the ability of peripheral Vγ9Vδ2 T 
cells to induce peripheral B cell activation, APC marker expression, differentiation 










In comparison to antigen-inexperienced naive B cells, memory B cells are antigen-
experienced long-lived, quiescent B cells that express high-affinity surface antibodies.  
Memory B cells are capable of eliciting rapid and robust responses upon re-encounter with 
the pathogen (Good-Jacobson and Shlomchik 2010; Klein and Dalla-Favera 2008; Tangye 
and Tarlinton 2009).  Furthermore, memory B cells are more sensitive to in vitro stimulation 
with the CD40 ligand (CD40L) plus IL-21, as well as with SAC plus IL-2, in differentiating 
into Ig-secreting plasma cells (Agematsu et al. 2000; Konforte et al. 2009; Tangye and 
Good 2007).  Accordingly, memory B cells would be more sensitive to help provided by γδ 
T cells whereas naïve B cells would require priming with specific antigen or with a 
powerful surface Ig cross-linker such as SAC, before they can be used for co-culture 
experiments.  Thus a good yield of memory B cells would be required for these co-culture 
experiments.  To determine the better source for memory B cells, I here investigated 
naïve/memory subsets and phenotypes of B cells from tonsils in comparison to B cells from 
peripheral blood. 
 
Percentages of total B cells and B cell subsets in peripheral blood and tonsils were evaluated 
in parallel.  Freshly isolated PBMCs and tonsillar mononuclear cells were stained for CD19, 
CD3, IgD and CD27 surface markers and analysed by flow cytometry.  B cells were 






Results showed that, in line with previous studies (Cernelc et al. 1979), the percentage of B 
cells amongst the lymphocyte population was significantly higher in the inflamed tonsils 
(73% ± 3%) than in the peripheral blood (10% ± 1%) (p<0.0001, paired t test) (Figure 
5.1A). 
 
In peripheral blood and tonsils, naïve and memory B cell subsets were identified on the 
basis of IgD and CD27 surface marker expression.  On the gated CD3− CD19+ B cell 
population a dot plot with IgD along the y-axis and CD27 on the x-axis was created.  
Quadrants in dot plots were set using isotype-matched control antibodies).  B cell memory 
subsets were identified as follows: Naïve = IgD+CD27−, unswitched memory = IgD+CD27+, 
switched memory = IgD−CD27+ and double negative = IgD−CD27− (Figure 5.1B) (Sanz et 
al. 2008).  Evidently, the proportions of naïve and memory B cell subsets in peripheral 
blood differed to those found in tonsils.  As expected, the percentage of naïve B cells 
amongst the B lymphocyte population was significantly higher in peripheral blood (64% ± 
6.7%) than in the tonsils (34% ± 2.4%) (P=0.0238, Mann-Whitney two-tailed test) (Weill et 


































Figure 5.1. Comparison of B cell subsets in tonsils and peripheral blood.   
PBMCs and tonsillar mononuclear cells were freshly isolated.  (A) The percentage of total 
B cells and (B and C) B cell subsets were determined by staining cells for flow cytometry 
with CD19, CD3, IgD and CD27 surface markers.  Cells were analysed for IgD and CD27 
expression, by gating on lymphocytes, live cells and CD3− CD19+ cells, quadrants were set 
using isotype-matched control antibodies. (B) Representative dot plots showing the 
percentage of peripheral blood and tonsillar B cells expressing IgD and CD27.  (B and C) 
Naïve/memory subsets were classified as follows: Naïve = IgD+CD27−, unswitched memory 
= IgD+CD27+, switched memory = IgD−CD27+ and double negative = IgD−CD27−.  Data are 
shown as mean percentage + SEM from nine (A) and three to five (C) independently 
assessed donors.  In (A) the percentage of B cells amongst the lymphocyte population was 
statistically different in tonsils compared to peripheral blood.  In (C) the percentage of naïve 
B cells amongst the B lymphocyte population was statistically different in tonsils compared 
to peripheral blood. 






















































I next examined freshly isolated peripheral blood and tonsillar B cells for surface marker 
expression of APC markers (CD40, HLA-DR and CD86), activation markers (CD25 and 
CD69) and the follicular homing chemokine receptor CXCR5.  Surface expression of CD40 
HLA-DR and CD86 was comparable between tonsillar and peripheral blood B cells (Figure 
5.2A and B).  A minor percentage of tonsillar and peripheral blood B cells expressed the 
activation markers CD25 and CD69 (Figure 5.2B).  The chemokine receptor CXCR5 was 
found to be uniformly expressed on both peripheral blood and tonsillar B cells (Figure 
5.2C).  However, in Figure 5.2C as indicated by the GMFI values and shift in fluorescence 
intensity of CXCR5 on B cells, as expected CXCR5 was much lower on tonsillar B cells 
(GMFI 4 ± 0.5) in comparison to peripheral blood B cells (GMFI 42 ± 11).  Thus, indicating 
that B cells down-regulate CXCR5 expression levels when in tonsillar tissue (Figure 5.2C).  
These findings are in agreement with published findings and literature (Fairfax et al. 2008). 
 
As expected, in comparison to peripheral blood, these studies confirmed tonsils to provide 
much higher yields of not only total but also switched memory B cells.  These switched 
memory B cells represent antigen-activated B cells that have undergone CSR in the GC, 
thus are capable of secreting IgG, IgA and IgE antibodies upon re-stimulation.  Concluding, 






































Figure 5.2. Cell surface phenotype of freshly isolated B cells from peripheral blood and 
tonsils.   
PBMCs and tonsillar mononuclear cells were freshly isolated and stained with antibodies 
directed towards the indicated surface markers, along with isotype-matched control 
antibodies.  Cells were analysed by flow cytometry for surface marker expression by gating 
on lymphocytes, live cells and CD3− CD19+ cells.  (A) CD40, HLA-DR and (C) CXCR5 
data are shown as mean fold change (± SEM) in GMFI, calculated as (geometric MFI of 
antibody)/(geometric MFI of isotype control).  (B) CD86, CD25 and CD69 data are shown 
as the mean percentage of CD19+ B cells positive for each marker.  Data are shown as mean 
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Humoral immune responses are initiated within B cell follicles of secondary lymphoid 
tissue, where naïve circulating B cells after recognition of their cognate antigen require help 
and support from T cells.  Tfh cells, known as true helper cells for B cells, have been shown 
to provide direct support for B cell responses in vivo, ex vivo and in vitro (Ebert et al. 2004; 
King et al. 2008; Macaulay et al. 1998; Stockinger et al. 1996).  IL-21, a major cytokine 
secreted by Tfh cells, plays a central role in stimulating B cells to undergo proliferation, 
isotype switching and differentiation (King 2009; King et al. 2008). 
 
Secondary lymphoid tissues, such as the human tonsils, provide a good source of both B and 
Tfh cells, thus allowing both cell types to be isolated from the tonsil of the same donor for 
in vitro functional T cell-B cell co-culture assays.  Unlike naïve resting peripheral blood B 
cells, the majority of tonsillar B cells are memory antigen experienced B cells (Figure 
5.1C).  Equally unlike the small percentage of resting Tfh cells found in peripheral blood 
(Chapter 3, Figure 3.12B), Tfh cells in tonsils are abundantly present and exist as activated 
cells (Chapter 4, Figure 4.7B).   
 
Here, the aim was to establish and optimise an in vitro T cell-B cell co-culture system that 
was consistent in supporting B cell antibody production.  I tested the methodology and 
conditions by examining the ability of tonsillar Tfh cells to induce antibody production by 
tonsillar B cells.  Simultaneously I also investigated the direct in vitro effects of IL-21 on 
tonsillar B cell antibody production. 
 
Tonsillar mononuclear cells were freshly isolated from tonsils.  To isolate Tfh cells from 
tonsillar mononuclear cells, first CD4+ T cells were positively isolated resulting in >98 % 




resulting in 85% purity (Figure 5.3B).  B cells were isolated from CD4 T cell depleted cells 
by negative selection, resulting in 97% purity (Figure 5.3C).  CXCR5+ B cells were isolated 
from the B cell population by positive selection, resulting in 96% purity (Figure 5.3D).  In 
secondary lymphoid tissue such as the tonsils, as CD19+ B cells differentiate into plasma 
cells surface expression of CXCR5 is down-regulated.  Therefore here I specifically 
selected for CXCR5 positive tonsillar B cells in order to exclude CD19+ CXCR5– plasma 
cells. 
 
Isolated tonsillar CXCR5+ B cells were cultured with either isolated tonsillar Tfh cells or 
with various concentrations of IL-21 (0.1, 0.5, 5, and 50 ng/ml) or neither.  After 10 days of 
culture, total IgM, IgG and IgA levels in culture supernatants were measured by ELISA. 
 
IL-21 induced a dose-dependent effect on IgM, IgG and IgA antibody production.  
Interestingly, stimulation of tonsillar B cells with 50 ng/ml of IL-21 induced IgM, IgG and 
IgA antibody levels that were comparable to those induced by tonsillar Tfh cells.  These 
results identified concentrations 50 ng/ml of IL-21 as most potent at inducing antibody 































Figure 5.3. Flow cytometric purity analysis of isolated tonsillar Tfh and CXCR5+ B 
cells.   
Tonsillar mononuclear cells were isolated from fresh human tonsils.  Tfh cells (CXCR5+ 
CD4+ T cells) and CXCR5+ B cells were purified from either freshly isolated or from frozen 
tonsillar mononuclear cells using the Miltenyi Biotec magnetic cell sorting system.  Cells 
were blocked with human Igs and stained with anti-CD4-FITC and CXCR5-PE.  (A) CD4+ 
T cells were isolated using the anti-FITC multiSort kit as follows:  FITC labeled CD4+ T 
cells were magnetically labeled with anti-FITC multiSort microbeads, following positive 
CD4+ T cell selection (98.5% purity) the magnetic particles were removed from the cells by 
using the multisort release reagent.  (B) CXCR5+ CD4+ T cells were isolated from the CD4+ 
T cell population using anti-PE microbeads, resulting in 85% purity.  (C) B cells were 
isolated from CD4 T cell depleted cells by negative selection, resulting in 97% purity.  (D) 
CXCR5+ B cells were isolated from the B cell population using anti-PE microbeads, 
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Figure 5.4. IL-21 induces a dose-dependent effect on IgM, IgG and IgA antibody 
production.   
Tfh and CXCR5+ B cells were purified from either freshly isolated or from frozen tonsillar 
mononuclear cells as described in Figure 5.3.  Purified B cells were cultured with either 
purified Tfh cells (at a ratio of 1:1), or with various concentrations of IL-21 (0.1, 0.5, 5, and 
50 ng/ml) or in medium alone (B cells only).  After 10 days of culture, total IgM, IgG and 
IgA levels in culture supernatants were assessed by ELISA.  Data are shown as mean + 
SEM from three to five individual wells and are representative of results from one of two 
similar experiments. 
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5.2.3.  Peripheral Vγ9Vδ2  T  cells  provide  help  for  tonsillar  B  cell 
antibody production 
 
There is increasing evidence, showing an involvement of γδ T cells in humoral immune 
responses.  γδ T cells have been found in several secondary lymphoid tissues such as the 
draining lymph node, Peyer’s patches, inflamed tonsils and inflamed appendix (Brandes et 
al. 2009; Dieli et al. 2003; Groh et al. 1989; Soo et al. 1995).  More specifically, γδ T cells 
have been found to be co-localised with CXCL13-producing cells within GCs of B cell 
follicles (Vermijlen et al. 2007).  As shown here and by others, γδ T cell expression of IL-
21R, CXCL13 and CXCR5 and long-term maintenance of co-stimulatory molecules 
strongly suggests a direct involvement in follicular B cell maturation (Brandes et al. 2003; 
Vermijlen et al. 2007).  Here, I proposed a model involving interaction of activated γδ T 
cells, B cells and Tfh cells in secondary lymphoid tissue whereby HMB-PP activated 
peripheral γδ T cells would acquire a LN homing phenotype allowing migration to 
secondary lymphoid tissue.  Within GC of B cell follicles, activated γδ T cells would 
respond to Tfh derived IL-21 equipping them to provide direct help for B cell activation, 
differentiation and production of antibodies (Vermijlen et al. 2007). 
 
To study and mimic my model in vitro, I employed a γδ T cell-B cell co-culture system.  To 
test whether or not γδ T cells were able to support B cells for antibody production initially I 
used a non-autologous system, whereby B cells were obtained from tonsils and Vγ9Vδ2 T 
cells from peripheral blood.  This initial approach was taken not only because tonsils 
provided B and Tfh cells in a state of pre-activation, but also because higher yields of both 
cell types could be obtained from tonsils in comparison to peripheral blood.  Equally, higher 
cell counts of Vγ9Vδ2 T cells were obtained from peripheral blood in comparison to tonsils.  
Here, obtaining practical number of all three B, Tfh and γδ T cells was important for initial 






To begin with, the ability of peripheral blood γδ T cells to induce B cell antibody production 
was evaluated using a two-step culture system.  Firstly, in order to rule out any direct effect 
on B cells, peripheral blood Vγ9Vδ2+ T cells were pre-stimulated to induce acquisition of a 
Tfh-like phenotype before adding them to autologous B cells as follows:  Purified blood 
Vγ9Vδ2+ T cells were pre-stimulated with HMB-PP (10 nM) or in medium alone.  After 42 
hours, HMB-PP stimulated cultures were treated with or without IL-21 (50 ng/ml) or IL-2 
(20 units/ml).  Non-stimulated Vγ9Vδ2 T cells cultured in medium alone served as negative 
control.  After a further 24 hours, stimulated and non-stimulated γδ T cells were harvested 
and washed several times to ensure removal of any residual HMB-PP, IL-21 and IL-2, thus 
minimising direct action of IL-21 or IL-2 on B cells. 
 
For antibody production CXCR5+ B and Tfh cells were freshly isolated from tonsils as 
described in Figure 5.3.  Non-stimulated, HMB-PP, IL-2+HMB-PP or IL-21+HMB-PP pre-
stimulated γδ T cells were co-cultured at a ratio of 1:1 with purified tonsillar CXCR5+ B 
cells, in the absence or presence of HMB-PP (10 nM) or in the presence of tonsillar Tfh 
cells.  As controls, tonsillar CXCR5+ B cells were cultured alone (B cells only), or in the 
presence of Tfh cells or with a concentration of IL-21 (0.5 ng/ml) representing 
residual/contaminating IL-21 that may have been present after washing.  After 10 days of 
culture, total IgM, IgG and IgA levels in culture supernatants were measured by ELISA. 
 
Use of internal positive and negative controls demonstrated the reliability of my in vitro co-
culture assay.  As positive controls, co-culturing of Tfh cells with B cells induced 
significant amounts of IgM, IgA and IgG antibody production whilst, as negative controls, 
little or very low levels of antibody were detected when B cells were cultured with 0.5 
ng/ml of IL-21 or in medium alone (Figure 5.5).  Furthermore, no significant difference 
was found between B cells stimulated with 0.5 ng/ml of IL-21 in comparison to B cells 
cultured in medium alone (Figure 5.5A).   
 
B cells cultured in the presence compared to the absence of non-stimulated Vγ9Vδ2 T cells 




production of IgA and a significant 4-fold increase in the production of IgG.  Co-culturing B 
cells with HMB-PP, IL-2 or IL-21 pre-stimulated γδ T cells did not further enhance IgM, 
IgA or IgG antibody levels (Figure 5.5A).  The addition of HMB-PP to co-cultures in the 
aim of re-stimulating γδ T cells did not improve the ability of γδ T cells to further enhance 
antibody production.  In contrast, in response to HMB-PP re-stimulation, IgG antibody 
production was somewhat reduced to levels that were no longer found to be statistically 
significant (Figure 5.5B).   
 
The synergistic effect of γδ T cells and Tfh cells on B cell antibody production was also 
examined.  IgM antibody production increased almost 2-fold when Tfh and B cells were 
cultured in the presence compared to the absence of non-stimulated Vγ9Vδ2 T cells 
(medium).  IgM antibody production increased to a lesser extent in the presence of HMB-PP 
stimulated Vγ9Vδ2 T cells whereas culturing of Tfh and B cells in the presence of IL-
2+HMB-PP or IL-21+HMB-PP pre-stimulated γδ T cells had little or no effect on 
enhancing IgM antibody production induced by Tfh cells alone.  Similarly, non-stimulated 
and HMB-PP, IL-2+HMB-PP or IL-21+HMB-PP pre-stimulated γδ T cells, had little or no 
effect on IgG or IgA antibody production already induced by Tfh cells alone (Figure 5.5C).  
 
Notably, as indicated by the error bars significant donor-to-donor variation in the level of 
antibody production was observed, thus making interpretation of data difficult.  In 
conclusion, cumulative data taken from 4-6 experiments indicated no clear effect of HMB-
PP, IL-2, or IL-21 stimulation on the ability of γδ T cells to provide B cell help (Figure 
5.5), although data from some (but not all) individual experiments did indicate an effect of 
IL-2, IL-21 and HMB-PP on γδ T cell induction of antibody production (data not shown).   
 
Data from these initial experiments using pre-stimulated γδ T cells highlighted the 
challenges of overcoming variability and maintaining consistency between donors and 
experiments.  Thus to this point, the idea of using pre-stimulated γδ T cells in investigating 


































Figure 5.5. Peripheral Vγ9Vδ2 T cells induce antibody production during co-culture 
with tonsillar B cells.    
Vδ2+ T cells and B cells were positively isolated from PBMCs using magnetic cell sorting, 
resulting in >96 % purity.  Peripheral Vδ2+ T cells were co-cultured with irradiated 
peripheral B cells at a 2:1 ratio in medium, or with HMB-PP (10 nM).  After 42 hours, 
HMB-PP stimulated cultures were treated with or without IL-21 (50 ng/ml) or IL-2 (20 
units/ml).  After 24 hours, stimulated and non-stimulated γδ T cells were harvested, washed 
and co-cultured at a ratio of 1:1 with purified tonsillar CXCR5+ B cells, in the (A) absence 
or (B) presence of HMB-PP re-stimulation or in the presence of (C) tonsillar Tfh cells (ratio 
of 1:1:1).  As controls, tonsillar CXCR5+ B cells were cultured in medium alone (grey bars), 
or with Tfh cells (ratio of 1:1) (white bars), or with IL-21 (0.5 ng/ml) alone (white bars).  
After 10 days of culture, total IgM, IgG and IgA levels in culture supernatants were 
measured by ELISA.  Data are shown as mean + SEM from four to six (A and C) and two 
(B) independent experiments.  P values show statistically significant differences between B 
cells only and the indicated culture conditions.  
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After having identified B helper-Tfh-like phenotypes on tonsillar Vγ9Vδ2 T cells, I 
addressed whether tonsillar Vγ9Vδ2 T cells were able to provide tonsillar B cell help.  Here, 
by obtaining all three cells types (Vγ9Vδ2 T cells, B cells and Tfh cells) from inflamed 
tonsils taken from the same donor, my model was examined using a more physiologically 
relevant and autologous system. 
 
The total percentage of Vγ9Vδ2 T cells found in human tonsils is very low (0.4 %) (Figure 
5.6A) in contrast to CD4+ T cells (32%) (Figure 5.3A) and B cells (73%) (Figure 5.1A).  
This made isolation of tonsillar γδ T cells more challenging and also limited the number of 
Vγ9Vδ2 T cells that could be isolated for use in co-culture experiments.  Nonetheless, 
tonsillar Vγ9Vδ2 T cells were successfully isolated to high purities (95-99 %) using the 
magnetic cell sorting system followed by purification using the MoFlo cell sorter (Figure 
5.6).  At the same time and from the same tonsil, Tfh cells and CXCR5+ B cells were also 
freshly isolated to high purities using the magnetic cell sorting system (as previously 






























Figure 5.6. Flow cytometric purity analysis of isolated tonsillar Vγ9Vδ2 positive T 
cells.   
Tonsillar mononuclear cells were isolated from fresh human tonsils.  Tfh cells were isolated 
as described in Figure 5.3.  (A) Vδ2+ T cells were positively isolated from the CD4 T cell 
depleted population using the magnetic cell sorting system from Miltenyi Biotec, resulting 
in 20-24 % purity.  (B) For a higher purity Vγ9Vδ2 positive cells were further purified by 
flow cytometry using a MoFlo cell sorter, resulting in 95-99 % purity.  Tonsillar CXCR5+ B 
cells were isolated from the Vγ9Vδ2 T cell depleted population as described in Figure 5.3.  
Results are representative of two experiments performed. 


























To test whether or not tonsillar γδ T cells were able to support tonsillar B cells for antibody 
production, tonsillar Vγ9Vδ2 T and B cells were co-cultured at a ratio of 1:1 in medium 
alone, or with HMB-PP (10 nM) in the presence or absence of IL-21 (50 ng/ml) or with IL-
21 alone (50 ng/ml).  To prevent occurrence of fungal contamination, all cultures were 
treated with an anti-fungal antibiotic (fungizone® antimycotic; 2.5 µl/ml).  After 10 days of 
culture, total IgM, IgG, IgA and IgE levels in culture supernatants were measured by 
ELISA.   
 
One of the major challenges of using tonsillar cells were obtaining inflamed tonsils from a 
donor that provided sufficient number of Vγ9Vδ2 T cells as well as B cells and Tfh cells for 
experimentation.  Tonsils obtained from patients undergoing tonsillectomy are chronically 
infected organs, thus maintaining long term cultures from such a primary tissue can be 
challenging.  Here, I encountered problems with maintaining long term cultures.  This was 
not due to failure of maintaining sterile conditions but due to pre-existing fungal 
contamination of tonsillar tissue being carried over to culture.  In some experiments, 
contamination of cultures was not eliminated after thoroughly washing tissue/cells several 
times in medium containing fungizone® and after culturing cells in the presence of 
fungizone®, which resulted in lose of cultures.  Due to these challenges and due to donor-
to-donor variation, results from two independent donors (donors 1 and 2) and experiments 
are shown, thus allowing for better interpretation of data (Figure 5.7).  
 
As positive controls, tonsillar B cells were co-cultured with an equal number of Tfh cells or 
with the mitogenic B cell stimulator SAC, in the presence of IL-2 (as described in Ebert et 
al. (2004)).  In comparison to B cells cultured in medium alone (B cells only), co-culturing 
of B cells with Tfh cells or with SAC in the presence of IL-2 induced considerable amounts 
of IgM, IgG and IgA antibody production (Figure 5.7). 
 
To test and account for any direct action of HMB-PP, IL-21 or HMB-PP+IL-21 stimulation 
on B cell antibody production, tonsillar B cells were cultured in medium alone, with HMB-




In comparison to B cells cultured in medium alone, HMB-PP stimulation had no direct 
effect on B cell IgM, IgG or IgA antibody production whereas stimulation of B cells with 
IL-21 alone (in the absence or presence of HMB-PP) induced considerable amounts of IgM, 
IgG and IgA antibody production, which in most cases was comparable to levels induced by 
Tfh cells, thus indicating a direct effect of IL-21 on tonsillar B cells (Figure 5.7). 
 
Strikingly, co-culturing of tonsillar Vγ9Vδ2 T cells with B cells in the presence of both IL-
21 and HMB-PP stimulation resulted in a substantial increase in the production of IgM.  
This was more striking in donor 1, where levels of IgM induced by Vγ9Vδ2 T cells were 2-
fold higher than levels induced by Tfh cells or IL-21 alone.  In contrast, tonsillar Vγ9Vδ2 T 
cells were unable to enhance IgM, antibody production in co-cultures of tonsillar B cells 
simulated with medium, HMB-PP or IL-21 alone thus indicating the requirement of both 
HMB-PP and IL-21 stimulation in equipping Vγ9Vδ2 T cells for providing support for 
tonsillar B cell IgM antibody production (Figure 5.7A). 
 
Co-culturing of tonsillar Vγ9Vδ2 T cells with tonsillar B cells in the presence of both IL-21 
and HMB-PP stimulation did not enhance IgG or IgA antibody production.  Equally 
tonsillar Vγ9Vδ2 T cells were unable to enhance IgG or IgA, antibody production in co-
cultures of tonsillar B cells simulated with medium, HMB-PP alone or IL-21 alone.  Here, 
substantial amounts of both IgG and IgA antibody production were induced by direct action 
of IL-21 alone.  Unlike IgM antibody production, IgG and IgA antibody production was 
more sensitive to the direct action of IL-21; this may have masked any additive effect/help 
provided by Vγ9Vδ2 T cells (Figure 5.7B and C).  IgE antibody levels were not detected in 
any of the supernatants taken from B cell or Vγ9Vδ2 T-B cells co-cultures (data not shown).  








































Figure 5.7. HMB-PP and IL-21 dependent tonsillar Vγ9Vδ2 T cells induce potent IgM 
antibody production during co-culture with tonsillar B cells.   
Vγ9Vδ2 T cells, B cells and Tfh cells were freshly isolated from tonsillar mononuclear cells 
and co-cultured at a ratio of 1:1 in medium alone, or with HMB-PP (10 nM) in the presence 
or absence of IL-21 (50 ng/ml) or with IL-21 alone (50 ng/ml) (black bars).  As controls 
tonsillar B cells were cultured in medium alone (grey bars), or with SAC and IL-2, or with 
Tfh cells, or with HMB-PP (10 nM) in the presence or absence of IL-21 (50 ng/ml), or with 
IL-21 alone (50 ng/ml) (white bars).  After 10 days of culture, total (A) IgM, (B) IgG and 
(C) IgA levels in culture supernatants were measured by ELISA.  Data are shown as mean + 
SEM from two to four individual wells and results from two individual donors (donor 1 and 
2) and experiments is shown. 
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To further investigate the potent effects of IL-21+HMB-PP stimulation on the ability of 
tonsillar Vγ9Vδ2 T cells to provide support for tonsillar B cell antibody production, for 
comparison, co-cultures in the presence of HMB-PP were concurrently stimulated with IL-2 
alongside IL-21.  In order to account for any direct action of IL-2 and HMB-PP stimulation 
on B cell antibody production, tonsillar B cells were cultured in medium in the presence of 
IL-2 (20 units/ml) and HMB-PP (10 nM).  In contrast to IL-21 (50 ng/ml), IL-2+HMB-PP 
stimulation had no direct effect on IgM antibody production (Figure 5.8A).   
 
In response to IL-2+HMB-PP stimulation, IgM antibody production increased 30-fold when 
B cells were cultured in the presence compared to the absence of Vγ9Vδ2 T cells.  Thus, 
similar to IL-21+HMB-PP stimulation, IL-2+HMB-PP stimulation, also equipped tonsillar 
Vγ9Vδ2 T cells for providing support for IgM antibody production.  Nevertheless, total 
levels of IgM induced by IL-2+HMB-PP stimulation were 3-fold lower in comparison to 
those induced by IL-21+HMB-PP stimulation, hence making IL-21 a more potent stimulator 
for IgM antibody production (Figure 5.8A). 
 
In contrast to IgM antibody production, IL-2+HMB-PP stimulation in the absence of 
Vγ9Vδ2 T cells, did have direct effects on IgG and IgA antibody production.  This was due 
to the direct effects of IL-2, which was less potent to the direct effects of IL-21.  The 
addition of Vγ9Vδ2 T cells to these cultures did not enhance the production of either IgG or 



































Figure 5.8. Comparison of IL-21 and IL-2 stimulation on tonsillar Vγ9Vδ2 T cells help 
in antibody production.   
Vγ9Vδ2 T cells, B cells and Tfh cells were freshly isolated from tonsillar mononuclear cells 
and co-cultured at a ratio of 1:1 in medium with HMB-PP (10 nM) in the presence of IL-21 
(50 ng/ml) or IL-2 (20 units/ml)(black bars).  As controls tonsillar B cells were cultured in 
medium alone (grey bars), or with Tfh cells (at a ratio of 1:1), or with HMB-PP (10 nM) in 
the presence of IL-21 (50 ng/ml) or IL-2 (20 units/ml) (white bars).  After 10 days of 
culture, total (A) IgM, (B) IgG and (C) IgA levels in culture supernatants were measured by 
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Next, I examined the synergistic effects of tonsillar γδ T cells and Tfh cells on B cell 
antibody production.  All three cell types, Vγ9Vδ2 T cells, B cells and Tfh cells were 
freshly isolated from the tonsil of the same donor (as described in Figure 5.6 and 5.3) and 
cultured at a ratio of 1:1:1 in medium alone or with HMB-PP (10 nM).  As controls B cells 
were cultured alone, or with Tfh cells in the absence or presence of HMB-PP (10 nM) 
(Figure 5.9). 
 
IgM, IgG or IgA antibody production was not further enhanced when Tfh and B cells were 
cultured in the presence compared to the absence of non-stimulated Vγ9Vδ2 T cells 
(medium).  The addition of HMB-PP to induce γδ T cell re-activation did not improve the 
ability of Vγ9Vδ2 T cells to further enhance antibody production already induced by Tfh 
cells (Figure 5.9).  Furthermore, decreasing the number of Vγ9Vδ2 T cells to Tfh and B 
cells from a 1:1:1 to a 1:125:125 ratio did not effect or enhance antibody production 







































Figure 5.9. Tonsillar Vγ9Vδ2 T cells do not further enhance antibody production 
induced by Tfh cells.   
Vγ9Vδ2 T cells, B cells and Tfh cells were freshly isolated from tonsillar mononuclear cells 
and co-cultured at a ratio of 1:1:1 in medium alone or with HMB-PP (10 nM) (black bars).  
As controls tonsillar B cells were cultured in medium alone (grey bars), or with Tfh cells (at 
a ratio of 1:1), with or without HMB-PP (10 nM) (white bars).  After 10 days of culture, 
total (A) IgM, (B) IgG and (C) IgA levels in culture supernatants were measured by ELISA.  
Data are shown as mean + SEM from two to four individual wells and results from two 
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Figure 5.10. Titration of tonsillar Vγ9Vδ2 T cells does not enhance antibody 
production induced by Tfh cells.   
Vγ9Vδ2 T cells, B cells and Tfh cells were freshly isolated from tonsillar mononuclear cells 
and co-cultured at the indicated ratios in medium alone (black bars).  As controls tonsillar B 
cells were cultured in medium alone (grey bars) or with Tfh cells at a ratio of 1:1 (white 
bars).  After 10 days of culture, total (A) IgM, (B) IgG and (C) IgA levels in culture 
supernatants were measured by ELISA.  Data are shown as mean + SEM from three 
individual wells. 
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5.2.5.  IL‐21  and  HMB‐PP  stimulated  peripheral  Vγ9Vδ2  T  cells 
induce  peripheral  B  cell  activation,  APC marker  expression  and 
antibody production 
 
After having established conditions that favour the acquisition of a B helper-Tfh-like 
phenotype on peripheral blood Vγ9Vδ2 T cells, here I addressed whether HMB-PP and IL-
21 stimulated peripheral Vγ9Vδ2 T cells were able to directly induce peripheral B cell 
activation, APC marker expression, differentiation and antibody production. 
 
Highly purified peripheral Vγ9Vδ2 T cells (98-99% purity) were co-cultured with highly 
purified un-touched peripheral B cells (95-99% purity) at a ratio of 1:1, in medium alone, or 
with HMB-PP (10 nM) in the absence or presence of IL-21 (50 ng/ml), or with IL-21 alone 
(50 ng/ml).  As controls B cells were cultured in medium alone (B cells only), or with SAC 
and IL-2 (100 units/ml), or with HMB-PP (10 nM) in the absence or presence of IL-21 (50 
ng/ml), or with IL-21 alone (50 ng/ml).   
 
In order to determine the ability of Vγ9Vδ2 T cells to induce B cell activation and APC 
marker expression, following 3 days of culture, B cells were examined for changes in 
expression of CD25 and CD69 activation markers, CD40 and CD86 and HLA-DR APC 
markers.  Culturing of B cells with SAC (in the presence of IL-2) resulted in sufficient 
activation of B cells.  SAC induced surface expression of CD69, a substantial increase in 
CD25 and CD86 expressing B cells, as well as an up-regulation of both CD40 and HLA-DR 
on B cells.  In the absence of Vγ9Vδ2 T cells, IL-21 and HMB-PP did not have any direct 
effects on B cell CD25, CD69, CD40, CD86 or HLA-DR expression (Figure 5.11). 
 
Co-culturing of Vγ9Vδ2 T cells with B cells in medium or IL-21 alone resulted in a minor 
increase in B cell CD69, CD25, CD40 and CD86 marker expression.  In contrast co-




an induction of CD69 (19 %), CD25 (7%), CD86 (28%), and an up-regulation of CD40 
(GMFI of 98) and HLA-DR (GMFI of 91) on B cells (Figure 5.11).   
 
Furthermore, co-culturing of Vγ9Vδ2 T cells with B cells in the presence of both HMB-PP 
and IL-21 in comparison to HMB-PP alone resulted in a higher proportion of B cells 
expressing CD69 (27%) and CD86 (31%) and higher expression levels of CD40 (GMFI of 
105) on B cells (Figure 5.11).  Thus, higher expression of some B cell markers was 
dependent on the presence of both HMB-PP and IL-21 stimulation 
 
In Chapter 3, I investigated expression of activation markers, co-stimulatory molecules and 
APC markers on Vγ9Vδ2 T cells that were cultured in PBMCs or co-cultured with 
irradiated B cells.  Here, following 3 days of culture I examined for surface CD25, CD69, 
CD27, CD86 and HLA-DR expression on purified Vγ9Vδ2 T cells cultured with purified 
un-touched peripheral B cells.  HMB-PP stimulation alone induced surface expression of 
CD69, CD25, and HLA-DR on a large proportion of Vγ9Vδ2 T cells, and CD86 on a 
smaller proportion of Vγ9Vδ2 T cells.  Furthermore, CD27 already expressed by 50 % of 
non-stimulated Vγ9Vδ2 T cells was up-regulated and found to be expressed by 70% of 
Vγ9Vδ2 T cells in response to HMB-PP stimulation alone.  The addition of IL-21 co-
stimulation did not further enhance Vγ9Vδ2 T cells surface expression of CD25, CD69, 
CD27, HLA-DR or CD86 (Figure 5.12). 
 
Collectively, these results demonstrate that HMB-PP activated and IL21 co-stimulated 
Vγ9Vδ2 T cells not only themselves become highly activated APC marker expressing cells, 
but also at the same time become well equipped in inducing B cell activation and 





























Figure 5.11. HMB-PP activated peripheral γδ T cells in co-cultures up-regulate 
activation and APC marker expression on B cells.   
PBMCs were freshly isolated blocked with human Igs and stained with anti-Vδ2-PE 
antibodies followed with anti-PE microbeads.  Vγ9Vδ2 T cells were positively isolated from 
PBMCs using the magnetic cell sorting system from Miltenyi Biotec, resulting in 98-99% 
purity.  B cells were isolated from Vγ9Vδ2 T cell depleted PBMC by negative selection, 
resulting in 95-99% purity.  Purified Vγ9Vδ2 T cells and B cells were co-cultured at a ratio 
of 1:1 in medium alone, or with HMB-PP (10 nM) in the absence or presence of IL-21 (50 
ng/ml), or with IL-21 alone (50 ng/ml).  As controls B cells were cultured in medium alone 
(grey bars), or with SAC and IL-2 (100 units/ml), or with HMB-PP (10 nM) in the absence 
or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml) (white bars).  After 3 days, 
cells were harvested and stained for CD69, CD25, CD86, CD40 and HLA-DR in 
combination with CD19 and CD3 surface markers.  Cells were analysed by flow cytometry 
for B cell surface marker expression by gating on lymphocytes, live cells and CD3− CD19+ 
cells.  CD69, CD25 and CD86 data are shown as the mean percentage of CD19+ B cells 
positive for each marker.  CD40 and HLA-DR expression data are shown as mean fold 
change in GMFI, calculated as (geometric MFI of antibody)/(geometric MFI of isotype 
control).  Data are shown as mean + SEM from two to three independently assessed donors. 
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Figure 5.12. HMB-PP activated peripheral γδ T cells in co-cultures up-regulate 
activation and APC marker expression.   
Peripheral blood Vγ9Vδ2 T and B cells were freshly isolated as described in Figure 5.11 
and co-cultured at a ratio of 1:1 in medium, or with HMB-PP (10 nM) in the absence or 
presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  After 3 days, cells were 
harvested and stained for CD69, CD25, CD27, CD86 and HLA-DR in combination with 
Vδ2 or Vγ9 and CD3 surface markers.  Cells were analysed by flow cytometry for γδ T cell 
CD69, CD25, CD27, CD86 and HLA-DR surface expression by gating on lymphocytes, live 
cells and CD3+ Vδ2+ or Vγ9 + cells.  Data are shown as mean percentage + SEM from two 
to three independently assessed donors. 
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Next I determined whether Vγ9Vδ2 T cells were able to induce B cell differentiation.  
Following 3 days of culture, B cell naïve/memory populations were identified based on IgD 
and CD27 surface expression and in response to various different culture conditions, 
changes in the percentage of B cell naïve/memory populations were examined. 
  
Culturing of B cells in medium alone without any stimulation did not induce B cell 
differentiation, here 75% of the B cells remained naïve after 3 days of culture (Figure 5.13), 
which is similar to the proportion found in freshly isolated PBMCs (Figure 5.1).  Whereas 
treatment with SAC (in the presence of IL-2) resulted in a dramatic loss of naïve (75% to 
25%) and memory B cells and a corresponding increase in the pool of double negative B 
cells (10% to 65%), demonstrating SAC to be a potent stimulator of peripheral B cell 
differentiation (Figure 5.13). 
 
Culturing of B cells with HMB-PP alone had no effect on naïve/memory B cell pools, 
whereas IL-21 stimulation alone resulted in a small decrease in the percentage of switched 
and unswitched memory B cells.  Co-culturing of B cells with Vγ9Vδ2 T cells in the 
absence or presence of HMB-PP or IL-21 stimulation did not change the percentage of 
naïve/memory B cell subsets; instead the proportions of naïve/memory B cell subsets were 
maintained.  Hence, during the relatively short 3 day culture period Vγ9Vδ2 T cells did not 





























Figure 5.13. HMB-PP and IL-21 stimulated Vγ9Vδ2 T cells do not induce B cell 
differentiation.   
Peripheral blood Vγ9Vδ2 T and B cells were freshly isolated as described in Figure 5.11 
and co-cultured at a ratio of 1:1 in medium alone, or with HMB-PP (10 nM) in the absence 
or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  As controls B cells were 
cultured in medium alone (grey bars), or with SAC and IL-2 (100 units/ml), or with HMB-
PP (10 nM) in the absence or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml) 
(white bars).  After 3 days, cells were harvested and stained for flow cytometry with CD19, 
CD3, IgD and CD27 surface markers.  B cells were analysed for IgD and CD27 expression, 
by gating on lymphocytes, live cells and CD3− CD19+ cells.  Naïve/memory subsets were 
classified as follows: Naïve = IgD+/CD27−, unswitched memory = IgD+/CD27+, switched 
memory = IgD−/CD27+ and double negative = IgD−/CD27−.  Data are shown as mean + 
SEM from two to three independently assessed donors. 
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To test whether or not peripheral γδ T cells were able to support peripheral B cells for 
antibody production, highly purified peripheral Vγ9Vδ2 T cells (98-99% purity) were co-
cultured with highly purified un-touched peripheral B cells (95-99% purity) at a ratio of 1:1, 
in medium alone, or with HMB-PP (10 nM) in the absence or presence of IL-21 (50 ng/ml), 
or with IL-21 alone (50 ng/ml).  As controls, B cells were cultured in medium alone (B cells 
only), or with SAC and IL-2 (20 units/ml), or with HMB-PP (10 nM) in the absence or 
presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).   After 10 days of culture, 
total IgM, IgG, IgA and IgE levels in culture supernatants were measured by ELISA.   
 
Culturing of B cells in medium alone without any stimulation did not induce any B cell 
antibody production whereas treatment with SAC in the presence of IL-2 induced 
considerable amounts of IgM, IgG and IgA antibody production, demonstrating SAC to be a 
potent stimulator of peripheral B cell antibody production (Figure 5.14). 
 
In the absence of Vγ9Vδ2 T cells, very low levels of IgM, IgA and IgG antibodies were 
detected in B cell cultures stimulated with IL-21, HMB-PP or both.  Hence, IL-21 and 
HMB-PP stimulation did not have any major direct effects on peripheral B cell IgM, IgG or 
IgA antibody production.  This is in contrast the strong direct effects of IL-21 on tonsillar B 
cells, previously shown in Figure 5.4.  However, co-culture of B cells in the presence of 
Vγ9Vδ2 T cells and in the presence of both IL-21 and HMB-PP stimulation resulted in a 10-
fold increase in the production of IgM and a 6-fold increase in the production of both IgG 
and IgA.  Antibody production to a lesser extent was also induced in Vγ9Vδ2 T-B cell co-
cultures stimulated with HMB-PP alone, whereby total IgM, IgG and IgA levels in culture 
supernatants were measured to be considerably lower in comparison to those induced in the 
presence of both IL-21 and HMB-PP stimulation.  More strikingly, in comparison to 
SAC+IL-2 stimulation, HMB-PP+IL-21 co-stimulated Vγ9Vδ2 T cells were more potent at 






Here, HMB-PP+IL-21 co-stimulated Vγ9Vδ2 T cells did not induce differentiation of B 
cells over 3 days in culture (Figure 5.13) but did provide help for antibody production over 
10 days in culture, thus indicating γδ T cell induction of B cell differentiation to plasma 
cells (Figure 5.14).  
 
In contrast, co-culturing of peripheral Vγ9Vδ2 T cells with peripheral B cells in medium or 
with IL-21 alone resulted in very little IgM, IgG or IgA antibody production.  Thus, 
indicating the requirement of both HMB-PP and IL-21 stimulation in equipping peripheral 
Vγ9Vδ2 T cells for providing potent support for peripheral B cell IgM, IgG and IgA 
antibody production (Figure 5.14).  Here, IgE antibody levels were not detected in any of 
the supernatants taken from B cell or Vγ9Vδ2 T-B cells co-cultures (data not shown). 
 
To further prove that antibody production induced in HMB-PP and IL-21 co-stimulated co-
cultures was dependent on the presence of Vγ9Vδ2 T cells, in co-cultures the number of 
Vγ9Vδ2 T cells to B cells was decreased from a 1:1 ratio.  Evidently, as the number of 
Vγ9Vδ2 T cells was decreased in HMB-PP stimulated co-cultures, equally the production of 
IgM, IgG and IgA antibody production also decreased accordingly (Figure 5.15A).  This 
effect was more prominent in HMB-PP and IL-21 co-stimulated co-cultures (Figure 5.15B).  
Therefore it was evidently clear that peripheral Vγ9Vδ2 T cells provided dose dependent 


































Figure 5.14. HMB-PP and IL-21 stimulated peripheral Vγ9Vδ2 T cells induce potent 
antibody production during co-culture with peripheral B cells.   
Peripheral blood Vγ9Vδ2 T and B cells were freshly isolated as described in Figure 5.11 
and co-cultured at a ratio of 1:1 in medium, or with HMB-PP (10 nM) in the absence or 
presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml).  As controls B cells were 
cultured in medium alone (grey bars), or with SAC and IL-2 (100 units/ml) or with HMB-
PP (10 nM) in the absence or presence of IL-21 (50 ng/ml), or with IL-21 alone (50 ng/ml) 
(white bars).  After 10 days of culture, total IgM, IgG and IgA levels in culture supernatants 
were measured by ELISA.  Data are shown as mean + SEM from two to three 



















































































Figure 5.15. HMB-PP and IL-21 stimulated peripheral Vγ9Vδ2 T cells provide dose 
dependent help on antibody production.   
Peripheral blood Vγ9Vδ2 T and B cells were freshly isolated as described in Figure 5.11 
and co-cultured at the indicated ratios in medium with (A) HMB-PP alone (10 nM) or (B) in 
the presence of IL-21 (50 ng/ml).  As controls B cells were cultured in medium alone (B 
cells only).  After 10 days of culture, total IgM, IgG and IgA levels in culture supernatants 
were measured by ELISA.  Data are shown as mean + SEM from two to three independent 
wells and is representative of results from one of two similar experiments. 
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The establishment of long-term humoral immunity depends on the production of high 
affinity, class switched antibodies capable of neutralising and opsonising invading 
pathogens.  These antibodies are generated through somatic hypermutation, class switch 
recombination and affinity maturation of activated B cells, processes that take place in the 
GCs of secondary lymphoid organs and depend on cognate help provided by CD4+ Tfh cells 
through expression of several molecules (Breitfeld et al. 2000; King et al. 2008; Schaerli et 
al. 2000).  The acquisition of Tfh-associated markers by Vγ9Vδ2 T cells in response to IL-
21 was first suggested by recent microarray studies (Vermijlen et al. 2007).  IL-21 turned 
out to have a similar capacity as the related cytokine IL-2 to support Vγ9Vδ2 T cell 
proliferation yet without promoting the supposedly ‘signatory’ molecules IFN-γ and TNF-α 
(Eberl et al. 2002a), thus highlighting a much greater plasticity of Vγ9Vδ2 T cell responses 
than previously appreciated.  The main focus of this PhD was to gain a better understanding 
of Vγ9Vδ2 T cell role in humoral immune responses and to provide functional validation of 
previously published microarray studies (Vermijlen et al. 2007).  Here, I investigated the 
effects of IL-21 co-stimulation on the ability of HMB-PP activated Vγ9Vδ2 T cells in 
providing B cell help. 
 
In order to try to mimic the physiological conditions in the GC, an in vitro system of 
autologous Vγ9Vδ2 T cells and B cells from tonsils or blood, the microbial metabolite 
HMB-PP and the Tfh-derived cytokine IL-21 was used.  The data presented in this thesis 
provide evidence that IL-21 contributes to the acquisition of B cell helper functions by 
human Vγ9Vδ2 T cells, thus suggesting a direct role for γδ T cells in the control of humoral 
immune responses.  The main findings are discussed below. 
 
Activation of Vγ9Vδ2 T cells by HMB-PP is dependent on the Vγ9Vδ2 TCR (Morita et al. 
2007; Tanaka 2006; Thedrez et al. 2007) and the effects of IL-21 can only be mediated by 
binding to the IL-21R (Spolski and Leonard 2008).  IL-21 is known to function as a T cell 
co-stimulator with the ability of possibly enhancing TCR signalling.  Furthermore, as shown 
here and stated in literature, IL-21 only induces proliferation of T cells that have been 




Binding of IL-21 to γδ T cells had so far only been described in mice (Ostiguy et al. 2007).  
In order to examine the effects of IL-21 stimulation on human Vγ9Vδ2 T cells surface 
expression of a functional IL-21R is essential.  Expression of IL-21R mRNA by Vγ9Vδ2 T 
cells was reported recently (Vermijlen et al. 2007), yet no data were available to date on the 
protein level nor on the activation-dependent regulation of IL-21R expression by human γδ 
T cells.  This study is the first to show that resting peripheral blood and tonsillar Vγ9Vδ2 T 
cells express IL-21R on their surface and that expression of IL-21R is greatly enhanced 
upon stimulation. 
 
IL-21R was found on Vγ9Vδ2 T cells and CD4+ T cells in freshly isolated PBMC and 
tonsils, as well as on peripheral B cells but not on monocytes.  The IL-2Rα chain CD25 
confers high-affinity responsiveness to IL-2, a cytokine closely related to IL-21, and is an 
early activation marker on T cells, including Vγ9Vδ2 T cells.  I therefore examined whether 
expression of IL-21R is similarly activation-dependent.  Indeed, incubation of PBMC in the 
presence of HMB-PP led to a significant up-regulation not only of CD25 but also of IL-21R 
on Vγ9Vδ2 T cells.  In the same PBMC cultures, no effect was seen on CD25 or IL-21R 
expression by CD4+ T cells, B cells and monocytes demonstrating the specificity of HMB-
PP for Vγ9Vδ2 T cells.  IL-21R was predominantly found on activated Vγ9Vδ2 T cells that 
co-expressed CD25 and CD69.  Time-course experiments showed that stimulation with 
HMB-PP led to a transient up-regulation of IL-21R on Vγ9Vδ2 T cells, peaking at 48 hours 
and returning to baseline levels within 4-5 days.  Furthermore, in response to HMB-PP and 
more so with IL-21 co-stimulation, high levels of surface CD25 remained detectable 
throughout the 5 day culture period, indicating the ability of Vγ9Vδ2 T cells to remain 
activated during long-term culture.  In the presence of IL-21 co-stimulation a less-rapid but 
more sustained (not transient) up-regulation of IL-21R expression was observed on HMB-
PP stimulated Vγ9Vδ2 T cells.  Differences in the pattern of IL-21R expression observed 
here, in response to HMB-PP in comparison to IL-21 co-stimulation could be due to the 
biphasic regulation of IL-21R.  In T cells, IL-21R is thought to be initially up-regulated 
following TCR stimulation with subsequent decline, a secondary spontaneous response 
requires stimulation via IL-21 (Leonard et al. 2008).  In contrast, IL-21R was no longer 




stimulation of PBMCs with IL-21 alone (without HMB-PP).  Binding of most chemokines 
to their receptors results in receptor down-regulation by internalization (Murdoch and Finn 
2000).  Similarly, IL-21R may have been undetectable due to receptor internalisation as a 
mechanism of down-regulating receptor signalling upon IL-21 ligation in the absence of 
TCR or BCR stimulation.   
 
These important findings imply that resting Vγ9Vδ2 T cells are directly responsive to IL-21 
in the microenvironment, and even more so shortly after activation with HMB-PP.  Vγ9Vδ2 
T cells are rapidly drawn to sites of infection where they will encounter invading pathogens 
and interact with other immune cells including neutrophils, monocytes and dendritic cells, 
thus defining an innate-like ‘first line of defence’ or sentinel function (Davey et al. 2011; 
Eberl and Moser 2009; Eberl et al. 2009).  However, activation of both human and mouse γδ 
T cells triggers changes in their migratory pattern and induces up-regulation of CCR7 
(Brandes et al. 2003; Shimura et al. 2010).  CCR7 mediates recruitment of circulating 
lymphocytes from the blood and lymphatic system to secondary lymphoid organs such as 
the lymph nodes.  Blood circulating lymphocytes enter lymph nodes via HEVs whilst 
lymphocytes within lymph fluid enter via afferent lymphatic vessels (Abbas et al. 2007; 
Förster et al. 2008).  Once recruited to secondary lymphoid organs, pre-activated Vγ9Vδ2 T 
cells may thus encounter IL-21 produced by Tfh cells and as a consequence express a 
distinct set of molecules associated with providing B cell help.  Lymph node-resident 
Vγ9Vδ2 T cells may also become stimulated by HMB-PP draining from the site of 
infection.   
 
Within lymph nodes, expression of the CXCL13 receptor, CXCR5 would allow activated 
Vγ9Vδ2 T cells to migrate into the CXCL13-rich B cell follicles of secondary lymphoid 
tissues, where they would contribute to humoral immune responses by interacting with B 
cells and Tfh cells.  Surface expression of CXCR5 on peripheral and tonsillar Vγ9Vδ2 T 
cells was therefore investigated.  From this study, my data indicate that IL-21 also plays a 
role in supporting expression of CXCR5 by tonsillar Vγ9Vδ2 T cells.  Of note, I was unable 




reports (Brandes et al. 2003) but at odds with others (Caccamo et al. 2006a).  Control 
experiments confirmed expression of CXCR5 on peripheral CD4+ T cells and B cells, and 
further up-regulation of CXCR5 on CD4+ T cells stimulated with PHA, thus validating the 
reagents and methodology used.  Also, lower CXCR5 expression values on tonsillar 
Vγ9Vδ2 T cells were observed in comparison to those reported by Caccamo et al. (2006a).  
However, here, stimulation of tonsillar Vγ9Vδ2 T cells with HMB-PP and IL-21 resulted in 
the rapid induction of CXCR5 expression within 24 hours.  Thus, data presented in this 
thesis confirm that activated tonsillar Vγ9Vδ2 T cells can clearly express CXCR5 (Caccamo 
et al. 2006a), providing a molecular explanation for their clustering in GCs (Brandes et al. 
2003; Vermijlen et al. 2007).  Furthermore, peripheral blood γδ T cells express high levels 
of the inflammatory chemokine receptor CXCR3, which has been shown to act as an 
alternative receptor for CXCL13 in the absence of CXCR5.  Thus, CXCR3 is thought to 
have a dual role in recruiting peripheral blood γδ T to sites of microbial infection as well to 
secondary lymphoid organs (Brandes et al. 2003; Caccamo et al. 2006a; Jenh et al. 2001). 
 
Expression of CXCR5 (or CXCR3) would permit Vγ9Vδ2 T cells responsive to CXCL13 
resulting in relocation from the T cell zone towards the B cell follicle.  Within GCs Vγ9Vδ2 
T cells would respond to the high concentrations of Tfh derived IL-21 by producing 
CXCL13, which would lead to further recruitment of CXCR5+ B cells and Tfh cells.  In 
support of the model proposed here, a previous study demonstrated on the mRNA level that 
CXCL13 is expressed by Vγ9Vδ2 T cells stimulated with HMB-PP in the presence of IL-21 
but not of IL-2 or IL-4, and that secretion of CXCL13 protein into the supernatants of 
PBMC stimulated with HMB-PP and IL-21 depends on the presence of Vγ9Vδ2 T cells 
(Vermijlen et al. 2007).  In order to directly confirm γδ T cells as the source of CXCL13, I 
established a flow cytometric method to detect intracellular CXCL13.  As positive control in 
these experiments, a proportion of tonsillar CD4+ T cells stained positive for CXCL13 when 
stimulated with PMA and ionomycin.  Data presented in this thesis unambiguously show 
that activated, CD25+ Vγ9Vδ2 T cells expressed CXCL13 when co-cultured with B cells in 
the presence of HMB-PP and IL-21.  These findings were further validated by 
immunofluorescence microscopy, where intracellular CXCL13 was clearly detectable in a 




the presence of HMB-PP and IL-21.  However, attempts to detect intracellular CXCL13 in 
tonsillar Vγ9Vδ2 T cells failed due to the small frequency of Vγ9Vδ2 T cells obtained from 
tonsils and methodology used.  Despite the low percentage of peripheral CXCL13+ Vγ9Vδ2 
T cells under these co-culture conditions, levels of CXCL13 secreted into the supernatant 
were substantial.  Of note, substituting IL-21 with IL-2 almost completely abrogated the 
CXCL13 production, confirming IL-21 as the main co-stimulatory factor in inducing 
CXCL13 expression by Vγ9Vδ2 T cells.  These findings demonstrated that IL-21 drives 
expression of CXCL13 in Vγ9Vδ2 T cells, thus suggesting a role for IL-21 stimulated 
Vγ9Vδ2 T cells in orchestrating immune cell trafficking to the GC. 
 
Secretion of CXCL13 by HMB-PP activated Vγ9Vδ2 T cells would provide as a mechanism 
of attracting circulating CXCR5+ B cells and Tfh cells towards Vγ9Vδ2 T cells.  This would 
allow Vγ9Vδ2 T cells to provide direct cell-to-cell contact with B cells via presentation of 
co-stimulatory molecules.  Such interactions would be essential for bidirectional 
communication, mutual co-stimulation and activation of cells (Frauwirth and Thompson 
2002).  Earlier studies involving the use of a weaker Vγ9Vδ2 T cell activator (IPP) in the 
absence of cytokine stimulation have shown up-regulation of some co-stimulatory 
molecules (CD40L, OX40, ICOS and CD70) involved in B cell help (Brandes et al. 2003).  
Here, by using IL-21 and HMB-PP, this study applied a more physiologically relevant and 
novel method of investigating Vγ9Vδ2 T cell expression of several Tfh-associated co-
stimulatory molecules.  Furthermore, in contrast to previous studies, the use of more recent 
and powerful technology such as 9-colour flow cytometry provided a means of analysing 
co-expression of several markers, not only on Vγ9Vδ2 T cells but also simultaneously (as a 
control) on CD4+ T cells.  Here, surface expression of co-stimulatory molecules CD40L, 
OX40, ICOS, CD70, CD28 and CD27 was studied on peripheral blood and tonsillar 
Vγ9Vδ2 T cells.   
 
Consistent with previous reports (Brandes et al. 2003), the co-stimulatory molecules 
CD40L, OX40, ICOS and CD70 were found to be absent on resting peripheral blood 




peripheral Vγ9Vδ2 T cells were found to express CD28 (67%) and CD27 (92%) (Lafont et 
al. 2000; Ribot et al. 2011; Takamizawa et al. 1995; Testi and Lanier 1989).  In comparison, 
a minor population of freshly isolated tonsillar Vγ9Vδ2 T cells readily expressed ICOS 
(6%) and OX40 (3%), but not CD40L, CD70 or CD28.  The expression of ICOS and OX40 
on freshly isolated tonsillar Vγ9Vδ2 T cells could be explained due to the findings that a 
minority of freshly isolated tonsillar Vγ9Vδ2 T cells readily expressed CD25 (3%) and 
CD69 (11%), thus indicating the presence of pre-activated Vγ9Vδ2 T cells in inflamed 
infected tonsils.  Furthermore the majority of tonsillar Vγ9Vδ2 T cells became rapidly 
activated (within 24 hours) in response to in vitro HMB-PP stimulation alone.  This 
indicated that in vitro activation of tonsillar Vγ9Vδ2 T cells was far more robust in 
comparison to peripheral blood Vγ9Vδ2 T cells.  Here, I also studied co-stimulatory 
molecule expression on in vitro activated peripheral blood and tonsillar Vγ9Vδ2 T cells.  
 
The early co-stimulatory molecules CD40L, is required during pre-Tfh cell and B cell 
interactions.  Ligation of CD40 on B cells by CD40L on Tfh cells induces GC B cell 
activation, survival, proliferation and in the presence of specific cytokines isotype switching 
(Daoussis et al. 2004; King 2009; Yong et al. 2009).  Here, the early co-stimulatory 
molecules CD40L was not found on HMB-PP or IL-21 co-stimulated peripheral or tonsillar 
Vγ9Vδ2 T cells, but was significantly up-regulated (24%) upon 3 hours stimulation with 
PMA+ionomycin.  CD40L is rapidly up-regulated at the very early stages (4-6 hours) of T 
cell stimulation (Daoussis et al. 2004).  Thus the time-points used here (1-2 days post HMB-
PP/IL-21 stimulation) may have been too late for detection of surface CD40L. 
 
OX40:OX40L and ICOS:ICOS-L interactions between Tfh and B cells follow 
CD40L:CD40 interactions (Croft et al. 2009; Deenick et al. 2011; Salek-Ardakani and Croft 
2006).  OX40 and ICOS are mainly found on activated T cells and are up-regulated 
following TCR engagement and CD28 signalling (Croft et al. 2009; Salek-Ardakani and 
Croft 2006).  However, ICOS can be found at low levels on the surface of resting naïve 
CD4+ T cells.  Co-expression of high levels of CXCR5 and ICOS is a defining feature of 




Vγ9Vδ2 T cells (Caccamo et al. 2006a) to provide follicular B cell help is in part mediated 
through ICOS.  Strikingly, IL-21 showed a strong co-stimulatory effect on ICOS, with 
expression levels reaching 50% of all Vγ9Vδ2 T cells over a period of 6 days, at a time 
point of considerable proliferative expansion (Vermijlen et al. 2007).  In parallel with ICOS, 
activated Vγ9Vδ2 T cells also transiently expressed the co-stimulatory molecule OX40, 
although the effect of IL-21 on OX40 levels was less pronounced.  However, the effects of 
IL-21 co-stimulation maintained expression of OX40 for a further 24 hours.   
 
When comparing the responsiveness of peripheral and tonsillar Vγ9Vδ2 T cells, tonsillar 
cells showed an increased sensitivity to IL-21 with regard to ICOS expression, while OX40 
was preferentially induced on peripheral Vγ9Vδ2 T cells. These time-course experiments 
helped elucidate the unique role of IL-21 in regulating ICOS expression on HMB-PP 
activated Vγ9Vδ2 T cells, which has never been shown before.  Tfh cells secrete IL-21 in an 
autocrine manner in response to ICOS stimulation which is thought to drive ICOS 
expression through a positive feedback mechanism (Bauquet et al. 2009).  IL-21 may also 
have similar effects in driving ICOS expression on Vγ9Vδ2 T cells.   
 
Other co-stimulatory molecules such as CD70 are also involved in stimulating B cell 
activation and promoting plasma cell differentiation (Borst et al. 2005; Elgueta et al. 2010; 
Jacquot 2000; Nolte et al. 2009).  Here, CD70 was also found to be up-regulated on both 
peripheral and tonsillar Vγ9Vδ2 T cells when exposed to a combination of HMB-PP and IL-
21.  Taken together, our data demonstrate a role for IL-21 in the acquisition by Vγ9Vδ2 T 
cells of markers associated with B cell help.  In particular, activation of peripheral and 
tonsillar Vγ9Vδ2 T cells in the presence of IL-21 leads to the expansion of ICOS+ Vγ9Vδ2 
T cells with a Tfh cell-like phenotype. 
 
Cytokines also have an influence on the outcome of humoral immune responses (Crotty 
2011).  γδ T cells have been well established as producers of pro-inflammatory (IFN-γ and 
TNF-α) and anti-inflammatory cytokines (IL-4 and IL-10) (Caccamo et al. 2006a; Hayday 




secondary lymphoid tissues may modulate the outcome of humoral immune responses.  For 
example, IL-4 is known to assists in T:B interactions, promotes B cell proliferation and 
plasma cell differentiation (King et al. 2008; Yong et al. 2009).  IL-4 also has an inhibitory 
effect on IgA production but drives production of IgE, and IFN-γ has been shown to inhibit 
switching of certain isotypes such as IgE (Konforte et al. 2009; Pistoia and Cocco 2009).  
Previous studies have shown activated human Vγ9Vδ2 T cells to provide help to B cells via 
secretion of IL-4 and IL-10 (Caccamo et al. 2006a).  Here, peripheral CXCL13+ Vγ9Vδ2 T 
cells were found to be IL-4 and IFN-γ producing cells.  IL-21 enhanced the expression of 
both IL-4 and IFN-γ in HMB-PP activated peripheral CXCL13+ Vγ9Vδ2 T cells.  Similarly, 
a small percentage of tonsillar Vγ9Vδ2 T cells upon PMA+ionomycin stimulation expressed 
IL-4, whilst a higher percentage expressed TNF-α, and IFN-γ.  In tonsils, the percentage of 
IFN-γ+ Vγ9Vδ2 T cells was significantly higher in comparison to IFN-γ+ CD4 T cells.  
Levels of cytokines secreted by Tfh cells within GCs are thought to be dependent on 
environmental conditions (Crotty 2011).  Thus, inflammatory conditions such as tonsillitis 
may favour secretion of IFN-γ by Vγ9Vδ2 T cells but not by CD4+ T cells.  Secretion of 
IFN-γ by Vγ9Vδ2 T cells may be a way of modulating function of Tfh cells and B cell 
antibody responses.  
 
Vγ9Vδ2 T cells may also contribute to the outcome of antibody responses by presenting 
antigen to Tfh cells.  Several studies have already reported activated human Vγ9Vδ2 T cells 
to express important markers required for antigen-presentation and to act as professional 
APCs (Brandes et al. 2009; Brandes et al. 2005; Himoudi et al. 2012; Landmeier et al. 2009; 
Meuter et al. 2010; Moser and Eberl 2011; Wu et al. 2009).  Here, consistent with previous 
studies, CCR7, HLA-DR and CD86 was absent or found on a very low percentage of 
freshly isolated peripheral Vγ9Vδ2 T cells.  However, CD40 was readily expressed on 
freshly isolated peripheral Vγ9Vδ2 T cells, which was further up-regulated along with 
CCR7, HLA-DR and CD86 upon HMB-PP stimulation.  In comparison to peripheral blood, 
an almost two-fold higher percentage of Vγ9Vδ2 T cells from tonsils readily expressed 
CCR7, CD40 and HLA-DR.  Culturing of mononuclear tonsillar cells with HMB-PP 
resulted in up-regulation of CD86 and further up-regulation of CD40 and HLA-DR on 




cells, as CD40, HLA-DR and CD86 found readily expressed by tonsillar CD4+ T cells were 
not further up-regulated in response to HMB-PP.  
 
Collectively, these data indicate that IL-21 drives Vγ9Vδ2 T cells to assume a Tfh-like 
phenotype, thus evoking the crucial effect of IL-21 in the generation of CD4+ Tfh cells 
(Vogelzang et al. 2008).  Furthermore, in the presence of HMB-PP, Vγ9Vδ2 T cells 
underwent potent crosstalk with B cells as evidenced by up-regulation of CD25, CD69, 
CD40 and CD86 on co-cultured B cells.  This effect was comparable to the effect of 
treatment of B cells with the mitogen SAC, indicating that HMB-PP-activated Vγ9Vδ2 T 
cells provided a strong stimulus for B cells.  The phenotypic characterisation of Vγ9Vδ2 T 
cells was further supported by the functional demonstration that co-stimulation with IL-21 
of co-cultures of peripheral Vγ9Vδ2 T cells and B cells enhanced the production of IgM, 
IgG and IgA in the presence of HMB-PP.  Of note, the stimulatory effect of peripheral γδ T 
cells on autologous B cells depended on the γδ T cell:B cell ratio, confirming the exquisite 
ability of HMB-PP-activated γδ T cells to provide B cell help, especially when co-
stimulated in the presence of IL-21.  A similar co-stimulatory effect of IL-21 was seen on 
IgM levels produced by co-cultures of tonsillar Vγ9Vδ2 T cells and B cells.  We are aware 
that the interpretation of these co-culture assays is hampered by a possible direct effect of 
IL-21 on B cells (Bryant et al. 2007; Linterman et al. 2010).  Although IL-21 on its own had 
no significant effect on antibody production by peripheral B cells, partial activation of B 
cells by IL-21 may have played a role in these experiments.  In co-cultures of tonsillar cells, 
there was a clear effect of IL-21 alone, suggesting that under those conditions HMB-PP and 
IL-21 acted synergistically.  In order to rule out any direct effect on B cells, we pre-
stimulated purified Vγ9Vδ2 T cells with HMB-PP and IL-21 before adding them to 
autologous B cells.  However, no conclusive data were obtained, most likely because any 
soluble factors of importance for supporting antibody production released during this pre-






Taken together, our present findings complement and extend previous observations on the 
potential of γδ T cells to provide B cell help, and ascribe an important role to IL-21 in 
contributing to this potential.  The interaction between HMB-PP-responsive Vγ9Vδ2 T cells 
with IL-21 producing Tfh cells and with B cells in secondary lymphoid tissues is likely to 
impact on the generation of high affinity, class-switched antibodies in microbial infections.  
Furthermore, the nature of γδ T cells to recognise non-peptide antigens on a diverse array of 
pathogens in concert with the recognition of a diverse array of peptide antigens by αβ (CD4+ 
and CD8+) T cells and lipid antigens by NKT cells, may allow for a more diverse repertoire 
of antibodies to be generated.  In conclusion, based on the major findings presented in this 
































Figure 6.1. Proposed interaction between γδ T cells, B cells and Tfh cells in secondary 
lymphoid tissue.   
Vγ9Vδ2 T cells recognise HMB-PP at sites of inflammation resulting in cell activation, up-
regulation of the IL-21R and acquisition of a lymph node homing phenotype.  Vγ9Vδ2 T 
cells migrate into secondary lymphoid organs such as the lymph node via expression of 
CCR7 and into GCs via expression of CXCR5 (or CXCR3).  Within GCs Vγ9Vδ2 T cells 
respond to Tfh derived IL-21. The co-stimulatory effect of IL-21 via IL-21R on HMB-PP-
activated Vγ9Vδ2 T cells induces secretion of CXCL13, secretion of pro-inflammatory 
(IFN-γ and TNF-α) and anti-inflammatory cytokines (IL-4), up-regulation of CXCR5 and 
co-stimulatory molecules (ICOS, OX40, CD40L and CD70).  This allows Vγ9Vδ2 T cells 
to interact with B cells, influence the outcome of humoral immune responses and support 
antibody production.  Secretion of CXCL13 by Vγ9Vδ2 T cells results in further 
recruitment of CXCR5+ B cells and Tfh cells.  This ‘ménage à trois’ of Vγ9Vδ2 T cells, Tfh 
cells and B cells in the GCs of secondary lymphoid tissues is likely to impact on the 
generation of high affinity, class-switched antibodies in microbial infections.  Additionally 
γδ T cells may also influence the outcome of humoral immune responses by differentiating 
into γδ T-APCs, which interact with CD4+ T cells (and CD8+ T cells) via CD86:CD28 and 






Although our present findings complement and extend previous observations, more research 
is required before any definitive conclusions can be drawn on the exact role and 
contribution of human Vγ9Vδ2 T cells in humoral immune responses. 
 
In vivo studies remain a challenge and limited, as Vγ9Vδ2 T cells and the responsiveness to 
HMB-PP are only found in higher primates including humans but are absent in all other 
vertebrates including rodents (Eberl and Moser 2009).  For example, one of the biggest 
challenges of human studies is obtaining suitable fresh tissue material such as lymph nodes, 
which would be more ideal for study of humoral immune responses.  Instead, here and used 
by many other researchers, tonsils provided the most easily obtained and most accessible 
form of human lymphoid tissue for study.  This was mainly due to routine tonsillectomies 
being carried out on a daily basis.  However, a tonsillectomy is usually carried out as a 
result of on-going chronic infection and is not performed during an episode of acute 
tonsillitis but after a response to infection is over.  Activated Vγ9Vδ2 T cells have been 
documented to be elevated during acute infections (Davey et al. 2011; Eberl and Moser 
2009; Moser and Eberl 2011).  Moreover, the majority of cases of tonsillitis are due to an 
infection caused by the Gram positive bacteria Streptococcus pyogenes (also know as “strep 
throat”) (Murray and Chennupati 2012; Sidell and Shapiro 2012), which do not produce 
HMB-PP, therefore in such cases does not result in stimulation/activation of γδ T cells 
(Eberl and Moser 2009).  For future studies it would be more appropriate to use a source of 
secondary lymphoid organ/tissue that represents acute infection caused by i.e. Gram 
negative HMB-PP producing bacteria (Eberl and Moser 2009).   
 
Future ex vivo studies would involve investigation of Vγ9Vδ2 T cell frequencies, 
phenotypes and B cell helper functional capabilities from inflamed infection-involved 
lymph nodes in comparison to non-inflamed.  This may not only support current data but 




immune response.  Immunohistochemical and immunofluorescence analysis of infection-
involved lymph node tissue sections could be used to demonstrate in vivo co-localisation of 
γδ T cells, B cells, and Tfh cells within GCs, along with staining for co-stimulatory markers, 
CXCL13 and CXCR5.  Direct immunofluorescence staining of markers would be essential.  
Thus an anti-human CXCL13 antibody that is directly conjugated to a fluorochrome would 
be essential.  
 
Ideas for future in vitro co-culture experimental work would include blocking of IL-21R in 
revealing the importance of exogenous and Tfh derived IL-21 on Vγ9Vδ2 T cells in 
delivering co-stimulation for enhancing B cell helper capability.  This would also involve 
investigating crosstalk between γδ T cells and Tfh cells in regulating cytokine production 
and B cell responses (i.e. antibody production and isotype switching), which would be 
carried out under several different culture conditions.   
 
Finally, the aspect of antigen specificity deserves attention.  Earlier studies in mice 
demonstrated that GC reactions that solely depend on γδ T cells are somewhat inefficient 
and result in relatively high titres of class-switched, self-reactive antibodies (Wen and 
Hayday 1997; Wen et al. 1994).  γδ T cells may thus provide general B cell help and 
enhance humoral immune responses, while MHC restricted αβ T cells ensure antigen 
specificity by regulating affinity maturation and clonal selection.  This view is supported by 
the fact that HMB-PP is present in the majority of bacterial pathogens, in malaria parasites 
and in Toxoplasma, and hence activation of human Vγ9Vδ2 T cells is likely to occur in a 
broad range of infections (Eberl and Moser 2009).  A ‘bystander’ role for Vγ9Vδ2 T cells in 
driving humoral responses may result in different antibody levels, isotypes or affinities upon 
infection with HMB-PP producing or HMB-PP deficient micro-organisms.  While such a 
role can only be postulated in humans and at best supported by indirect epidemiological 
evidence, infection and/or vaccination experiments in non-human primates might address 
the contribution of Vγ9Vδ2 T cells to the generation of high-affinity, class-switched 
antibodies.  Such studies could exploit the availability of convenient pathogen models such 




2004) or HMB-PP overproducing strains of Mycobacterium tuberculosis (Brown et al. 
2010). 
 
Recent findings also point toward a more antigen-restricted role of Vγ9Vδ2 T cells in 
providing B cell help, given their potential to take up exogenous antigens and present them 
to CD4+ and CD8+ T cells (Brandes et al. 2005; Moser and Eberl 2011).  Antigen-presenting 
γδ T cells may thus be able to interact directly with Tfh cells.  In mice, epidermal γδ T cells 
leave the skin upon activation and reach the draining lymph node where they may help the 
production of antibodies specific for non-self antigen applied onto, or artificially expressed 
within, the skin (Shimura et al. 2010; Strid et al. 2009).  It remains to be investigated 
whether HMB-PP or related compounds with activity on Vγ9Vδ2 T cells, such as the 
aminobisphosphonate zoledronate, might be useful in boosting humoral responses.  A recent 
vaccine trial in cynomolgus monkeys did address a possible adjuvant effect of the HMBPP 
analogue Picostim on the immune response against mycobacterial antigens yet did not 
measure levels of anti-mycobacterial antibodies (Cendron et al. 2007).  Similarly, the effect 
of aminobisphosphonate treatment on anti-tumour antibody responses in cancer patients has 
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The cover shows a histological analysis of an ear section from a C57BL/6 mouse that was first
sensitised with 2,4-dinitrofluorobenzene on the belly and then challenged 4 days later with
2,4-dinitrofluorobenzene on the ear. Haematoxylin and eosin staining shows massive skin
infiltration by mononuclear cells and granulocytes 24 h after challenge. The image is from
Rouzaire et al. (pp. 80–88) in which the authors show that NK cells and T cells induce different
types of inflammatory reactions in the skin during recall responses to haptens; of note, NK cell-
mediated pathogenesis does not rely on cellular infiltrate.
A ‘me´nage a` trois’ in the germinal centre involving human
cd T cells
Vg9/Vd2 T cells comprise a minor subset of
unconventional T cells in the blood which
uniquely respond to HMB-PP, a non-peptide
metabolite produced by a large range of
microbial pathogens. For reasons that are
not understood Vg9/Vd2 T cells and immune
responsiveness to HMB-PP are found only in
higher primates and are absent in all other
vertebrates including mice. In this issue,
Bansal et al. demonstrate that HMB-PP
induces upregulation of the IL-21 receptor
on human Vg9/Vd2 T cells. The authors show
that IL-21 plays a co-stimulatory role in the
induction of CXCL13, CXCR5 and ICOS
expression by HMB-PP-activated Vg9/Vd2
T cells and in the potential of these cells to
provide B-cell help. These findings suggest
that the ‘me´nage a` trois’ of Vg9/Vd2 T cells,
TFH cells and B cells in the germinal centres of
secondary lymphoid tissues is likely to impact
on the generation of high-affinity, class-
switched antibodies in microbial infections.
(pp 110–119)
The heart of HIV-associated tuberculosis
Compared with those not infected with HIV,
HIV-infected individuals are up to 30 times
more likely to develop tuberculosis, with an
increased risk of extrapulmonary disease. In
this issue, Matthews et al. show that in the
pericardial form of extrapulmonary tuberculo-
sis, increased HIV replication at the tubercu-
lous disease site leads to the elimination of the
CCR51 effector memory CD41 T-cell popula-
tion by the virus. This elimination of the
memory population is accompanied by the
recruitment of less differentiated cells to the
disease site. The presence of polyfunctional
CD41 T cells expressing TNF, IL-2 and IFN-g is
consistent with the less mature phenotype of
CD41 memory T cells at the disease site of
HIV-1-infected patients. Interestingly, and
unlike other extrapulmonary tuberculous
disease sites, there are instances where the
compartmentalisation of antigen-specific
T cells is not detectable. As this lack of
compartmentalisation might limit diagnostic
application in pericardial tuberculosis, the
underlying reasons require further elucidation.
(pp 147– 157)
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Hybrids, not just for cars: cd T-cell transcriptome is a hybrid of ab
T-cell and NK-cell signatures
Human gd T cells reactive to non-peptide
phosphoantigens represent promising new
anti-cancer immunotherapeutics, but they
are hitherto poorly characterized. In this issue,
Pont et al. perform the first Affymetrix-based
transcriptome analysis of human phosphoanti-
gen-specific gd T cells in resting and activated
conditions. In comparison with a broad
collection of transcriptomes from both healthy
lymphocytes and lymphoma cells, phospho-
antigen-specific gd T cells are found to cluster
with – and between – healthy ab T and NK
cells. gd T cells show gene expression signa-
tures corresponding to both ab Th1 and NK
cell functional activities, but not to phagocytic
or antigen-presenting cell (APC) bioactivities.
Functional studies show that Th1 cytokine,
chemokine and cytotoxic activities reflect a
high mitotic activity at later time points rather
than antigen-presenting functions. The tran-
scriptomes from these phosphoantigen-speci-
fic gd T cells are therefore strikingly distinct
from that of NK/T or peripheral T-cell
lymphomas of the gd subtype.
(pp 228– 240)
(pp 120– 129)Natural antibody-producing B-1 cells exist in the bone marrow
A small subset of B cells, B-1 cells, is thought
to generate ‘‘natural antibodies’’ (nAbs) –
antibodies that are generated without overt
immunization and importantly contribute to
antimicrobial defenses and tissue homeosta-
sis. However, while nAb production occurs
mainly in the spleen and bone marrow (BM),
B-1 cells are most prominent in the body
cavity of mice and are not thought to exist in
BM. In this issue, Choi et al. resolve this
apparent conundrum by identifying, for the
first time, nAb-secreting B-1 cells in the BM.
BM B-1 cells share many characteristics
with splenic B-1 cells, but are distinct from
their counterparts in body cavities, which
despite their relative abundance contribute
little to the nAb pools. nAb-producing B-1
cells are also distinct from conventional
plasma cells. These data highlight the signifi-
cant contribution of BM B-1 cells as nAb-
producers and supports the view that body
cavity B-1 cells function as rapidly inducible
cellular reservoirs, but not pools, of nAb-
producing cells.
From our sister journals –
Come on in! How antibodies can also act inside cells
It was recently discovered that – besides
providing extracellular protection against
pathogens – antibodies bound to adenovirus
can also enter the cell and lead to the disposal
of the virus intracellularly. McEwan et al.
describe how this antibody-dependent intracel-
lular neutralisation (ADIN) works: inside the
cell the antibodies are recognized by the
receptor TRIM21, which binds to IgG with
high affinity. The binding of TRIM21 to IgG
subsequently recruits the ubiquitin-proteasome
system, leading to the degradation of the virus.
Furthermore the authors discuss how this
discovery alters our view of the way in which
antibodies neutralize viral infection and what
implications this may have for future research.
McEwan et al.,
BioEssays 2011. 33: 803–809
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IL-21 enhances the potential of human cd T cells
to provide B-cell help
Raj R. Bansal1, Charles R. Mackay2, Bernhard Moser1
and Matthias Eberl1
1 Department of Infection, Immunity and Biochemistry, School of Medicine, Cardiff University,
Cardiff, United Kingdom
2 Faculty of Medicine, Nursing and Health Services, Monash University, Clayton, Australia
Vc9/Vd2 T cells are a minor subset of T cells in human blood and differ from all other
lymphocytes by their specific responsiveness to (E)-4-hydroxy-3-methyl-but-2-enyl pyro-
phosphate (HMB-PP), a metabolite produced by a large range of microbial pathogens.
Vc9/Vd2 T cells can be skewed towards distinct effector functions, in analogy to, and
beyond, the emerging plasticity of CD41 T cells. As such, depending on the micro-
environment, Vc9/Vd2 T cells can assume features reminiscent of Th1, Th2, Th17 and Treg
cells as well as professional APCs. We here demonstrate that Vc9/Vd2 T cells express
markers associated with follicular B helper T (TFH) cells when stimulated with HMB-PP in
the presence of IL-21. HMB-PP induces upregulation of IL-21R on Vc9/Vd2 T cells. In
return, IL-21 plays a co-stimulatory role in the expression of the B-cell-attracting
chemokine CXCL13, the CXCL13 receptor CXCR5 and the inducible co-stimulator by acti-
vated Vc9/Vd2 T cells, and enhances their potential to support antibody production by
B cells. The interaction between HMB-PP-responsive Vc9/Vd2 T cells, IL-21-producing TFH
cells and B cells in secondary lymphoid tissues is likely to impact on the generation of high
affinity, class-switched antibodies in microbial infections.
Key words: Bacterial infections . B cells . cd T cells . IL-21 . TFH cells
Introduction
The establishment of long-term humoral immunity depends on
the production of high-affinity antibodies capable of neutralising
and opsonising invading pathogens. These antibodies are
generated through somatic hypermutation, class switch recombi-
nation and affinity maturation of activated B cells, processes that
take place in the germinal centres (GCs) of secondary lymphoid
organs and depend on cognate help provided by CD41 follicular
B helper T (TFH) cells [1, 2]. Human TFH cells are defined by the
expression of characteristic markers [3–7]: the transcriptional
repressor Bcl-6 that directs TFH lineage commitment; the
chemokine receptor CXCR5 that enables TFH cells to migrate
into the B-cell follicles; the CXCR5 ligand CXCL13 that
attracts further CXCR51 cells such as naı¨ve B cells and early
activated CD41 T cells; the co-stimulatory molecules, inducible
co-stimulator (ICOS) and programmed cell death 1 (PD-1), which
interact with their corresponding ligands on B cells; and the
cytokine IL-21 that steers B-cell differentiation and antibody
production. Murine TFH cells express the same panel of markers
with the exception of CXCL13.
While the crucial role of TFH cells in providing B-cell help is
undisputed, other T-cell subsets including CD81 T cells, NKT cells
and gd T cells contribute to the outcome of humoral immune
responses [8–10]. gd T cells support antibody production in
immunised and infected mice [11–13]. Of note, GCs are present in
TCR-a/ and TCR-b/ mice and develop in SCID mice upon
adoptive transfer of gd T cells and B cells, demonstrating that
gd T cells are sufficient to orchestrate follicular responses [14–16].
In humans, gd T cells can be found in secondary lymphoid tissues
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[17, 18], where they are scattered throughout the T zone and
clustered within GCs [8]. Early studies in lupus patients led to the
isolation of human gd T-cell lines capable of inducing autoantibody
production by autologous B cells [19]. Subsequent investigations
demonstrated that in vitro activated human gd T cells can readily
provide help to B cells via contact-dependent mechanisms invol-
ving CD40L and ICOS and soluble factors including IL-4 and IL-10
[8, 20]. Activated human gd T cells may also express additional
markers of relevance for a possible interaction with B cells
including OX40, PD-1, CD27 and CD70 [8, 21, 22].
Vg9/Vd21 gd T cells comprise an enigmatic human gd T-cell
subset that normally constitutes 1–5% of circulating T cells [23] but
expands rapidly in response to infections with microbes producing
the metabolite (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate
(HMB-PP) [24]. For reasons that are not yet understood, Vg9/Vd2
T cells and the responsiveness to HMB-PP are only found in higher
primates including humans despite the ubiquitous distribution of
potentially harmful, HMB-PP producing micro-organisms [25].
Freshly isolated human Vg9/Vd2 T cells are characterised by a
largely pro-inflammatory cytokine profile comprising IFN-g, TNF-a
and GM-CSF although co-expression of IL-4 is frequently observed
[26–28]. Importantly, however, they can be skewed towards
distinct effector functions depending on the microenvironment, in
analogy to, and even beyond, the emerging plasticity of CD41 ab
cells. As such, under appropriate culture conditions, Vg9/Vd2
T cells divert from the ‘default’ Th1/CTL-like phenotype and
assume features reminiscent of Th2 cells [27, 29], Th17 cells
[30, 31], Treg cells [32] and even professional APCs [33]. Our
earlier microarray studies revealed that Vg9/Vd2 T cells express a
range of TFH-associated molecules when stimulated with HMB-PP
in the presence of IL-21 suggesting a potential role in the GC
reaction [27]. We here sought to provide a functional validation of
these findings and investigated the effect of IL-21 on the acquisition
of TFH-associated features by Vg9/Vd2 T cells. Our present data
demonstrate that HMB-PP induces upregulation of IL-21R on Vg9/
Vd2 T cells, thereby enhancing their responsiveness to IL-21. In
return, IL-21 plays a co-stimulatory role in the expression of
CXCL13, CXCR5 and ICOS by activated Vg9/Vd2 T cells and their
potential to provide B-cell help as evidenced by supporting anti-
body production.
Results
HMB-PP induces upregulation of the IL-21 receptor on
human cd T cells
We recently reported the expression of IL-21R mRNA by Vg9/Vd2
T cells [27], yet no data are available to date on the protein level
nor on the activation-dependent regulation of IL-21R expression
by human gd T cells. Here, a monoclonal antibody against human
IL-21R [34, 35] specifically stained B cells, CD41 T cells and
Vg9/Vd2 T cells but not monocytes in freshly isolated PBMCs
(Fig. 1A). Similarly, IL-21R was expressed by both CD41 T cells
and Vg9/Vd2 T cells in tonsils.
The IL-2Ra chain CD25 confers high-affinity responsiveness to
IL-2, a cytokine closely related to IL-21, and is an early activation
marker on T cells, including Vg9/Vd2 T cells. We therefore
examined whether the expression of IL-21R is similarly activa-
tion-dependent. Indeed, incubation of PBMCs in the presence of
HMB-PP led to a significant upregulation not only of CD25 but
also of IL-21R on Vg9/Vd2 T cells. In the same PBMC cultures, no
effect was seen on CD25 or IL-21R expression by CD41 T cells,
B cells and monocytes (not shown), demonstrating the specificity
of HMB-PP for Vg9/Vd2 T cells. IL-21R was predominantly found
on activated Vg9/Vd2 T cells that co-expressed CD25 and CD69
(Fig. 1B). Time-course experiments showed that stimulation with
HMB-PP led to a transient upregulation of IL-21R on Vg9/Vd2
T cells, peaking at 48h and returning to baseline levels within
4–5 days (Fig. 1C). Taken together, these data suggest that HMB-
PP-activated Vg9/Vd2 T cells are able to respond in vitro to
exogenously added IL-21 and in vivo to IL-21 released from
bystander cells in the microenvironment, such as TFH cells in
secondary lymphoid tissues.
IL-21 co-stimulates the expression of CXCL13 by
activated cd T cells
Migration and positioning of T cells and B cells in lymph node
follicles are tightly controlled by the chemokine CXCL13 and its
receptor CXCR5. We previously demonstrated on the mRNA level
that CXCL13 is expressed by Vg9/Vd2 T cells stimulated with
HMB-PP in the presence of IL-21 but not of IL-2 or IL-4, and that the
secretion of CXCL13 protein into the supernatants of PBMCs
stimulated with HMB-PP and IL-21 depends on the presence of
Vg9/Vd2 T cells [27]. To directly confirm gd T cells as the source of
CXCL13, we established a flow cytometric method to detect
intracellular CXCL13. As a control in these experiments, a proportion
of tonsillar CD41 T cells stained positive for CXCL13 when
stimulated with PMA and ionomycin (Fig. 2A). Our data unambig-
uously show that activated, CD251 Vg9/Vd2 T cells expressed
CXCL13 when co-cultured with B cells in the presence of HMB-PP
and IL-21 (Fig. 2A). These findings were further validated by
immunofluorescence microscopy, where intracellular CXCL13 was
clearly detectable in a proportion of Vg9/Vd2 T cells co-cultured with
B cells in the presence of HMB-PP and IL-21 (Fig. 2B). Despite the
low percentage of CXCL131 Vg9/Vd2 T cells under these co-culture
conditions, the levels of CXCL13 secreted into the supernatant were
substantial (Fig. 2C). Of note, substituting IL-21 with IL-2 almost
completely abrogated the CXCL13 production (not shown), confirm-
ing IL-21 as the main co-stimulatory factor in inducing CXCL13
expression by Vg9/Vd2 T cells.
IL-21 co-stimulates the expression of CXCR5 on
tonsillar but not on peripheral cd T cells
The expression of the chemokine receptor CXCR5 allows
activated T cells to migrate into the CXCL13-rich B-cell follicles
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of secondary lymphoid tissues, where they instruct B cells to
undergo somatic hypermutation and differentiate into plasma
cells. CXCR5 was clearly expressed on B cells and on a subset of
CD41 T cells in freshly isolated PBMCs and in tonsils, in line with
previous reports [36], yet we failed to detect CXCR5 on Vg9/Vd2
T cells (Fig. 2D). Of note, stimulation with neither PHA nor
HMB-PP induced upregulation of CXCR5 on peripheral Vg9/Vd2
T cells (Fig. 2E), whereas peripheral CD41 T cells readily
upregulated CXCR5 expression in response to PHA (not shown).
However, and in contrast to peripheral Vg9/Vd2 T cells, tonsillar
Vg9/Vd2 T cells did express CXCR5 after stimulation with
HMB-PP, and even more so (po0.05) after stimulation with
HMB-PP and IL-21 (Fig. 2E). CXCR5 expression on activated
tonsillar Vg9/Vd2 T cells reached up to 30% within 24 h and
declined after 3 days (Fig. 2F). Taken together, these data
suggest that Vg9/Vd2 T cells activated in the periphery may reach
the draining lymph nodes and start expressing CXCR5 and
CXCL13 upon exposure to TFH cell-derived IL-21, thereby
contributing to the formation of the GC.
IL-21 co-stimulates the expression of ICOS by
peripheral and tonsillar cd T cells
Co-expression of high levels of CXCR5 and ICOS is a defining
feature of TFH cells [37], and the ability of TFH cells [38] as well
as Vg9/Vd2 T cells [20] to provide follicular B-cell help is
in part mediated through ICOS. Here, resting peripheral Vg9/Vd2
T cells did not express ICOS but readily upregulated its
expression in response to HMB-PP (Fig. 3A). Of note, IL-21
showed a strong co-stimulatory effect on ICOS, with expression
levels reaching 50% of all Vg9/Vd2 T cells over a period of 6 days,
at a time point of considerable proliferative expansion (data not
shown and [27]). In parallel with ICOS, activated Vg9/Vd2
T cells also transiently expressed the co-stimulatory molecule
OX40, although the effect of IL-21 on OX40 levels was less
pronounced (Fig. 3A).
When comparing the responsiveness of peripheral and
tonsillar Vg9/Vd2 T cells, tonsillar cells showed an increased
sensitivity to IL-21 with regard to ICOS expression, while OX40
was preferentially induced on peripheral Vg9/Vd2 T cells
(Fig. 3B). Other markers that were upregulated similarly on both
peripheral and tonsillar Vg9/Vd2 T cells exposed to a combina-
tion of HMB-PP and IL-21 included CD25, CD70, CD86 and
HLA-DR (Fig. 3B). Taken together, our data demonstrate a role
for IL-21 in the acquisition by Vg9/Vd2 T cells of markers asso-
ciated with B-cell help. In particular, the activation of tonsillar
Vg9/Vd2 T cells in the presence of IL-21 leads to the expansion of
ICOS1 Vg9/Vd2 T cells with a TFH cell-like phenotype.
IL-21 enhances the potential of human cd T cells to
provide B-cell help
We next tested the effect of IL-21 on the potential of peripheral
Vg9/Vd2 T cells to stimulate autologous B cells. In the presence of
HMB-PP, Vg9/Vd2 T cells underwent potent crosstalk with B cells
as evidenced by the upregulation of CD25, CD69, CD40 and
CD86 on co-cultured B cells (Fig. 4). This effect was comparable
to the effect of treatment of B cells with the mitogen
Staphylococcus aureus Cowan 1 (SAC), indicating that HMB-PP-
activated Vg9/Vd2 T cells provided a strong stimulus for B cells.
This activation of B cells occurred irrespective of the presence of
IL-21 in the medium, suggesting that under the conditions tested
Figure 1. Expression of IL-21R by Vg9/Vd2 T cells. (A) IL-21R expression on Vg9/Vd2 T cells, CD41 T cells, B cells and monocytes in blood, and on
Vg9/Vd2 T cells and CD41 T cells in tonsils. Shaded histograms indicate background staining with an isotype control. Data shown are
representative of three individual donors. (B) Co-expression of IL-21R with CD69 and CD25 on Vg9/Vd2 T cells in PBMCs cultured for 2 days in
medium alone or in the presence of HMB-PP. Data shown are representative of three experiments performed. (C) Expression of IL-21R and CD25 on
resting and activated Vg9/Vd2 T cells. PBMCs were stained either directly or after culture for up to 5 days in medium alone or in the presence of
HMB-PP. Data shown are means7SEM from four individual donors. po0.05, po0.01, po0.001 between HMB-PP-treated cultures and medium
controls, as determined by two-tailed Student’s t-tests.
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IL-21 on its own did not have a direct effect on B cells. However,
addition of IL-21 to the medium significantly enhanced the
resulting levels of IgM, IgG and IgA antibodies secreted by
gd T-cell/B-cell co-cultures, indicating that HMB-PP and IL-21
acted synergistically (Fig. 5A). IgE antibodies were not
detectable under these conditions (data not shown). Of note,
the stimulatory effect of gd T cells on autologous B cells
depended on the gd T-cell/B-cell ratio, confirming the exquisite
potential of HMB-PP-activated gd T cells to provide the B-cell
help, especially when co-stimulated in the presence of IL-21
(Fig. 5B). Finally, we confirmed the role of IL-21 in enhancing
B-cell helper function of gd T cells by using co-cultures of tonsillar
Vg9/Vd2 T cells and autologous tonsillar CXCR51 B cells. While
IL-21 or HMB-PP alone induced IgM production by tonsillar
B cells, the combination of both had a synergistic effect on the
overall levels produced and resulted in IgM levels comparable to
those obtained with CXCR51 B cells stimulated polyclonally with
SAC1IL-2 or co-cultured with autologous tonsillar CXCR51 TFH
cells (Fig. 5C).
Discussion
We here provide evidence that IL-21 contributes to the acquisi-
tion of B-cell helper functions by human Vg9/Vd2 T cells. We
used an in vitro system of autologous Vg9/Vd2 T cells and B cells
from tonsils or blood, the microbial metabolite HMB-PP and the
TFH-derived cytokine IL-21 to try to mimic the physiological
conditions in the GC. Our report is the first to show that resting
Vg9/Vd2 T cells express IL-21R on their surface, and that the
expression of IL-21R is greatly enhanced upon stimulation.
Binding of IL-21 to gd T cells had so far only been described in
mice [39]. Our findings imply that resting Vg9/Vd2 T cells
are directly responsive to IL-21 in the microenvironment,
and even more so shortly after activation with HMB-PP. Vg9/
Vd2 T cells are rapidly drawn to sites of infection where
they will encounter invading pathogens and interact with other
immune cells including neutrophils, monocytes and DCs, thus
defining an innate-like ‘first line of defence’ or sentinel function
[24, 25, 28]. However, activation of both human and mouse
Figure 2. Expression of CXCL13 and CXCR5 by Vg9/Vd2 T cells. (A) CXCL13 expression by peripheral Vg9/Vd2 T cells after 2 days of co-culture with
autologous B cells in medium alone or with HMB-PP and IL-21. Data shown are representative of independent experiments with cells from three
individual donors. Tonsillar CD41 T cells stimulated with PMA and ionomycin served as a control. (B) Immunofluorescence analysis of peripheral
Vg9/Vd2 T cells after 3 days of co-culture with autologous B cells in medium alone or with HMB-PP and IL-21. Cells shown are representative for
CXCL13/1 Vd21 T cells and CXCL13 Vd2 B cells; images are representative of two experiments (scale bar, 4mm). (C) CXCL13 secretion into the
supernatant of peripheral Vg9/Vd2 T cells after 3 days of co-culture with autologous monocytes in medium alone or with HMB-PP, in the absence or
presence of IL-21, shown as means1SEM from 3 to 4 individual donors. (D) CXCR5 expression by peripheral (top) and tonsillar (bottom) Vg9/Vd2
T cells, CD41 T cells and B cells. Data shown are representative of n5 7 (peripheral cells) and n5 3 (tonsillar cells) individual donors. (E) CXCR5
expression by peripheral Vg9/Vd2 T cells (top) after 2 days of culture in the presence of PHA or HMB-PP and IL-21, and by tonsillar Vg9/Vd2 T cells
(bottom) after 2 days of culture in the presence of HMB-PP with and without IL-21. Data shown are representative of n5 7 (peripheral cells) and
n5 4 (tonsillar cells) individual donors. (F) Expression of CXCR5 on resting and activated tonsillar Vg9/Vd2 T cells. Tonsillar cells were stained either
directly or after culture for up to 3 days in medium alone or with HMB-PP, in the absence or presence of IL-21, shown as means7SEM from four
individual donors. Statistical significances between HMB-PP and HMB-PP1IL-21-treated tonsillar cultures were determined by ANOVA (po0.05).
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gd T cells triggers changes in their migratory pattern and induces
upregulation of CCR7 [8, 40]. Once recruited to secondary
lymphoid tissues, pre-activated Vg9/Vd2 T cells may thus
encounter IL-21 produced by TFH cells and as a consequence
express a distinct set of molecules associated with providing
B-cell help. Lymph node-resident Vg9/Vd2 T cells may also
become stimulated by HMB-PP draining from the site of infection.
The acquisition of TFH-associated markers by Vg9/Vd2 T cells
and their dependence on IL-21 was first suggested by our recent
microarray studies [27]. IL-21 turned out to have a similar
capacity as the related cytokine IL-2 to support Vg9/Vd2 T-cell
proliferation yet without promoting the supposedly ‘signatory’
molecules IFN-g and TNF-a [41], thus highlighting a much
greater plasticity of Vg9/Vd2 T-cell responses than previously
appreciated. The demonstration that IL-21 drives the expression
of the B-cell-attracting chemokine CXCL13 suggests a role for
IL-21-stimulated Vg9/Vd2 T cells in orchestrating immune cell
trafficking to the GC. Our present data indicate that IL-21 also
plays a role in supporting the expression of the CXCL13 receptor,
CXCR5, by tonsillar Vg9/Vd2 T cells. Of note, we were unable to
induce significant levels of CXCR5 on peripheral Vg9/Vd2 T cells,
in line with previous reports [8] but at odds with others [20].
Control experiments confirmed the expression of CXCR5 on
peripheral CD41 T cells and B cells, and further upregulation of
CXCR5 on CD41 T cells stimulated with PHA, thus validating the
reagents and methodology used. We also observed lower CXCR5
expression values on tonsillar Vg9/Vd2 T cells than those repor-
ted by Caccamo et al. [20]. However, stimulation of tonsillar
Vg9/Vd2 T cells with HMB-PP and IL-21 resulted in our hands in
the rapid induction of CXCR5 expression within 24 h. Thus, our
data confirm that activated tonsillar Vg9/Vd2 T cells can clearly
express CXCR5 [20], providing a molecular explanation for their
clustering in GCs [8, 27]. An increased and more rapid respon-
siveness to IL-21 of tonsillar Vg9/Vd2 T cells, compared with that
of peripheral Vg9/Vd2 T cells, was also apparent with respect to
the induction of ICOS. These data indicate that IL-21 drives Vg9/
Vd2 T cells to assume a TFH-like phenotype, thus evoking the
crucial effect of IL-21 in the generation of CD41 TFH cells [35].
The phenotypic characterisation was further supported by the
functional demonstration that co-stimulation with IL-21 of
co-cultures of peripheral Vg9/Vd2 T cells and B cells enhanced
Figure 3. Expression of ICOS and OX40 by Vg9/Vd2 T cells.
(A) Expression of ICOS and OX40 on resting and activated peripheral
Vg9/Vd2 T cells. PBMCs were stained either directly or after culture for
up to 6 days in medium alone or with HMB-PP, in the absence or
presence of IL-21, shown as means1SEM from three individual donors.
po0.05 between HMB-PP and HMB-PP1IL-21-treated cultures, as
determined by two-tailed Student’s t-tests. (B) Peripheral and tonsillar
Vg9/Vd2 T-cell responses to HMB-PP and IL-21. PBMCs and tonsillar
cells were cultured with HMB-PP and IL-21. Expression of CD25, ICOS,
OX40, CD70, CD86 and HLA-DR by Vg9/Vd2 T cells was assessed on
freshly isolated cells and on days 2 and 3, shown as means1SEM from
2 to 4 individual donors each. po0.05, po0.01, as determined by two-
tailed Student’s t-tests.
Figure 4. Activation of peripheral B cells. Peripheral B cells alone or co-
cultures of peripheral Vg9/Vd2 T cells and B cells at a ratio of 1:1 were
incubated in medium alone or with HMB-PP, in the absence or presence
of IL-21. As a positive control, B cells were stimulated with SAC1IL-2.
Data shown are means1SEM from 2 to 3 individual donors for CD69,
CD25, CD40 and CD86 expression levels on B cells after 72 h in culture.
CD40 and HLA-DR expression data are shown as the ratio of geometric
MFI compared with that of an isotype-matched negative control
(MFI5 1). po0.05, po0.01 between stimulated B cells and B cells
cultured in medium alone, as determined by two-tailed Student’s
t-tests.
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the production of IgM, IgG and IgA in the presence of HMB-PP,
and that a similar co-stimulatory effect of IL-21 was seen on IgM
levels produced by co-cultures of tonsillar Vg9/Vd2 T cells and
B cells. We are aware that the interpretation of these co-culture
assays is hampered by a possible direct effect of IL-21 on B cells
[42, 43]. Although IL-21 on its own had no significant effect on
antibody production by peripheral B cells, partial activation of
B cells by IL-21 may have played a role in these experiments. In
co-cultures of tonsillar cells, there was a clear effect of IL-21
alone, suggesting that under those conditions HMB-PP and IL-21
acted synergistically. To rule out any direct effect on B cells, we
pre-stimulated purified Vg9/Vd2 T cells with HMB-PP and IL-21
before adding them to autologous B cells. However, no conclusive
data were obtained (data not shown), most likely because any
soluble factors of importance for supporting antibody production
released during this pre-stimulation period would have been
washed away before setting up Vg9/Vd2 T-cell/B-cell co-cultures.
Finally, the aspect of antigen specificity deserves attention.
Earlier studies in mice demonstrated that GC reactions that solely
depend on gd T cells are somewhat inefficient and result in
relatively high titres of class-switched, self-reactive antibodies
[12, 44]. gd T cells may thus provide general B-cell help and
enhance humoral immune responses, while MHC-restricted ab
T cells ensure antigen specificity by regulating affinity maturation
and clonal selection. This view is supported by the fact that HMB-
PP is present in the majority of bacterial pathogens, in malaria
parasites and in Toxoplasma, and hence activation of human Vg9/
Vd2 T cells is likely to occur in a broad range of infections [25]. A
‘bystander’ role for Vg9/Vd2 T cells in driving humoral responses
may result in different antibody levels, isotypes or affinities upon
infection with HMB-PP-producing or HMB-PP-deficient micro-
organisms. While such a role can only be postulated in humans
and at best supported by indirect epidemiological evidence,
infection and/or vaccination experiments in non-human primates
might address the contribution of Vg9/Vd2 T cells to the
generation of high-affinity, class-switched antibodies. Such
studies could exploit the availability of convenient pathogen
models such as specially engineered HMB-PP-deficient strains of
Listeria monocytogenes [45] or HMB-PP overproducing strains of
Mycobacterium tuberculosis [46].
Recent findings also point towards a more antigen-restricted
role of Vg9/Vd2 T cells in providing B-cell help, given their
potential to take up exogenous antigens and present them to
CD41 and CD81 T cells [33, 47]. Antigen-presenting gd T cells
may thus be able to interact directly with TFH cells. In mice,
epidermal gd T cells leave the skin upon activation and reach the
draining lymph node where they may help the production of
antibodies specific for non-self-antigen applied onto, or artifi-
cially expressed within, the skin [40, 48]. It remains to be
investigated whether HMB-PP or related compounds with activity
on Vg9/Vd2 T cells, such as the aminobisphosphonate zole-
dronate, might be useful in boosting humoral responses. A recent
vaccine trial in cynomolgus monkeys did address a possible
adjuvant effect of the HMB-PP analogue Picostim on the immune
response against mycobacterial antigens yet did not measure the
levels of anti-mycobacterial antibodies [49]. Similarly, the effect
of aminobisphosphonate treatment on anti-tumour antibody
responses in cancer patients has so far been overlooked.
Taken together, our present findings complement and extend
previous observations on the potential of gd T cells to provide
B-cell help and ascribe an important role to IL-21 in contributing
to this potential. The interaction between HMB-PP-responsive
Vg9/Vd2 T cells with IL-21-producing TFH cells and with B cells in
secondary lymphoid tissues is likely to impact on the generation
of high affinity, class-switched antibodies in microbial infections.
Materials and methods
Cell isolation
PBMCs were isolated from peripheral blood of healthy volunteers
using Lymphoprep (Axis-Shield). To study cells from secondary
lymphoid tissues, mononuclear cells were also isolated from fresh
tonsils of patients undergoing tonsillectomy. Ethical approval was
obtained from the South East Wales Local Ethics Committee (08/
WSE04/17) and conducted according to the principles expressed
in the Declaration of Helsinki. All patients and volunteers
provided written informed consent.
For functional assays, cell subpopulations were purified by
MACS (Miltenyi): peripheral B cells (498%) using anti-CD19
microbeads (for feeder cells) or the untouched B-cell isolation kit
(for antibody production); tonsillar CXCR51 B cells (495%)
using the untouched B-cell isolation kit followed by CXCR5-PE
mAbs (51505.111; R&D Systems) and anti-PE microbeads;
tonsillar CXCR51 TFH cells (485%) using CD4-FITC mAbs and
the anti-FITC multisort kit followed by CXCR5-PE mAbs and anti-
PE microbeads; and peripheral Vg9/Vd2 T cells (495%) using
Vd2-PE (B6.1; BD Biosciences) or Vg9-PE-Cy5 (Immu360; Beck-
man-Coulter) mAbs and anti-PE microbeads. Tonsillar Vg9/Vd2
T cells (499%) were enriched from CD4-depleted tonsillar cells
using Vd2-PE mAbs and anti-PE microbeads, followed by further
purification on a MoFlo cell sorter (Dako Cytomation) as
Vg91 Vd21 CD31 CD4 CD19 lymphocytes. Purities of all cell
populations obtained were determined by flow cytometry.
Flow cytometry
Cells were acquired on a nine-colour CyAn ADP (Beckman
Coulter) and analysed with FloJo 7.5 (TreeStar), using mAbs
directed against TCR-Vd2 (B6.1), CD3 (SK7, UCHT1, HIT3a),
CD4 (RPA-T4), CD14 (MOP9), CD25 (M-A251), CD27
(1A4CD27), CD45RA (HI100), CD45RO (UCHL-1), CD69
(FN50), CD70 (Ki-24), CD86 (2331), CD134/OX40 (ACT35),
CD278/ICOS (DX29), HLA-DR (L243) and IgD (IA6-2) (all from
BD Biosciences) and TCR-Vg9 (Immu360), CD4 (SFCI12T4D11)
and CD40 (mAB89) from Beckman Coulter; CD19 (SJ25C1) from
eBioscience; CD19 (HD37) from Dako; IL-21R (9N1; [34, 35]);
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and rat anti-CCR7 (3D12; [50]); together with appropriate
isotype controls and secondary reagents. Cells of interest were
gated based on their appearance in side scatter and forward
scatter area/height and exclusion of live/dead staining (fixable
Aqua; Invitrogen). For intracellular detection of CXCL13,
brefeldin A (Sigma) was added to cultures at 10 mg/mL 4h prior
to harvesting; cells were then fixed and permeabilised using the
Fix&Perm kit (eBioscience) and stained with mouse anti-CXCL13
(53610; R&D Systems) followed by an goat anti-mouse secondary
antibody (Dako) and surface staining as above.
Figure 5. Induction of antibody production by peripheral and tonsillar B cells. (A) Peripheral B cells alone or co-cultures of peripheral Vg9/Vd2
T cells and B cells at a ratio of 1:1 were incubated in medium alone or with HMB-PP, in the absence or presence of IL-21. As a positive control, B cells
were stimulated with SAC1IL-2. IgM, IgG and IgA levels shown are means1SEM from 2 to 3 individual donors after 10 days in culture. po0.05,
po0.01 to B cells cultured in medium alone, as determined by two-tailed Student’s t-tests. (B) Co-cultures of Vg9/Vd2 T cells and B cells at the
indicated ratios were incubated with HMB-PP, in the absence or presence of IL-21. As controls, B cells were cultured in medium alone (B cells only).
IgM, IgG and IgA levels shown are means1SEM after 10 days in triplicate cultures and are representative of two individual donors. (C) Tonsillar B
cells alone or co-cultures of tonsillar Vg9/Vd2 T cells and B cells at a ratio of 1:1 were incubated in medium alone or with HMB-PP, in the absence or
presence of IL-21. As a positive control, B cells were stimulated with SAC1IL-2 or cultured together with tonsillar TFH cells. IgM levels shown are
means1SEM after 10 days in triplicate cultures and are representative of two individual donors. po0.001, as determined by two-tailed Student’s
t-tests.
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Cell culture
The medium used was RPMI-1640 with 2mM L-glutamine, 1% non-
essential amino acids, 1% sodium pyruvate, 50mg/mL penicillin/
streptomycin, 50mM b-mercaptoethanol and 10% foetal calf serum
(Invitrogen). PBMCs or tonsillar cells were cultured for up to 7 days
in the presence of 10nM synthetic, i.e. LPS-free HMB-PP [51] with
or without 10–100U/mL IL-2 (Proleukin; Chiron) or 50–100ng/mL
IL-21 (Zymogenetics). As controls, cells were stimulated with
1mg/mL PHA (Sigma) for up to 3 days or with 10ng/mL PMA
(Sigma) and 1mg/mL ionomycin (Sigma) for 6h. For functional
assays, purified B cells were co-cultured with purified gd T cells or
TFH cells at a ratio of 1–5 B cells per T cell, unless otherwise
indicated. In some experiments, B cells alone were stimulated with
0.01% SAC (Pansorbin; Merck) in the presence of 100U/mL IL-2.
Immunofluorescence
Immunofluorescence microscopy was performed using a Nikon
microscope (Eclipse 80i, Nikon). After 3 days of culture, cells
were fixed, permeabilised and stained with mouse anti-CXCL13,
followed by Alexa Fluor488-conjugated goat anti-mouse IgG1
(green), anti-Vd2-PE (red) and counterstaining with DAPI (blue).
Images were captured with a Nikon digital camera (DXM1200F)
controlled by ACT-1 2.70 imaging software and processed with
Adobe Photoshop 6.0.
Culture supernatants
Cell culture supernatants were analysed for CXCL13 by ELISA
(R&D Systems). Antibody levels were determined using the
human IgM, IgG, IgA and IgE quantitation kits (Universal
Biologicals). All samples were measured in duplicate on a Dynex
MRX II reader.
Statistical analysis
Data were analysed using two-tailed Student’s t-tests or two-way
ANOVA (GraphPad Prism 4.0), with differences considered
significant as indicated in the figures: po0.05; po0.01;
po0.001.
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